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Abstract 
Long-term exposure to diabetes mellitus is associated with metabolic abnormalities such as 
chronic hyperglycemia and redox imbalance. Uncontrolled hyperglycaemia and genetic 
factors are implicated in the pathogenesis of diabetic microvascular diseases. Genetic 
mutation through the genes coding for enzymes involved in glucose metabolism and 
immuno-regulatory mechanisms may contribute to the susceptibility to type I diabetes 
mellitus (TfDM) and its chronic microvascular diseases. Previous studies have shown that 
the transcription factor, nuclear factor kappa 8 (NFKB) and heat shock proteins (HSPs) are 
two redox-sensitive cellular responses of most immune and inflammatory diseases 
including diabetes and its late vascular complications. NFKB promotes the transcription of 
a wide array of proinflammatory mediators and adhesion molecules. HSPs are proposed to 
have a cytoprotective effect; in contrast they have the capacity to promote pathogenic 
processes. In this study, polymerase chain reaction (PCR)-based microsatellite analysis and 
restriction fragment length polymorphism (RFLP) analysis were used to genotype the 
genes coding for NFKB, HSP70-A2, sorbitol dehydrogenase (SORD) and protein kinase C-
~ (PKC-~). The A I 0 allele of the NFKB gene and H3 and H7 alleles of the HSP70-A2 
gene were identified as risk markers of TIDM (P< 0.0 I). These alleles were not associated 
with microvascular complications. No evidence of associations was obtained between 
either PKC-~ or SORD genes with TIDM and its late complications. Uncontrolled 
hyperglycaemia may alter the transcription mechanism of many genes, which control 
vascular homeostasis. The electrophoresis mobility shift assay (EMSA) was used to assess 
the transcription factor, heat shock factor-! (HSF-1) and NFKB-DNA binding activity in 
response to a concentration of 31 mM D- glucose in peripheral blood mononuclear 
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cells (PBMCs) from patients with TIDM with and without microvascular complications. 
Hyperglycaemia induced significant increases in both NFKB and HSF-1-DNA binding 
activities in PBMCs from patients (p= 0.003 and 0.017 respectively). The protein activity 
was more pronounced in PBMCs from patients with microvascular complications. 
Hyperglycaemia-induced NFKB-DNA binding activity was correlated to that of HSF-1 (p< 
0.0 I). Patients with TrDM with microvascular complications demonstrated a significant 
increase in NFKB-DNA binding activity compared to patients with a short duration of 
diabetes (SO) or diabetic controls (DC) (p= 0.003 and p = 0.047 respectively). 
A significant positive correlation was found between the duration of diabetes and 
hyperglycaemia-induced NFKB-DNA binding activity (p=0.035). These results suggest 
that hyperactive flux through the polyol pathway is relevant to hyperglycaemia-induced 
protein activity since the aldose reductase inhibitors (ARis) zopolrestat and sorbinil 
reduced HSF-1 and NFKB-DNA binding activity in PBMCs. In conclusion, these results 
suggest that NFKB and HSP70-A2 genes may contribute to the genetic susceptibility to 
TIDM. Uncontrolled hyperglycaemia in diabetes may alter the transcription mechanism 
and magnify the proinflammatory responses, which accelerate the development of diabetic 
microvascular complications. 
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Introduction 
Introduction 
1.1 Diabetes mellitus: Overview of diabetic research and genetic studies 
Diabetes is the most common metabolic syndrome and is characterised by hyperglycaemia. 
The disease is a disorder of glucose homeostasis due to defects in insulin secretion, insulin 
action, or both (The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus, 1998; World Health Organization (WHO), 1999). Insulin deficiency is associated 
with increased levels of diabetogenic hormones including epinephrine, glucagon, cortisol, 
and growth hormones, which promote insulin resistance (Marks et al., 1996). The National 
Diabetes Data Group (NDDG) and WHO differentiate diabetes into two main types: 
insulin dependent diabetes mellitus (most recently known as TIDM) and non- insulin 
dependent diabetes mellitus known as type 11 (TIIDM) (NDDG, 1979; WHO, 1985). 
Diabetes, like certain other diseases such as cancer, asthma, and hypertension, tends to run 
in families but does not show typical Mendelian pedigree patterns (Froguel, 1999; 
Gambaro et al., 2000). People with diabetes are at increased risk of progressive 
development of cardiovascular, peripheral and cerebro-vascular diseases (Diabetes Control 
and Complications Trials (DCCT), 1993). 
Chronic hyperglycaemia is the main initiator of late diabetic vascular complications, which 
are the major cause of morbidity and mortality in patients with diabetes (DCCT, 2000; UK 
Prospective Diabetes Study (UKPDS) 35, 2000). The mechanisms underlying the long-
term vascular abnormalities of diabetes have attracted considerable attention. There have 
been numerous diabetes prevention and control trials throughout the world to determine if 
TLDM and its late vascular complications could be prevented or delayed. DCCT and the 
NDDG are clinical studies conducted by the National lnstitute of Diabetes and Digestive 
and Kidney Diseases (NIDDK) of the National lnstitute of Health (Nlli) in United States 
of America (USA). ln the United Kingdom (UK), the UKPDS was a multi-centre study 
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looking at TIIDM. These studies showed that keeping blood glucose level as close to 
normal as possible may limit the progress of diabetic complications (DCCT, 1993; NTI-1, 
1994; 2002; UKPDS 33 and 34, 1998; UKPDS 35, 2000). 
Identification of people at risk for diabetes and its complications may help to reduce its 
morbidity and mortality and reduce the costs associated with treatment. Genome-wide 
scanning and candidate genes are general lines that help to identify the genetic causes of 
TIDM and its complications. Association analysis, family studies and animal models help 
to identify candidate genes. 
Association analysis describes a comparison of the frequency of polymorphic genes in 
patients versus matched control populations (ethnic, sex, age, and lifestyle) and may 
suggest a causative role for the gene polymorphism (Cavan et al ., 1992). Multiplex family 
linkage analysis could determine whether there is evidence for eo-segregation of a 
susceptibility locus and a disease marker in families with multiple affected persons (Wolf 
et al., 1983; Hashimoto et al. , 1994; Davis et al., 1994). In the UK, the largest collection of 
multiplex families is contained in the DUK Warren Repository formerly British Diabetic 
Association (BOA) (Bain et al. , 1990). The transmission disequilibrium test is a family-
based association test. It considers a population sample of the disease (trios of affected 
individuals and their parents). A significant difference between transmitted and un-
transmitted alleles could confirm the associations. However, an unknown mode of 
inheritance of the disease (polygenic), low penetrance, inadequate family size and 
environmental effects may reduce the power of family studies (Cavan et al., 1992; Bennett 
et al. , 1995). So, affected sib-pair linkage analysis could determine the proportion of 
shared alleles. 
24 
Introduction 
Animal models have enhanced understanding of the aetiology of TIDM and support the 
understanding of the molecular mechanisms of the disease and its complications. Animal 
studies have facilitated close investigation of linkage and segregation of marker genes with 
various diseases. The Bio breeding rat (BB) and non-obese diabetic mouse (NOD) are the 
main animal models of autoimmune diabetes. They have diabetogenic loci within the 
major histocompatibility complex (MHC), and spontaneously develop a diabetic syndrome 
similar to human TIDM (Yoon et al. , 2001). 
1.1.1 Classification of diabetes mellitus 
1.1.1.1 Type I diabetes mellitus (TIDM) 
TIDM is the third most prevalent chronic disease of childhood after asthma and mental 
retardation (Rewers et al. , 1997). It is an autoimmune-inflammatory disease, leading to 
progressive loss of pancreatic islet~ cells and decreased insulin production (DCCT, 1993; 
The expert committee on the diagnosis and classification of diabetes mellitus 1998; 
American Diabetes Association (ADA), 2002). TIDM was formerly termed juvenile 
diabetes because it presents mainly in children and young adult. The peak incidence is 
between 5-15 years and it accounts for 10% of people with diabetes worldwide (DERIG, 
1990; Karvonen et al. , 2000). Patients with TIDM are dependent on insulin to preserve life. 
Extensive exposure to diabetes contributes to the development of microvascular 
complications, which is associated with increased incidence of morbidity and mortality 
(DCCT, 1993). The disease is described as a complex trait because its pathogenesis 
involves both environmental and genetic factors (polygenic). Environmental triggers such 
as infection may activate autoimmune mechanisms in genetically susceptible individuals. 
TIDM belongs to a family of diseases characterised by their association with the MHC and 
appearance of antibodies against self-proteins (Todd, 1995; Todd et al. , 2001). 
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TIDM can be associated with other endocrine disorders and represents an autoimrnune 
polyendocrine syndrome in which patients develop problems in numerous glands including 
insulin deficiency, hypogonadism, adrenal insufficiency, and hyper or hypothyroidism 
(Nagamine et al., 1997). TIDM can co-exist with other autoimrnune diseases such as 
systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis 
(RA) (Dotta et al. , 1997; Todd et al. , 2001). 
1.1.1.2 Type II diabetes mellitus 
Adult (maturity) onset diabetes is known as TIIDM. The onset is usually after the age of 30 
years and is characterised by insulin resistance in peripheral tissues which is usually 
combined with a functional defect of~ cell and insulin deficiency (The Expert Committee 
on the Diagnosis and Classification of Diabetes Mellitus, 1998; UKPDS 33 and 34, 1998). 
Obesity and environmental factors are probably involved in the pathogenesis of TliDM. 
Studies have shown that TIIDM is the most common type of diabetes and accounts for 85-
90% of all patients with diabetes (Zimrnet, 1999; Kukreja et al., 1999). 
1.1.1.3 Impaired glucose tolerance 
Impaired glucose tolerance (IGT) is identified as borderline or sub-clinical diabetes. The 
fasting plasma glucose level (FPG) during an oral glucose tolerance test (OGTT) is above 
normal but below those that are defined as diabetic (fasting< 7mmol/1, after 2 hours 7-11 
mmol/1) (The expert committee on the diagnosis and classification of diabetes mellitus 
1998). IGT may produce symptoms of either TIDM or TIIDM. It may remain for many 
years or return back to normal glucose tolerance. The prevalence of hypertension and 
atherosclerosis increases in this class of individuals (The Expert Committee on the 
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Diagnosis and Classification of Diabetes Mellitus, 1998; Alberti et al., 1998). 
1.1.1.4 Gestational diabetes mellitus 
Any degree of glucose intolerance during pregnancy has been identified as gestational 
diabetes mellitus (GDM). During pregnancy the placenta may cause hormonal disturbance 
and reduce the insulin effect. Pregnant women at increased risk include obese women and 
those with a family history of diabetes . The risk for progression to IGT and TITDM is 
increased in women who had GDM. Postpartum plasma glucose levels may meet the 
criteria of TIIDM and IGT or may return back to the normal glucose level (The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998; Alberti et al. , 
1998). 
1.1.1.5 Maturity-onset diabetes in the young 
Maturity onset diabetes in the young (MODY) is an atypical form of diabetes . It presents a 
typical clinical course of TIIDM in young age (The Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus, 1998). Clinical examination, family history, an 
immunologic, genetic and metabolic characters could distinguish this class from TIDM. 
1.1.1.6 Other types of' diabetes mellitus 
Genetic defects, such as in ~ cell function , insulin action and/or insulin receptor may 
contribute to the pathogenesis of diabetes. Pancreatic, endocrine, metabolic diseases. 
infection and trauma may lead to the development of secondary diabetes (Alberti et al. , 
1998; WHO, 1999). 
27 
Introduction 
1.2 Type I diabetes mellitus 
1.2.1 A brief history of diabetes mellitus and insulin discovery 
Diabetes is a Greek word meaning pipe-like due to the frequent and voluminous urination 
by patients accompanied with thirst. Mellitus is a Latin word for honey to differentiate the 
disease from diabetes insipidus, which is a result of a deficiency of antiduretic hormone 
with excessive sugar-free urine output. The fust use of the term diabetes mellitus was 
accredited to the Greek physician Cappadocia in the second century AD (Bliss, 1996). 
The disease was known since the writings from the earliest civilizations (Egypt, China, and 
lndia). They showed that the disease was linked to the type of diet and associated with 
symptoms of polyuria, polydipsia, polyphagia and loss of weight. Later, the physicians 
referred to it as a disease of the blood, kidneys, liver, or stomach. As early as 1788, 
Thomas Crawley established a link between poor pancreatic functions and diabetes (Bliss, 
1996). 
The pancreas is a digestive gland found behind the lower part of the stomach in the left 
side of the body. In 1869, Paul Langerhans discovered the existence of two systems of 
cells: the acinar (exocrine) cells, which secrete the digestive pancreatic enzymes and also 
identified cells that accounted for -2% of total with un-determined functions and scattered 
in groups between the exocrine cells that were later identified as islets of Langerhans 
(Kloppel et al. , 1997). Islets of Langerhan are classified into 4 types: I) Alpha cells that 
secrete the counter-regulatory hormone glucagon. 2) Beta (/3) cells, which produce insulin 
form 70-80% of the endocrine mass and play a central role in the regulation of 
carbohydrate metabolism through the action of insulin. 3) Delta cells produce 
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somatostatin, which is a potent inhibitor of insulin and glucagon. 4) Pancreatic polypeptide 
cells (PP), which may modulate the intra-islet horneostasis. The interaction of these various 
cell types is critical for maintaining the integrity of the tissue (Kloppel et al. , 1997). 
ln 1889, Minkowski showed that pancreatectomy in the dog resulted in diabetes. 1n 1893, 
Hedon confirmed that a total pancreatectomy was necessary to cause diabetes. ln 1921 , 
Banting and Best discovered insulin. Finally, the fatal disease had been controlled and 
Nobel prizes were awarded to Banting and Best in 1923, 1958, and 1964 (Bliss, 1996). 
1.2.2 Epidemiology of TIDM 
The diabetes epidemiology research international group (DERIG) and the WHO play a key 
role in analysing epidemiological data between countries. Reports from a number of 
countries have suggested that there is a worldwide increase in incidence of TIDM (3.0 % 
per year) and this rate is expected to be more than double over the next 25-30 years 
(Onkarno et al. , 1999). Currently, a vast global network of registers of patients with TIDM 
and major international collaborations are covering incidence, prevalence, morbidity, and 
mortality rates of TIDM. The disease is common in the western world and is principally a 
disease of Caucasians (Kukreja et al. , 1999). There is a range of global variation in the 
incidence of TIDM among children aged less than 14 years of age (WHO, 1999). It has 
been reported that Finland and Sardinia show the greatest incidence rates while China and 
South America show the lowest incidence rates (DERIG, 1988; Green et al. , 1992; 
Karvonen et al., 2000). A great difference has been detected in the incidence between the 
countries around the Baltic Sea (Padaiga et al. , 1997). ln Kuwait as a part of the WHO 
research group, a higher incidence of TIDM has been observed compared with the other 
Gulf areas (Shaltout et al., 1995). It is supposed that ethnic and racial distribution may 
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imply the involvement of both the environmental and genetic factors in that variation. 
Further, reports have shown seasonal trends for TIDM incidence with the highest incidence 
in winter and a decline during summer time (DERIG, 1988; Zimmet 1999). 
1.2.3 Glucose homeostasis 
Glucose is the main energy source for cells. Insulin and glucagon are the main hormonal 
regulators of blood glucose homeostasis (Marks et al., 1996; Kloppel et al ., 1997). Insulin 
is an anabolic hormone, which increases the storage of glucose, fatty acids and amino acids 
in cells and tissues (elevated in the post-prandial state) while glucagon is a catabolic 
hormone, which mobilizes glucose, fatty acids and amino acids from stores to blood 
(elevated during fasting). After a typical meal the blood gluco e level rises from a fasting 
level of 80-lOOmg/dL (-5.5 mM) to a level of 120-140 mg/dL (8mM) within 30-60 
minutes then reverts back to the fasting level within 2 hours (Figure 1.1 A). High glucose 
levels in blood stimulate insulin secretion that is degraded within minutes in the liver and 
kidneys (Marks et al ., 1996). 
The initial step of the glucose-insulin pathway is the attachment of insulin to the insulin 
receptor on the f3 cell membrane. The glucose transporter (Glut) facilitates the transport of 
glucose into the cell . Glucose is then phosphorylated with an adenosine-tri-phosphate 
(ATP)-dependent glucokinase, which is the key regulatory enzyme of glycolysis. The 
increased levels of A TP in the cell prompt the potassium ion channels (ATP-sensitive K+ 
channels) to close and calcium ion (Ca2+) channels to open leading to Ca2+ influx and 
insulin secretion (Figure 1.1 B). 
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Figure (A) is a graph that shows blood glucose level rising from a fasting level of -5 mM 
to a level of 8rnM within 30-60 minutes after a meal and back to the fasting level within 2 
hours. Figure (B) shows the insulin release from the ~ cell. Glucokinase (G-6-P) is the 
rate-limiting step in glycolysis (1), which leads to an increase in ATP/ADP ratio (2), 
closure of K+ channel (3), depolarisation (4), and opening of the Ca2+ channel (5). Ca2+ 
influx initiates insulin release (6). 
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This mechanism is underpinned by cycles of changes acros the cell membrane and is 
supported by a dense network of blood vessels, an array of neurons and signalling 
information. Subsequently, a cascade of protein kinases are recruited to amplify the effects 
of insulin to lower blood glucose levels, which is over a million fold higher than that of 
insulin. fJ cell-released insulin correlates with the glucose levels in the blood stream. fJ cell 
contains insulin granules and its precursor molecule (C-peptide) in a 1:1 molar ratio. The 
insulin dose of 40 fU (IU= 25xl09 insulin granules) is needed for physiological demand 
/day. The major actions of insulin are: 1) facilitation of glucose transport through certain 
membranes; 2) enhancement of the conversion of glucose to glycogen; 3) slowing down of 
gluconeogenesis in liver and muscle cells; 4) promotion of protein synthesis and growth 
(Marks et al ., 1996; Kloppel et al., 1997). 
1.2.4 Pathogenesis of~ cell destruction 
TIDM is an incurable progressive autoimmune disease due to immune-mediated pancreatic 
P cell destruction. There is no clear explanation for the onset of the djsease. Glutamic acid 
decarboxylase (GAD) (Baekkeskov et al. , 1 990), insulin autoantibodies (IAA) (Serreze et 
al. , 1988), and islet cell antibodies (ICA) (Bottazzo et aJ. , 1974) serve as auto-antigens and 
direct the immune system to attack the~ cell . 
Macrophage , B cell , and T cell are all implicated in the pathogenesis of autoimmune 
TLDM (V an Noort et al. , 1998). Macrophages are the first group of cells, which infiltrate 
the islets during the early stage of insulitis. They play an important role in ~ cell 
destruction through the generation of reactive oxygen species (ROS) and the release of 
cytokines including interferon gamma (IFN-y), tumor necrosi factor-alpha (TNF-a) and 
interleukin-1 beta (lL- 1~) (Yoon et al. , 1998). Macrophage-derived cytokines recruit T 
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cells, and macrophages act as antigen presenting cell (APC) for ~ cell auto-antigens to T 
cells and initiate T cell- auto reactive response (Yoon et al., 2001). It is known that T cells 
are classified according to the glycoproteins co-receptors of two types: CD4+ and CD8+. 
Antigen response occurs in two phases: 1) the activation phase in which the antigen is 
displayed by the APC with the help of class 11 MHC and binds to CD4 (incomplete 
immune response). 2) an elimination phase (immune response) in which eo-stimulatory 
molecules activate transcription factors in T cells that bind to cytokines promoter region, 
initiate their transcription and contribute toT cell proliferation. 
It has been suggested that apoptosis (programmed cell death) is the main mode of f3 cell 
damage leading to TIDM (Eizirik et al., 2001a and 2001b; Mandrup-Poulsen 2001). 
Apoptosis is a complicated cascade of pathological events that starts with an initial signal 
and ends in DNA fragmentation . Studies have shown that ll..-1~ , TNF-cx. and IFN-y either 
alone or in combination, are able to induce f3 cells apoptosis (Green et al., 1999; Kukreja et 
al., 1999; Eizirik et al. , 200 la and 200 l b). IL- l~ plays a crucial role in the pathogenesis of 
TIDM through three major pathways: the activation of the transcription factor, NFJCB, 
mitogen-activated protein kinases (MAPKs), and PKC (Eizirik 1996; Eizirik et al. , 2001; 
Cardozo et al. , 2001 ). Specific inhibition of ll...-1 ~ could be a target for therapeutic 
programs (Cailleau et al., 1997). Studies have shown that TNF-cx. enhances the presentation 
of islet antigen to both effectors CD4+ and CD8+ T cells and it can participate in the 
autoimmune reaction through activation of NFJCB (Green et al. , 1999; Yoon et al. , 1999). 
Animal studies have shown that the process of f3 cell destruction is chronic and takes days 
to weeks (Kukreja et al. , 1999), while this process could proceed for several months or 
years in the human (Eizirik et al. , 2001 ). Human islet f3 cell has been shown to be more 
resistant than animal's suggesting an interspecies difference in the destruction and repair 
mechanisms (Eizirik et al. , 1994). It is shown that cytokines in general and IL-l~ in 
particular can induce HSPs and superoxide dismutase that may protect against damage 
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(Bellmann et al., 1995; Eizirik, 1996; Burkart et al., 2000). 
1.2.5 Clinical diagnosis of TIDM 
Clinical diagnosis of TIDM includes two main stages: l) pre-clinical (insulitis); 2) overt 
diabetes, which often leads to the development of acute and chronic complications (Rewers 
et al. , 1997). 
1.2.5.1 Insulitis 
Autoimmune destruction of fJ cells is thought to be completely asymptomatic until 80-90% 
of the cells are lost (Tisch et al. , 1996). The mechanjsm of destruction is variable from 
patient to patient (Kukreja et al., 1999). However, animal studies have shown that insulitis 
does not progress to diabetes in all cases (Benoist et al. , 1997; Noorchashm et al. , 1997; 
Van Noort et al., 1998). Human insulitis starts several years before the clinical stage of the 
disease and can be diagnosed by antibodies. ICA, IAA and GAD are the prevalent 
immunonologicaJ factors in patients with TIDM (Bottazzo et al. , 1974; Serreze et al., 1988; 
Baekkeskov et al. , 1990; Leslie et al., 1999). 
1.2.5.2 Overt TIDM 
The ADA and the WHO state that FPG level of 7 mmol /L or above confirms a diagnosis 
of diabetes (Alberti et al., 1998; ADA, 200 l ). The diagnosis of TIDM is straightforward in 
almost all cases. In asymptomatic subjects, the diagnosis of diabetes is based on at least 
two abnormal FPG results. The detection of glucose in the urine is often the first indicator 
of the diagnosis of the disease. However, about 20-40% of patients present in djabetic 
ketoacidosis (DKA) (DCCT, 1993). 
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Symptoms of diabetes are clearly identified. A classical phenotype of the disease is weight 
loss, polyuria, polydipsia, polyphagia, blurred vision and fatigue (DCCT, 1993; The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998). There are no 
clear macroscopic pathological changes of the pancreas from patients with recent TIDM 
( <1 year), but the chronic disease shows a noticeable decrease in the weight and size of the 
pancreas due to cell atrophy. Those changes depend on the duration of the disease, age at 
onset, and the degree of the rnicroangiopathy. lrrununocytochernistry and electron 
rnicroscopy reveal that the majority of islets are devoid of p cells in patients with TIDM 
(Kloppel et al ., 1997). 
1.2.6 Susceptibility factors to TIDM 
TIDM is a complex trait; both genetic and environmental factors are involved in the 
aetiology of the disease. Family and twin studies have shown that genetic factors play an 
important role in the susceptibility to TTDM. The frequency of the disease in siblings of 
diabetics is 15 times more common than in the general population (Field, 2002). Twin 
studies have demonstrated a higher rate in monozygotic twins ( I 00 % shared genes) than in 
dizygotic twins (average 50% shared genes) (Barnett et al. , 1981 ; Kumar et al. , 1993). 
However, concordance rates in monozygotic twins are not I 00%, suggesting that non-
genetic factors must also contribute to the development of TIDM. The genetic component 
to TIDM is polygenic and heterogeneous. Mapping the whole genome identified several 
combinations of susceptibility and protective genes. The power of genome wide screening 
studies depends on the number of families, the quality of clinical phenotyping and the 
selection criteria (reviewed in Cavan, 1992; Todd, 1995; Field, 2002). 
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1.2.6.1 Genetic factors 
TIDM accounts for 10% of cases of diabetes in the UK, approximately 60-70 % of genetic 
susceptibility is associated with MHC class II markers (Cavan et al. , 1992; Bamett et al. , 
1994). The identification of non-MHC loci was helped by the generation of polymorphic 
markers, which are spread throughout the human genome, PCR-based microsatellite 
markers and DNA from numerous multiplex families. The genetic mapping of 
susceptibility loci for TIDM has proposed more than 20 putative diabetes-predisposing 
genes. Most of the identified risk markers may modify aT cell-dependent progression from 
a benign to a destructive stage and contribute to the development of the disease. However, 
these genetic loci display a much weaker linkage to disease than the MHC region 
susceptibility genes and they are in strong linkage disequilibrium (Cavan et aJ. , 1992; 
Field, 2002). All identified susceptibility loci are thought to be equally important and 
necessary for the disease development. Perhaps, if the predisposing genes act together, 
they could alter the immunological responsiveness and cause disease. 
1.2.6.1.1 Major histocompatibility complex (MHC) 
The human version of the MHC is the human leukocyte antigen (HLA) on chromosome 6. 
The MHC is critical for the function and regulation of the immune response. HLA 
molecules play a fundamental role in presenting self and foreign antigens to the T cells 
(Klein et aJ. , 2000). It consists of several genes, which are highly polymorphic, closely 
linked and fall into three classes. Class I genes consist of HLA-A, B, and C. Class II genes 
are divided into the main sub-regions DP, DQ and DR. Each family contains two subunits 
a and ~ chain respectively (Owerbach et al., 1996; Klein et al. , 2000). Class liJ genes 
encode complement components (Owerbach et al., 1996). 
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In diabetes, the early serological studies have shown that class I HLA antigen was 
associated with TIDM (Nerup et al ., 1974). Further studies have shown that HLA class II 
on 6p21.3 contains one or more major genetic determinants of susceptibility to TIDM. The 
DQ and DR molecules have been suggested to influence the efficiency of autoantigen 
presentation and the degree of pancreatic ~ cell destruction during the course of the disease 
(Platzet al., 1981; Wolf et al., 1983; Todd, 1987; Becker, 1999). 
In Caucasoid populations, family studies have shown that HLA DR3 and/or DR4 alleles 
are strongly associated with susceptibility to TIDM. The relative risk for TIDM in 
individuals who have both DR3 and DR4 susceptibility alleles (heterozygous) is greater 
than in those homozygous for either DR3 or DR4 (Platz et al. , 1981; Wolf et al., 1983). 
Sequencing studies have shown that DQB 1 is strongly associated with susceptibility to 
TIDM when it encodes a non-aspartic acid (Asp) at residue 57 of the ~-chain . Studies have 
revealed that disease associated haplotypes containing HLA-DR3 and HLA-DR4 have 
alanine (Ala) or serine (Ser) at residue 57 of the ~-chain, while protective haplotypes 
contain HLA-DR2 and Asp at position 57 (Todd et al., 1987; Khalil et al., 1990). 
DR3, DR4 and DQ markers are associated with TIDM in populations with widely different 
ethnic origins. However, this association was not confirmed in a Chinese or Japanese 
populations suggesting that their presence is necessary but it is not the primary disease 
determinant (reviewed in Cavan et al. , 1992; Todd, 1995; Field, 2002). The most potent 
susceptibility genes to TIDM in the HLA region are collectively referred to as IDDMl 
(Davies et al., 1994; Hashimoto et al., 1994). 
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1.2.6.1.2 Non- MHC loci 
1.2.6.1.2.1 Insulin-region 
Any abnormality of insulin secretion or processing is a possible etiological factor for 
TIDM. The human insulin gene (INS) was cloned and mapped to chromosome 11 (Bell et 
al., 1980). A polymorphic region in the 5' untranslated region on the INS gene was ftrst 
shown to be associated with TIDM in a case-control study in 1984. The marker consists of 
a variable number of tandem repeats (VNTR) 14 basepair (bp) oligonucleotides and 
revealed alleles of three sizes (Bell et aJ., 1984). ln unrelated Caucasoid populations, RFLP 
analysis showed that the frequency of short-length alleles (class I) was increased in 
patients with TIDM as compared with control populations and the long-length allele (clas 
Ill) decrease the risk of the disease (Bell et aJ. , 1984; Hitman et al., 1985). General 
population association studies have also shown an increase in the frequency of the class I 
alle1es in patients with TIDM. However, some family studies have been unable to confirm 
linkage of these alleles to the disease (reviewed in Todd, 1995; Field 2002). This marker is 
now referred to as IDDM2 (Davies et al., 1994; Hashimoto et al., 1994). 
Genes for tyrosine hydroxylase (TH) and insulin-like growth factor ll (IGF2) have been 
identified on the INS gene region (Bell et al., 1985). They may influence pro-insulin gene 
expression or may initiate the insulin resistance process. For more detailed analysis, they 
have been investigated as marker loci . They are in strong linkage disequilibrium with each 
other and have revealed in-conclusive results (Lucassen et al., 1993; Bennet et al., 1995). 
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1.2.6.1.2.2 Other putative susceptibility loci for TIDM 
Previous studies have reported an association between TIDM and several candidate genes. 
Current diabetes susceptibility loci have their provisional IDDM gene symbol as assigned 
by the Human Gene Mapping Nomenclature Committee (Field, 2002) (Table 1.1 ). 
1.2.6.2 Environmental factors 
Studies have revealed that the lifestyle contributes to the development of TIDM as well as 
genetic components. Data from monozygotic twins have shown that 20-40% of identical 
twins may be susceptible for the disease because of environmental factors (Bamett et al., 
1981 ; Kumar et al. , 1993; Leslie et al., 1994). Environmental factors could have a 
precipitating effect for those biochemical changes in indi victuals genetically susceptible to 
TIDM and its complications. Geographical factors, nutritional habits, and infectious 
diseases are termed as environmental factors, which are believed to influence the onset of 
TIDM and alter the course of the disease. 
1.2.6.2.1 Geographical factors 
The incidence rate of TIDM varies between countries. When individuals migrate from a 
country with a low frequency to a country with a high frequency they become more 
susceptible to the disease (DERIG, 1988; Patrick et al ., 1989). The great majority of 
patients with TIDM are seen in Europe and North America (Onkamo et al. , 1999). 
Southern Europe regions had generally higher rates (Green et al., 1992). More information 
concerning the geographical variance has been mentioned in the epidemiology of TIDM 
(1 .2.2). 
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IDDM1 
IDDM2 
IDDM3 
IDDM4 
IDDMS 
IDDM6 
IDDM7 
IDDM8 
IDDM9 
IDDM 10 
IDDM 12 
IDDM 13 
Unnamed 
Unnamed 
Gene map 
6p21.3 
11p15.5 
15q26 
1lql3 
6q25 
18q21 
2q31 
6q27 
3q21-q25 
10p11 -q 11 
2q33 
2q35 
12q14-15 
7p21 
Table 1.1: Genetic susceptibility loci to TIDM 
Introduction 
Reference 
Platz et al ., 1981 ; Wolf et al., 
1983 
Bell et al., 1984; 
Hitman et al., 1985 
Field et al., 1994 
Hashimoto et al., 1994 
Davies et al., 1994; 
Delepine et al., 1997 
Merriman et al. , 1996 
Davies et al., 1994 
Delepine et al., 1997 
Todd, 1995 
Reed et al., 1997 
Kukreja et al. , 1999 
Field, 2002 
Jahromi et al ., 2000 a 
J ahromi et al., 2000 b 
The table presents some genetic factors that contribute to the development of TIDM as 
identified by the Human Gene Mapping Nomenclature Committee. The table was modified 
from the original table (Field, 2002) . 
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1.2.6.2.2 Dietary agents 
Studies have shown that nutritional elements could affect the course of TIDM. Feeding 
babies with cows' milk and cessation of breast-feeding have been associated with TIDM. 
With the help of DERIG-supplied diabetes registries, Dahl-Jorgensen et al in 1991 found a 
significant positive correlation with TIDM incidence rate in children 0-14 years of age and 
fluid cow's milk consumption in 12 countries including UK, Denmark, Sweden, Finland 
and USA (Dahl-Jorgensen et al. , 1991). There was an increased incidence of antibodies to 
several cows' milk proteins. Some of these proteins may have a similar molecular structure 
to ICA (Schrezenmeir et al. , 2000). Interestingly, an unusually high incidence of TIDM in 
boys born in October in Iceland has been linked to the high nitrosamine content of a 
smoked mutton, which is traditionally consumed at Christmas (Helgason et al., 1981 ). 
1.2.6.2.3 Infectious diseases 
Viral infections may also act as initiators of the immune-mediated destruction of the 
pancreatic fJ cell in genetically susceptible individuals. Epidemiological reports have 
shown that there was a seasonal peak in the incidence of acute TIDM in autumn and viral 
infection preceding the onset of the disease (Von Herrath et al., 1998; Karvonen et al. , 
2000; Yoon et al. , 2001 ). Mumps, rubella, measles, chickenpox and Coxsackie B viruses 
induce an immune-inflammatory response that may play a role in fJ cell destruction 
(Parkkonon et al., 1992; Yon Herrath et al. , 1998; Yoon et al. , 1999, 2001 ). Animal studies 
have shown that antibodies to viral proteins might cross-react with islet cells (Hy6ty et al., 
1995, Yoon et al. , 1999). Gestational infection (congenital rubella syndrome) is a major 
risk factor for the development of TIDM due to persistent virus infection (Noorchashm et 
al. , 1997). 
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Currently, it is suggested that rubella vaccine could prevent a small proportion of TIDM, 
which is due to congenital rubella infection (Rewers et al., 1997). 
1.2.6.2.4 Other factors 
Several reports have shown that the incidence of TlDM varies according to weather and 
temperature with a peak incidence in autumn and winter (DERlG, 1990). There are many 
other environmental factors, which might play an important role in the pathogenesis of the 
disease such as hygiene and toxins. Further, reports from different countries have 
demonstrated that the incidence of TlDM is related to the economic status. The disease is 
positively associated in the richest countries such as USA, Germany, and among wealthy 
Jewish people suggesting that stressful life styles might contribute to the development of 
TIDM (DERlG, 1988; 1990). 
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1.3 Diabetic vascular complications 
Diabetes is the leading cause of blindness, heart disease, end stage renal disease (ESRD) 
and debilitating neuropathies (DCCT, 1993; UKPDS, 2000). The endothelium is a major 
target of damage in susceptible tissues and leads to macro and micro vascular diabetic 
abnormalities (Calles-Escandon et al., 2001 ). 
Macro-vascular diseases refer to atherosclerotic changes due to deposition of low-density 
lipoprotein (LDL) to vascular smooth muscle cells (VSMC). These types of complications 
are more common in TIIDM. The association of TIIDM with altered lipid metabolism, 
obesity and hypertension would accelerate the development of myocardial infarction and 
stroke (UKPDS 34, 1998; Donnelly, 2000; Calles-Escandon et al., 2001). Hyperglycaemia 
and insulin resistance are implicated in the pathogenesis of late diabetic vascular 
complications in TIDM and TllDM (UKPDS 33, 1998). 
The natural history of diabetic microvascular complications has a multistage course and 
has an inter-individual variation, which reflects the difference in the underlying 
pathogenic, genetic and environmental aetiologies. Diabetic microvascular diseases may 
require I 0-20 years to develop in patients with TlDM (DCCT, 1993; NlH, 1994; 2002) 
while they may develop within 9 years of diagnosis in patients with TIIDM or be present at 
the time of diagnosis (UKPDS 35, 2000). In general, the intensity and the progression of 
diabetic vascular complications may depend on the duration of the disease, the degree of 
hyperglycaemia, age at onset of the disease, gender and family history (DCCT, 1993; 
UKPDS 33, 34, 1998). 
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1.3.1 Patho-physiology of late diabetic microvascular complications 
Microcirculation processes are responsible for the exchange of metabolites between blood 
and tissues. The exchange processes act via fine capillaries of arterioles and venules that 
have less smooth muscle and they are extensively innervated by sympathetic nerve fibres. 
These critical processes are regulated by the local concentration of metabolites (Pocock 
and Richards, 1999). 
Endothelium is the internal lumen of all vessels and the physical barrier between blood and 
VSMC. In normal conditions, Endothelial cells (EC) exert their action on both blood cells 
and VSMC to maintain the vascular homeostasis through the action of a complicated 
system of chemical mediators that include nitric oxide (NO) and endothelin (ET) (Anrather 
et al., 1997). The EC play a key role in the pathological mechanisms including 
inflammatory responses and controlling the trafficking of immuno-components. 
The mechanisms of diabetes-induced endothelial abnormalities are not clear. During the 
course of diabetes, chronic hyperglycaemia and its metabolic consequences are highly 
expressed in endothelial and mesangial cells (Derubertis et al., 1994). These biochemical 
anomalies increase the vascular permeability and abnormal blood tlow, which retlects 
vasoconstriction (Calles-Escandon et al., 200 I). However, chronic diabetic microvascular 
complications are associated with alterations in the capillary basement membrane 
thickness, permeability, and variances in blood flow regulation within the retina, renal 
glomeruli, and nerves (Sheetz et al., 2002). 
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EC activation is associated with transcriptional induction of ET-I, E-selectin, vascular cell 
adhesion molecules (V CAM-I), intracellular adhesion molecules (ICAM-1), cytokines 
(Guha et al., 2000) and other proinflarnmatory genes. All of these factors are up regulated 
by NFKB, which plays a pivotal role in inflammation in different types of cells (Pieper et 
al., 1997; Quehenberger, 2000). Furthermore, endothelial dysfunction is associated with a 
variable degree of insulin resistance in patients with TfDM since hyperglycaemia can 
induce insulin resistance (Vuorinen-Markkola et al., 1992; Yib et al., 1993). 
Polyol pathway hyperactivity, oxidative stress, increased advanced glycated end-proteins 
(AGEs), and activation of PKC isoforms are implicated in the pathogenesis of diabetic-
induced endothelial dysfunction and the development of diabetic complications (King et 
al., 1996; Nishikawa et al., 2000a; Brown lee 200 I; Raptis et al., 2001; Way et a! 2001 ). 
1.3.1.1 Polyol pathway 
Under normal conditions, the polyol pathway plays a minor role in glucose metabolism 
(Marks et al., 1996; Yabe-Nishimura, 1998). However, in diabetes, hyperglcemia elevates 
polyol pathway activity (Nishikawa et al., 2000a; Brown lee 200 I). The rate-limiting step 
of the polyol pathway is the reduction of glucose to sorbitol by aldose reductase (ALR2) 
with the reduced form nicotinamide adenine dinucleotide phosphate (NADPH) as a 
cofactor. Sorbitol is one of the organic osmolytes that balance the osmotic pressure in the 
body. Sorbitol accumulation may play a key role in the pathogenesis of diabetic 
complications (Yabe-Nishimura. 1998). 
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In the polyol pathway, sorbitol is subsequently converted to fructose by sorbitol 
dehydrogenase (SORD), which is the second regulating enzyme (Figure 1.2). This reaction 
is catalysed by nicotinamide adenine dinucleotide (NAD+). The polyol pathway flux 
activates ALR2 with overflow of the sorbitol, redox imbalance, pseudohypoxia, ROS, and 
hyperosmolality (HO). Such metabolic imbalances provoke the early tissue damage in the 
target organs, such as lens, retina, peripheral nerves, and renal glomeulus (Williamson et 
al., 1993; Rossing 1998). 
Recently it has become evident that polyol pathway hyperactivity is a major contributor to 
the pathogenesis of vascular diseases in diabetes through redox imbalance and oxidative 
stress (Williamson et al., 1993; Obrosova et al., 1999 Nishikawa et al., 2000a; 2000b; 
Brownlee 2001). Previous studies have yielded that the inhibition of polyol pathway may 
reduce the development of late diabetic microvascular complications (Obrosova et al., 
2001; Okayama et al., 2002). 
1.3.1.2 Oxidative stress 
Oxidative stress occurs when redox homeostasis within the cell is altered. Normally, ROS 
are formed continuously in the body due to many sources of stress including metabolism, 
exercise, growth, aging and repair. ROS are in equilibrium with antioxidants and HSPs 
(Jacquier-Sarlin et al., 1996; Fehrenbach, 2001 ). Antioxidants include superoxide 
dismutase. catalase, glutathione peroxidase, and methionine reductase. ROS includes free 
oxygen radical (0.), superoxide (02), hydroxyl radical (-OH), NO, and hydrogen peroxide 
(H20 2). Oxidative destruction of tissues has been linked to many diseases such as arthritis, 
hypertension, cancer, tuberculosis and diabetes (Telci et al., 2000). 
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Figure 1.2: Patho-physiology of late diabetic microvascular complications 
Hperglycemia-activated polyol pathway and its metabolic consequences. AGEs and redox-
imbalance activate signal transduction pathways and transcription factors . The subsequent 
activation of cytokines and adhesion molecules contribute to the development of the late 
diabetic microvascular complications. HG=hyperglycaemia, ALR2= aldose reductase, 
SORD= Sorbitol dehyrogenase, NADPH= reduced form nicotinamide adenine dinucleotide 
phosphate, NADP+=nicotinamide adenine dinucleotide phosphate, NAD+= nicotinamide 
adenine dinucleotide, NADH= reduced form nicotinamide adenine dinucleotide. PKC= 
protein kinase C, MAPK= mitogen activated protein kinases. ICAM= intracellular 
adhesion molecules. VCAM= vascular cell adhesion molecules. ET -1 = endothelin-1 , 
VEGF= vascular endothelial growth factor. 
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The chronic hyperglycaemia activated polyol pathway is the main source of ROS in 
addition to glucose autoxidation, AGEs, and decreased antioxidants (Ceriello et al, 2000; 
Nishikawa et al., 2000a; b). Generally, ROS may lead to apoptosis and necrosis through 
DNA damage (Soulis-Liporota et al., 1995; Mohamed et al., 1999; Fehrenbach et al., 
2001). Oxidative stress may be responsible for vascular abnormalities and hypertension 
through the deformation of red blood cells, osmotic fragility, coagulation and delayed 
replication of the endothelium cells (Nishikawa et al., 2000a). Additionally, ROS leads to 
endothelial damage and impaired production of endothelium derived relaxation factor, 
which is commonly known as NO and required to relax arterial smooth muscle. Decreased 
NO level has been linked to hypertension. ROS are implicated in several metabolic 
pathways and may function as intracellular messengers that modulate signalling pathways 
leading to the activation of PKC, MAPK and a number of transcription factors, including 
the NFK:B and activator protein-( (AP-1) (Jacquier-Sarlin et al., 1996; Mohamed et al., 
1999). ROS control the inducible expression of a number of genes involved in cell growth, 
differentiation, inflammation and immune responses. 
Studies have suggested that oxidative stress contributes to the development of the diabetic 
complications through the regulation of the redox-sensetive transcription factor NFKB 
(Mohamed et al. 1999) and heat shock proteins (Yabunaka et al., 1995; Johannesen et al., 
2001). 
· 1.3.1.3 Advanced glycated end products (AGEs) 
The reaction between glucose and pnmary amino groups of proteins produces AGEs. 
Hyperglycaemia-induced intra and extra cellular non-enzymatic AGEs are chemically 
irreversible and recognised by specific cell surface receptors (RAGE) (Hudson et al., 
2001). AGEs damage the target cells through different mechanisms: I) they may alter the 
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structure and functions of intracellular and extracellular proteins (Brown lee, 200 I); 2) 
AGEs are angiogenic factors and may contribute to the development of diabetic angiopathy 
by promoting monocyte migration, production of cytokines and growth factors (Soulis-
Liparota et al., 1995; Morigi 1998; Friedman 1999; Yamagishi et al., 2002); 3) AGEs can 
be formed on DNA and may cause mutations and alter the genetic functions (Nishikawa et 
al., 2000a); 4) AGEs formation is accompanied by oxidative stress and represents a major 
source for ROS and subsequent activation of NFK:B (Bierhaus et al., 1997; Mohamed et al., 
1999) and MAPK p38 (Hattori et al., 2002). Studies have detected the role of AGEs in the 
pathogenesis of diabetic complication and shown that AGEs level correlates with duration 
of diabetes and severity of complications, especially nephropathy (Doria, 1998; Ceriello et 
al., 1999). Current data have shown that AGEs inhibitors inhibited a broad range of 
diabetic complications (Polak et al., 1997; Brownlee 2001). 
1.3.1.4 Signal transduction pathways 
Extra-cellular signal stimulates cell receptors. The signal transduction pathways transfer 
signals across the cytoplasm to the nucleus. This mechanism is regulated by a group of 
protein kinases and phosphatases. Serine/threonine and tyrosine are specific kinases, which 
initiate the appropriate transcriptional response (Considine et al., 1993; Keenan et al., 
1997; Greenham et al., 1998; Murphy et al., 1998; Ceolotto et al., 1999). 
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1.3.1.4.1 Protein kinase C 
PKC is regulated by calcium, phospholipase C, and diacylglycerol (DAG) (Derubertis et 
al., 1994) and is classified into three main types according to its structures and 
physiological role. Conventional PKC (cPKC) are Ca2+ and phospholipase-dependent 
protein kinases. Novel PKC (nPKC) and atypical PKC (aPKC) are Ca2+ and phospholipid-
independent protein kinases (Ceolotto et al., 1999). The PKC system consists of 9 
1soenzymes, whose activity varies in different tissues. PKC-P isoform is present in 
pancreatic islet cells, monocytes, and many vascular tissues including retina, renal 
(Derubertis et al., 1994) and neural tissues (Way et al., 2001). 
In diabetes, hyperglycaemia directly induces PKC activation (DAG-PKC pathway) through 
the glycolytic pathway and increased levels of intracellular glyceraldhyde-3-phosphate. 
Also, PKC can indirectly be activated by ROS and AGE (Derubertis et al., 1994; Haneda et 
al., 1997; Koya et al., 1998, Ceolotto et al., 1999; Tomlinson, 1999; Igarashi, et al., 1999). 
Once PKC is activated, it induces a number of biochemical events that have a devastating 
effect on EC and VSMC (Aiello et al., 1997; Koya et al., 1998; Igarashi et al., 1999). In 
addition, PKC activation can also impact other signalling pathways such as those using 
MAPKs and nuclear transcription factors including the proinflammatory NFKB (Pieper et 
al., 1997; Tomlinson, 1999). Reduced PKC activity has been linked to reduced nerve 
conduction and Na+-K+-ATPase activity in neural tissues (Derubertis et al., 1994) while 
increased PKC activity have been observed in glomeruli, retinae, aorta and heart 
(Derubertis et al., 1994; King et al., 1996; Ishii et al., 1998). In vitro and in vivo studies 
have shown that specific PKC-P isoform inhibitors can prevent the vascular dysfunction 
(Ishii et al., 1998; Murphy et al., 1998; Ceolotto et al., 1999; Park et al., 2000; Way et al., 
2001; Frank, 2002). Inhibition of PKC-P can block hyperglycaemia -induced NFK:B 
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activity, suggesting that PKC induces its devastating effects in diabetes through NFKB 
activation (Yerneni et al., 1999). 
1.3.1.4.2 Mitogen activated protein k.inases 
The MAPKs consist of three main groups: extra-cellular signal regulated kinases (ERK), 
C-Junction N-terminal kinases (JNK) and p38. Each of these has many groups. ERKs are 
growth factor signalling inducers through tyrosine-kinase receptors leading to cell 
proliferation and differentiation. JNK are stress-activated protein kinases (SAPK), which 
are triggered by cytokines and environmental stimuli and implicated in cellular responses 
(Tomlinson, 1999). Studies have suggested that MAPKs have an important role in the 
pathogenesis of diabetic complications (Haneda et al., 1997; Tomlinson 1999; Igarashi et 
al., 1999). MAPKs have direct downstream effect on HSPs (Haire et al., 1988) and NFKB 
(Schulze- Osthoff et al., 1997). 
1.3.2 Types of microvascular diabetic complications 
1.3.2.1 Diabetic nephropathy 
Diabetic nephropathy (DN) is a microvascular complication of diabetes marked by 
albuminuria and a deteriorating course from normal renal function to ESRD (Figure 1.3). 
More than 30-40 % of patients with TIDM develop DN after 25 years of the diagnosis of 
the disease, the peak incidence of DN is at 15-16 years of diabetes duration then it declines 
rapidly (Kofoed-Enevoldsen et al.. 1987). DN is the most common cause of ESRD in the 
Western world (Rossing 1998). 
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1- Normal Kidney 
2- Diabetic Kidney 
3- ESRD 
Figure 1.3: Gross anatomy of kidney during the course of diabetes. 
The pictures show the deteriorating course from normal renal function to end stage renal 
disease (ESRD). Picture 1 shows a normal healthy kidney, diabetic kidneys are shown in 
picture 2. Small sized atrophied kidneys in the ESRD as shown in picture 
3(www.nephron.com). 
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ON develops in 5 stages (lbrahim et al.; 1999): 1) Elevated glomerular filtration rate 
(GFR) by 40% and begins within 0-2 years of disease onset. 2) Increased extra cellular 
matrix (ECM) and thickening of the basement membrane starts from 2-15 years of disease 
onset and is clinically silent. This stage is the major histological characteristic of ON 
(Figure 1.4). The severity of mesangial expansion correlates with the loss of the renal 
function (Schwartz et al., 1998; Osterby et al., 2002). 3) Microalburninuria (MA), an 
established risk factor for renal disease progression in TlOM and its presence is the earliest 
clinical sign of DN. MA occurs after 10-15 years of disease. ON is suspected when the 
urinary albumin excretion rate (UAER) is 20-200).1g/min. To determine microalbuminuria, 
2 out of 3 samples collected over a 6-month period should show abnormal UAER, which is 
<20 ).lg/min in normal. 4) Overt nephropathy (onset 15-20 years), the UAER is more than 
200mg /24h for three frequent samples. 5) ESRO develops after 20-25 years of disease 
with a loss of kidney function of up to 3% per month (Bilous, 1997b; lbrahim et al.; 1999). 
Patients with DN are at high risk for macrovascular diseases and always accompanied with 
diabetic retinopathy (OR) (Bilous, 1997 a and 1997b; Schwartz et al., 1998). In patients 
with TIDM, there is a familial clustering of diabetic renal disease and development of 
cardiovascular diseases at younger ages (Raptis et al., 2001). Studies have shown that the 
progression of DN correlates with arterial hypertension, smoking, the family history of 
nephropathy, the duration, the control of the disease and age at onset (Rossing, 1998; 
lbrahim et al.; 1999). 
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(A) (B) 
Figure 1.4: Histo-pathology of diabetic nephropathy 
The figure shows pictures by light microscopy of renal tissues with acid-Schiff stain. (A): 
mesangial hypercellularity with a diffuse expansion, small nodule formation, and thickened 
glomerular basement membrane (original magnification X200). 
(B): established nephropathy, illustrated with large nodules of matrix within mesangial 
areas with lesser cellularity and apparent thickness in the glomerular basement membrane, 
original magnification X400). The arrows point the glomerular basement membrane 
thickening. N = nodule. Pictures were adopted from atlas of renal pathology No.5 (Fogo, 
1999). 
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1.3.2.2 Diabetic retinopathy (DR) 
OR is the progresstve damage to the retina and its blood supply in diabetes. The 
abnormalities of the capillary bed of the retina in diabetes include microaneurysms, 
exudates, and proliferative (angiogenesis) changes. OR is the most common cause of 
impaired vision, cataract and blindness in people aged 30-69 years (Hamman, 1997; 
DCCT, 2000). The incidence of OR correlates with duration of diabetes. OR develops in 
17% of patients with TIDM of less than 5 years duration and 97.5% in those who had 
diabetes for 15 or more years (DCCT, 2000). At the beginning, most patients do not notice 
any changes in their vision, but as OR progresses, macular oedema and a few 
microaneurysms will develop and lead to blurring vision (Figure 1.5) (Freund, 1997). In the 
advanced (proliferative) stage, retina stimulates the growth of new blood vessels (Figure 
1.6). The new vessels can cause vitreous hemorrhage, retinal detachment, and uncontrolled 
glaucoma (Freund, 1997). The pathological changes are clinically diagnosed by 
ophthalmoscope, wide angle camera (45) and stereofundus camera (30") (Hamman, 1997). 
1.3.2.3 Diabetic neuropathy 
Diabetic neuropathies (DNU) are a family of nerve disorders caused by diabetes. The 
damage may involve small fibres, the large fibres or both. People with diabetes can 
develop nerve problems at any time. The prevalence rate of DNU is 7.5% to 50% in 
patients who had diabetes for 25 years (Hamman, 1997; NlH, 2002). 
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(A) (B) 
Figure 1.5: Diabetic retinopathy 
Ophthalmoscopic examination. Figure A is a photograph of normal retina. Figure B shows 
a macular oedema (1) and angiogenesis (2) (Freund, 1997). 
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Figure 1.6: Proliferative diabetic retinopathy 
Ophthalmoscopic examination. The picture demonstrates proliferative OR 
(neovascularization) (1) and vitreous hemorrhage (2) (Freund, 1997). 
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Chronic sensory DNU is the most common type in diabetes and occurs in up to 66% of all 
diabetics. It is symmetrical and affects the distal sensory nerves and may involve small and 
large nerve fibres of the arms and legs. It causes either pain or loss of feeling in the toes, 
feet, legs, hands, and arms (Figure 1.7). 
Motor DNU is symmetrical or asymmetrical and causes muscle weakness in hips or thighs 
with or without pain (Sima et al., 1997). Autonomic DNU causes changes in digestion, 
bowel and bladder function in addition to sexual dysfunction. It can also affect the nerves 
that serve the heart and control blood pressure. The symptoms include diarrhoea or 
constipation, dizziness or faintness due to a drop in postural blood pressure. Focal 
neuropathy results in the sudden weakness of one nerve, or a group of nerves, causing 
muscle weakness or pain (Edmonds et al., 1997). 
Diabetic foot can be classified into sensory and motor neuropathy (Huntley, 1995). In 
sensory DNU, the patient is unable to feel the trauma due to loss pain sensation that 
initiates the tissue damage leading to callus and ulceration (Figure 1.8). Repetitive trauma, 
persistent hyperemia and chronic inflammation lead to progressive loss of bone strength. 
X-rays can show the bone and joint destruction. Consequently, many patients eventually 
progress to amputation following infection or severe deformity (Huntley, 1995; Sima et al., 
1997). In motor neuropathy, there is a weakness of foot muscles results in dorsiflexion and 
the toes drown upwards. 
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Figure 1.7: Peripheral neuropathy 
The shadow parts present the distribution of chronic sensory neuropathy in a symmetrical 
pattern. The picture is adopted from Nlli Publication No. 02-3185, May 2002 (Nlli, 2002). 
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Figure 1.8: Charcot foot 
The left side is a picture for the diabetic sensory neuropathy of the foot, which is 
oedematous and swollen (1). The right side picture shows callus (2) and ulcer (3) in the 
affected foot (Huntley 1995). 
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The DNU is diagnosed on the basis of signs and symptoms. A comprehensive foot 
examination assesses skin, circulation, and sensation. Physical examination for muscle 
strength, reflexes, and sensitivity to position, vibration and temperature gives a clear 
neurologic assessment. Electromyography and quantitative sensory testing show the 
response activity of the muscles to stimuli and ultrasound produces an image of internal 
organs (Edmond et al., 1997, Sima et al., 1997). 
1.3.3 Susceptibility factors to diabetic microvascular complications 
1.3.3.1 Genetics susceptibility 
Microvascular diseases in TIDM have different patho-physiological background. They are 
multistage diseases in which several genetic and environmental factors promote the 
phenotype of each stage. The fact that some diabetic subjects suffer from or are protected 
against diabetic complications suggests a strong role of genetic factors. Family studies can 
confirm the role of genetic variation of the candidate genes that influence the risk of micro-
vascular diseases in TIDM. Microvascular complications more frequently occur in first-
degree relatives (parents, siblings, or offspring) of patients with diabetes with a history of 
the disease (DCCT, 1997). Studies have shown that a parental history of diabetes or 
cardiovascular disease is significantly associated with the presence of microvascular 
complications (Earle et al., 1992). Siblings of patients with TfDM with DN have shown a 
higher risk to develop DN (Seaquist et al., 1989). A family study on Pima Indian families 
with TIIDM has determined that proteinuria developed in 45.9% of the offspring if both 
parents had diabetes while 23% if only one parent was with DN and 14% if both parents 
had no renal disease (Pettitt et al., 1990). 
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Genomic screening of the factors involved in glucose metabolism, vascular homeostasis 
and growth factors may facilitate the identification of the individuals at risk for developing 
microvascular complications in patients with TIDM. Many candidate genes conferring 
susceptibility to microvascular complications in diabetes, some of the putative 
susceptibility loci are listed in Table 1.2. 
1.3.3.1.1 Aldose reductase 
The action of this enzyme was described in the polyol pathway (1.3.1.1). Studies have 
suggested that ALR2 activation contributes to the development of chronic diabetic 
microvascular complications (Yabe-Nishimura, 1998; Ramana et al., 2002). Some studies 
have shown that ALR2 expression was significantly elevated in patients with diabetic 
microvascular complications (Shah et al., 1998; Hodgkinson et al., 2001 b). 
The ALR2 gene is localised to human chromosome 7q35 (Graham et al., 1991 ). The (CA) 
dinucleotide repeats (5' ALR2) located 2.1 kb upstream of the transcription site of the 
ALR2 gene was first shown an association with OR and ON in Chinese patients with 
TIIOM (Ko et al., 1995). The risk allele (Z-2) of this polymorphism was found in 
association with ON and ONU in Caucasoid patients with TIDM (Heesom et al., 1997). 
Another hi-allelic polymorphism (C -I 06 T) at the promoter region of the ALR2 gene may 
have a functional role on the gene expression (Kao et al., 1999). The C-106 and the Z-2 
alleles are strongly associated with OR in patients with TlOM (Kao et al., 1999; Oemaine 
et al., 2000). However, the T -I 06 allele together with the Z-2 5' ALR2 were associated 
with ON in patients with TIDM (Moczulski et al., 2000). The association between diabetic 
complications and two polymorphisms in the promoter region of the ALR2 gene implicates 
the polyol pathway in the development of microvascular diseases in TIDM. 
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7q35 (AKRlBl) 
1q42-43 (AO 
17q23 (ACE) 
16p11.2 (PRKCB1) 
1p35 (GLUT-1) 
7q21.3 (PON 1) 
7q21.3 (PON 2) 
6p12 (VEGF) 
19q13.2 (ApoE) 
6p21.3 (RAGE) 
Complication 
TIDM-DN, 
DNU and 
DR 
TIIDM-DN 
TIDM-DN 
TIDM-DN 
TIIDM-DN 
TIDM-DN 
TirDM-DN 
TIDM-DN 
TIDM-DR 
TlDM-DN 
TliDM-DR 
TlDM-DN 
TIDM-DN 
TIIDM-DR 
TIDM-DN 
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Reference 
Moczulski et al., 2000 
Heesom et al., 1997 
Kao et al., 1999; Demaine 
et al., 2000 
Ko et al., 1995 
Marre et al., 1997 
Rigat et al., 1990; Marre et 
al., 1994; Parving et al., 
1996; Fujisawa et al., 1998; 
Solini et al., 2002 
Araki et al., 2000a 
Liu et al., 1999 
Hodgkinson et al., 200Ia 
Kao et al., 2002 
Kao et al., 2002 
Awata et al., 2002 
Yang et al., 2003 
Arakietal.,2000b 
Hudson et al., 2001 
Poirier et al., 2001 
Table 1.2: Candidate genetic loci for susceptibility to diabetic microvascular 
complications 
The table presents some genetic factors that contribute to susceptibility to microvascular 
complications in diabetes. AKR 1 B 1 = aldo-keto reductase family I, member B 1. AI= 
angiotensin I. ACE= angiotensin !-converting enzyme. PRKCB I= protein kinase C, beta-
!. GLUT -1 = glucose transport. PON I & 2= Paraoxonase I & 2. VEGF= Vascular 
endothelial growth factor. ApoE= apolipoprotein E. RAGE= Receptor of the advanced 
glycated end products. q= long arm and p= short arm of the chromosomes. 
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However, other studies have looked at 5' ALR2 microsatellite in diabetic complications and 
found no association between any of the Z-2 allele and ON or OR and suggested that 5'-
ALR2 microsatellite polymorphism is a weak marker for susceptibility to diabetic 
complications in TIDM (Dyer et al., 1999; Maeda et al., 1999; Ng et al., 2001; Fanelli et 
al., 2002). 
1.3.3.1.2 Renin-angiotensin system 
The renin-angiotensin system is important in the control of hemodynamic status. This 
system consists of four components: renin, angiotensinogen, angiotensin-converting 
enzyme (ACE), and the angiotensin receptor. Renin is a proteolytic enzyme that is secreted 
by the kidneys in response to a fall in the sodium concentration. Renin converts 
angiotensinogen (inactive peptide in the blood) to angiotensin I (Al), which in turn is 
converted to angiotensin II (A Il) by ACE. The later stimulates the secretion of aldosterone 
from the adrenal cortex and causes vasoconstriction. The system contributes to the 
development of hypertension and ON (Pocock and Richards, 1999). 
The ACE can modulate the risk of ON due to hyperglycaemia through its generating effect 
for A ll, which increases the intraglomerular hydraulic pressure leading to 
glomerulosclerosis and nephropathy. ACE and angiotensinogen levels may be related to 
polymorphisms within the genes (Doria, 1998, Rossing 1998). The VD polymorphism at 
intron 16 of the ACE gene (17q23), first described by Rigat et al. and was associated with 
differences in the serum levels of ACE (Rigat et al., 1990). This polymorphism has been 
extensively proposed as a genetic marker for ON. Several studies have proposed that the D 
allele is an independent risk factor for the progression of ON in TIDM (Marre et al., 1994; 
Parving et al., 1996) and TIIDM (Fujisawa et al., 1998; Solini et al., 2002). However, 
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several studies have found no association between the 0 allele and ON in either TIDM or 
TIIDM (Tarnow et al 2000; Fujisawa et al., 1995). GENEDlAB study group in France and 
Belgium have revealed that the T235 allele of the angiotensinogen gene has been 
associated with renal function impairment in patients with TIDM (Marre et al., 1997). 
1.3.3.1.3 Glucose transporter 
Glucose transporter-) (GLUT I) facilitates cellular glucose uptake. It is an important 
modulator for cellular abnormalities (Marks et al., 1996). GLUTl might contribute to the 
development of renal complications through hyperglycaemia -induced extra-cellular matrix 
production in glomerular mesangial cells (Wahab et al., 1996). The polymorphic site (Xba-
1) has been identified in the second intron of the GLUT I gene. The RFLP analysis revealed 
that the 1.1 allele is associated with ON in Chinese patients with TIIOM (Liu et al., 1999) 
and in Caucasoid TIDM patients with ON (Hodgkinson et al., 200la). 
1.3.3.1.4 Vascular endothelial growth factor 
Vascular endothelial growth factor (YEGF) is a major mediator of vascular permeability 
and angiogenesis. The YEGF is an important growth factor in the pathogenesis of OR and 
intra-ocular neovascularization (Aiello et al., 1995). Studies have shown that YEGF may 
contribute to the development of diabetic complications in either TIDM or TIIOM through 
activation of PKC (Aiello et al., 1997). Several polymorphisms have been identified in the 
promoter region of the YEGF gene. In a Japanese population. a significant association was 
found between the C allele of the C ( -634) G polymorphism and OR in patients with 
Tl!DM (Awata et al., 2002). The D allele of the (1/0) polymorphism at -2549 has been 
significantly associated with ON in Caucasoid patients with TlDM (Yang et al., 2003). 
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1.3.3.2 Environmental risk factors to diabetic microvascular complications 
1.3.3.2.1 Hyperglycaemia 
The risk of developing diabetic complications greatly increases with uncontrolled glucose 
levels either in TIDM or TIIDM (DCCT, 1993; 1995; UKPDS 33, 1998; Gabir et al., 
2000). Intensive insulin therapy markedly reduces the risk of microvascular complications 
(DCCT, 1993; 2000). Hyperglycaemia induces endothelial dysfunction and activation of 
inflammatory cells adhesion resulting in impairment of cellular supply with oxygen and 
nutrients in microvessels of retina, kidney, and nerves (King et al., 1996: Donnelly et al., 
2000; Calles-Escandon et al., 2001; Sheetz et al., 2002). 
In many populations, uncontrolled hyperglycaemia has been implicated in the pathogenesis 
of microvascular complications. A prospective study in the Berlin has shown that the rate 
of OR was found to increase with deteriorating glycaemic control (Danne et al., 1994). In 
Denmark, another study has determined that the overall increase in AER and the 
development of persistent rnicroalbuminuria was increased in patients with poor glycaemic 
control (Rossing et al., 2002). A study in Norway showed a decrease in motor and sensory 
nerve conduction with uncontrolled HbAic (Amthor et al., 1994). However, it is shown 
that the intensive treatment of hyperglycaemia with insulin in patients with diabetes retards 
the development of these complications (DCCT, 1993). 
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1.3.3.2.2 Duration of diabetes 
The duration of DM is an important contributor to the development of late microvascular 
complications (DCCT, 1993). Studies have shown that DR may develop shortly after 5 
years of the diagnosis of the disease. Prevalence of DR increases with increasing duration 
of the disease, since one third of patients who have diabetes for 10 years develop DR while 
up to 75% of those with duration of 20 years or over have DR (Hamman, 1997). The 
duration of diabetes may have less effect on the development of DN than on DR. The DN 
develops after 25 years of the diagnosis of the disease; the peak incidence is at 15-16 years 
of diabetes duration (Kofoed-Enevoldsen et al., 1987). There is no doubt that the duration 
of diabetes has a negative influence on peripheral nerve function (DCCT, 1993). 
1.3.3.2.3 Hypertension 
Hypertension is diagnosed when the average of diastolic blood pressure is 90 mmHg or 
greater or systolic blood pressure is 140 mmHg or greater. National Heart, Lung, and 
Blood Institutes in the NIH have shown that hypertension with diabetes together strongly 
increase the rate of morbidity and mortality (NIH, 1994). Hypertension poses more risk of 
cardio-vascular diseases to patients with diabetes, more frequently in patients with TIDM 
that have nephropathy (Rossing et al., 1996; Weidmann et al., 1997). Patients who have 
both diabetes and hypertension have more atherogenic risk factors, including dyslipidemia, 
hyperuricemia, and elevated fibrinogen. These factors increase the incidence of renal 
diseases and also contribute to the development of DR and DNU (Perin et al., 2001; NIH, 
2002). The progression of DN correlates with a rise in blood pressure that might be 
prevented by aggressive blood pressure reduction (DCCT, 1993; 2000; NIH, 1994). A 
strong family history of essential hypertension and diabetes appears to identify those 
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persons who are most likely to develop hypertension and diabetic complications. 
1.3.3.2.4 Diet 
Type of food, amount of proteins, alcohol intake, overweight, and no physical activity are 
the main factors, which contribute to the development of vascular diseases. Studies have 
shown that diet contributes to the development of diabetic complications. Protein content 
of the diet can affect glomerular filtration rate and the function of proximal tubular cells 
(Pedrini et al., 1996). Dietary intake of pre-formed AGEs reacts with proteins in the body 
to form effective AGEs, which promote the pathogenesis of vascular diseases (Brownlee, 
2001). Excessive fat may increase cholesterol and LDL, which are associated with 
hypertension and ON (Groop et al., 1996). A vegetarian diet and vitamins may be 
beneficial to delay the development of vascular diseases (Bursell et al., 1999). 
1.3.3.2.5 Smoking 
Smoking is the most important modifiable cause of premature death in general and patients 
with diabetes in particular (Rossing et al., 1996). The combination of smoking and diabetes 
accelerates the development of macrovascular and microvascular disease (UKPDS, 1991; 
NlH, 1994; ADA, 2000). Smoking affects circulation, slows down healing and accelerates 
the cell damage (Haire- Joshue et al.. 1999). Tobacco smoke contains glycotoxins, which 
can rapidly react with proteins and increase AGEs formation in blood vessels (Nicholl et 
al., 1986). Studies have shown that smoking associates with the progression of ON m 
patients with TIDM (Sawicki et al., 1994). 
68 
Introduction 
1.4 Prevention and treatment strategies of TIDM and its complications 
1.4.1 Prevention of TIDM and its complications 
To limit the progress of diabetic microvascular complications it is essential to keep blood 
glucose under control. However, DCCT have reported that good glycaemic control was 
insufficient to prevent the development of complications, strongly suggesting a role of 
genetic factors (DCCT, 1993). Individuals with a family history of TIDM should be 
screened for the disease. ICA, IAA and GAD-positive relatives of patients with TIDM are 
the first targets in clinical trials to prevent the disease (Rewers et al., 1997; Yoon et al., 
1998; 1999; 2001). It has been shown that the risk for TIDM varies from 0-1% in 
individuals with only one positive antibody to 62-100% in subjects who were positive for 
three or more antibodies (Yoon et al., 2001). 
Controlling hypertension and regular check of renal function are the preventive strategies 
to avoid vascular and renal diseases in TIDM. Blood pressure control can reduce 
microvascular disease by approximately 33% (N IH, 1994 ). The N IH urges all patients with 
diabetes to have a proper foot care and urine analysis for microalbuminuria and a dilated 
pupils eye examination at least once a year (McGill et al., 1997; NIH 2002; 1994). 
Lifestyle modifications are particularly relevant for all patients with diabetes. Weight 
management, diet, moderation of alcohol intake, increased physical activity, and cessation 
of smoking are the cornerstones of metabolic control. Weight loss can improve both 
hypertension and diabetes; it may reduce cholesterol levels and triglycerides. It has been 
suggested that weight reduction may enhance tissue sensitivity to insulin. Reduction of 
total energy intake maintains the balance of metabolic rate and avoids the risk to cardiac 
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heart diseases (DCCT, 1993; NIH, 1994). Protein intake is recommended to be 15-20% of 
a diabetic diet, this can reduces albuminuria, improve renal haemodynamics, lower the 
incidence of nephropathy and other microvascular complications in TIDM (Mann et al., 
1997). 
1.4.2 Treatment of TIDM and its complications 
1.4.2.1 Insulin therapy 
Patients at risk for the development of late microvascular complications require aggressive 
control of blood glucose levels and regular clinical examination. Insulin therapy can 
modulate the vascular tone and improve endothelial cell functions through the activation of 
NO and inhibition of PKC (Kuboki et al., 2000). Some hypoglycaemic agents prevented 
the glomerular dysfunction through prevention of the glomerular hyperfiltration, 
albuminuria, decrease ECM proteins, and reduce glomerular hyperglycaemic-induced PKC 
(lsshiki et al., 200 I). 
Statistical studies have shown that the development of diabetic microvascular 
complications can be reduced by 50-75% by intensive insulin therapy (DCCT, 1993; 2000; 
NlH, 1994; UKPDS, 1998; 2000). Studies have reported a reduction in the incidence of 
DR by 76%, 54% lower for DN, and 60% lower in DNU compared with the conventional 
insulin therapy (NlH, 1994; 2002: UKPDS, 1998; 2000). The successful improvement in 
glycaemic control was proposed with psychological support, parents' education, and 
patients self-monitoring 3-times/ day (McGill et al., 1997). However, insulin overdose 
could induce hypoglycaemia, which may lead to death (DCCT, 2000). 
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1.4.2.2 Supportive therapy 
Previous studies have shown that treatment of patients with TIDM with special classes of 
drugs may improve and limit the progress of microvascular complications. Such 
therapeutic agents include PKC-P inhibitors (Murphy et al., 1998; Meier et al., 2000; Ways 
et al., 2000), antioxidants, and vitamins (Bursell et al., 1999). It is suggested that these 
drugs could compensate the oxidant damage in the vascular system and reduce the 
devastating effects of hyperglycaemia and the other biochemical abnormalities. 
ACE inhibitors have a special interest in the treatment of diabetic complications. It is 
shown that they reduce albuminuria and progression of renal complications to a greater 
extent than other agents that lower blood pressure. It is recommended that small doses of 
ACE inhibitors can be given to protect the kidneys in patients with TIDM without lowering 
the blood pressure (DCCT, 2000). 
ARis are a new class of drugs. Most of the putative therapeutic mechanisms are dependent 
on the first half of the polyol pathway and inhibition of ALR2. ARls can attenuate the 
action of the ALR2 enzyme and reduce levels of sorbitol in several tissues including lens, 
retina, kidney, blood vessels, and peripheral nerves (Cameron et al., 1997; Mizuno, et al., 
1999). On the other side, the inhibition of the SORD enzyme in the second half of the 
polyol pathway will reduce the production of fructose, which is a very effective glycating 
agent and could contribute to the pathogenesis of diabetic complications (Cameron et al., 
1997). 
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Furthermore, a precise knowledge of the defects underlying TIDM is essential for 
designing appropriate therapeutic strategies. Gene therapy is approaching an improvement 
in the insulin expression and immuno-modulation to treat diabetes. A considerable amount 
of effort has yielded gene delivery vectors based on adenoviral and retroviral. Genetically 
engineered rodent models have created their impact on treatment of human diabetes. 
Despite the number of successes in vitro and in animal models, safety trials in humans 
have not yet been attempted (Olefsky, 2000). HSP 60 has been shown to act as auto-
antigen and initiate the autoimmune ~cell destruction (Elias et al., 1990; Birk et al., 1996). 
Studies have suggested that the DiaPep277, a laboratory-made peptide, which mimics the 
action of HSP 60 could prevent the autoimmune-destruction of~ cells (Elias et al., 1995; 
Vastag, 2002). 
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1.5 Candidate genes and possible pathways in the pathogenesis of 
TIDM and its late microvascular complications 
1.5.1 Transcription factor nuclear factor kappa B 
NFKB is an eukaryotic transcription factor that is intricately involved in mediating the 
immune-inflammatory response through a wide array of pro-inflammatory molecules 
(Baeuerle 1991; Brand et al., 2001 ). 
1.5.1.1 Molecular biology of NFKB 
The NFKB is a multicomponent protein of the Rei-family (Baeuerle et al., 1991; 1996; 
Brand et al., 2001). The classical dimer is composed of p50 and p65 (Rei A) (Ghosh et al., 
1998; Christman et al., 2000). The p50 unit is necessary for nuclear translocation and p65 
contributes to the transcription mechanism, both subunits of the NFKB dimer bind DNA 
(Lin et al., 1995; Anrather et al., 1997). The inactive forms of the p50/p65 dimer are bound 
to the inhibitor kappa B (IKB) and sequestered in the cytoplasm. Phosphorylation of IKB 
leads to the breakdown of IKBINFKB complexes. Degraded IKB unmasks a nuclear 
localisation sequence that allows translocation of the NFKB dimer into the nucleus. 
Activated NFKB binds to a cognate DNA sequence (5'- GGG GAC TTT CC) on the target 
genes and activates the transcription mechanism (Hunter et al., 1992; Baeuerle et al., 
1998). Figure 1.9 illustrates the activation pathway of NFKB and transcription mechanism. 
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Cellulur membrane 
Figure 1.9: Illustration of the transcription factors activation 
Inactive forms of the transcription factors NFKB and HSF-1 are in the cytoplasm. On 
phosphorylation (p), NFKB dimer (p50/p65) dissociates from the complex with IKB and 
HSF-1 monomers aggregate in a trimers form. Activated factors translocate to the nucleus 
and bind to the promoter region of the target genes to initiate the transcription mechanism. 
5' UTR= un-translated region= promoter region. 
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1.5.1.2 Pathological importance of NFICB 
NFKB activation is a redox-sensitive mechanism (Baeurele et al., 1996; Barnes et al., 
1997). [t is suggested that the role of NFKB m the pathogenesis of the inflammatory 
process is through the up-regulation of the synthesis of llcB-a (Du et al., 1999; Yamamoto 
et al., 2001 ). NFKB promotes the expression of over 150 target genes including those 
coding for cytokines such as TNF-a, IL-l~. chemokines, adhesion molecules as well as 
increased expression of HLA molecules (Taylor et al., 1998; Yamamoto et al., 200 I). [t 
has been shown that NFKB is involved in the induction of human inducible nitric oxide 
synthase (iNOS), which is over-expressed in a number of human inflammatory diseases 
(Taylor et al., 1998). NFKB is involved in the pathogenesis of many inflammatory diseases 
such as atherosclerotic diseases (Brand et al., 2001; Hamuro et al., 2002), MS and RA (Tak 
et al., 200 I), ~ cell apoptosis (Eizirik et al., 1996, 200 I a; 200 I b; Cardozo et al., 200 I). 
cancer (Y amamoto et al., 200 I ) . 
The molecular mechanisms that provoke the tissue damage in response to hyperglycaemia 
stress are still not clear. Until 1997, there had been no studies on the effect of 
hyperglycaemia on the expression of NFKB (Pieper et al., 1997). After then, several studies 
have shown that NFKB expression is increased in patients with diabetes and its 
microvascular complications (Hofmann et al., 1998; 1999, Bierhaus et al., 2001). In 
experimental models of diabetic complications, the increased expression of NFKB is found 
in retinal pericytes (Romeo et al., 2002) and VSMC (Yemeni et al., 1999) in response to 
high concentration of glucose. 
There is increasing evidence that NFKB may play an important role in accelerating the 
tissue damage caused by hyperglycaemia (Yemeni et al., 1999; Marumo et al., 2000; 
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Tanaka et al., 2000). Studies have postulated that NFKB accelerates the development of 
diabetic vascular complications through inhibition of endothelial cell migration (Hamuro et 
al., 2002). It has been shown that NFKB activity correlates with monocyte chemoatractant 
protein-1 expression (MCP-1 ), which mediate monocytes infiltration (Rovin et al., 1995). 
1.5.1.3 NFJCB is a therapeutic target 
Several studies have shown that inhibition of NFKB activity might control or cure the 
progress of inflammatory and immuno- destructive mechanisms such as cytokines-induced 
~-cell destruction (Giannoukakis et al., 2000), RA (Bondeson et al., 1999), cancer 
(Yamamoto et al., 2001). Blocking NFKB activity can also inhibit production of the 
proinflammatory molecules in intestinal epithelial cells (Jobin et al., 1998). Antioxidant 
enzymes such as Mn superoxide dismutase, catalase and glutathione peroxidase may 
attenuate NFKB-induced inflammatory effects (Christman et al., 2000). 
1.5.2 Heat shock proteins 
HSPs are a family of proteases, which are known as stress proteins, they mediate the 
degradation of damaged proteins and have apoptosis-regulatory function (Garrido et al., 
2001). HSPs are intracellular molecules and encoded by several genes. They can be 
released in pathological situations and have a range of immunoregulatory activities. For 
many years, HSPs have been regarded as cytoprotective proteins. However, studies have 
shown that stress proteins have the capacity to induce pro-inflammatory responses 
(Pockley et al., 2000). 
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1.5.2.1 Molecular biology of HSPs 
HSPs have been classified into four major families according to their molecular weights: 
HSP 90 KDa, 70 KDa, 60 KDa, and the small HSPs (Hendrick et al., 1993). They are 
constitutively expressed under normal conditions and can be markedly induced by a range 
of cellular stressors including oxidative stress (Kurucz et al., 2002), protein glycation 
(Ganea et al., 1995) and the pro-inflammatory NFKB (Feinstein et al., 1996; DeMeester et 
al., 1997 & 200 I). Heat shock factors (HSFI and 2) are specific transcription factors that 
control HSPs' expression (Goldenberg et al., 1988; Fawcett et al., 1994; Wu 1995). They 
are part of a transcriptional signalling cascade with both positive (protective HSPs) and 
negative (proinflammatory) properties. HSFI has the main transcription function for HSPs 
in vertebrates (Fawcett et al., 1994; Wu 1995). It is present as inert monomers within the 
cytoplasm. Under stressful conditions it is phosphorylated by MAPKs subfamilies, JNK 
and p38 in particular (Kim et al., 1997). Active HSF-1 is oligomerized to a trimer, which 
translocates to the nucleus and binds to a heat shock element (HSE, nGAAn) in promoters 
of different genes, HSPs in particular (Goldenberg et al., 1988; Wu, 1995; Schafer et al., 
2000; Christians et al., 2002) (Figure 1.9). 
1.5.2.2 Pathological importance of heat shock proteins 
Expression of the stress proteins has been observed as an adaptive response to oxidative 
stress in eukaryotes and prokaryotes (Jacquier-Sarlin et al., 1996). Studies have indicated 
that HSF-1 is a redox-sensitive transcription factor (Bijur et al., 1999) and it could be 
activated in response to environmental changes such as osmolality (Caruccio et al., 1997). 
HSF-DNA binding activity is regulated by HSP70 (Morimoto, 1993; Caruccio et al., 1997; 
Schett et al., 1998; Schafer et al., 2000). It has been supposed that the protective effect of 
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HSPs is through the inhibition of the prointlammatory gene expression (Feinstein et al., 
1996; Wong et al., 1997b). In vitro studies have postulated that HSPs decrease NFJCB 
nuclear translocation and activation in lung epithelium cells (Wong et al., 1997a) and 
endothelium cells (DeMeester et al., 1997). 
HSPs, particularly those of HSP60 and HSP70 families are implicated in the pathogenesis 
of autoimmune diseases (Pockley et al., 2000). Studies have shown a link between HSPs 
and the pathogenesis of multiple sclerosis (Georgopoulos, et al., 1993), systemic lupus 
(Minota et al., 1988) and acute lung injuries (Wong et al., 1997a). Furthermore, it has been 
suggested that HSPs influence the pathogenic processes of organ allograft rejection and 
vascular diseases and mediate endothelial cytotoxicity (Pockley et al., 2000). Individuals 
with borderline hypertension have shown an increase in the levels of HSP60 and HSP70 
(Pockley et al., 2000). Also, studies have shown an increase in HSP70 level in peripheral 
and renal vascular diseases (Wright et al., 2000). 
With respect to diabetes, studies have demonstrated that antibodies to HSP-65 and HSP-60 
contribute to the development of autoreactive T-cells and~ cell destruction and may play a 
role in the aetiology of TIDM (Elias et al., 1990; 1995; Birk et al., 1996). In addition, there 
is evidence that HSP70 may play a role in autoimmune destruction of ~ cell in TIDM 
(Strandell et al., 1995; Figueredo, et al., 1996). Studies have shown that HSP70 is 
increased in the mononuclear cells of patients with TIIDM (Yabunaka et al., 1995) and in 
IL-l~ and streptozotocin-induced diabetic rats (Strandell et al., 1995; Yamagishi et al., 
2001 ). Previous studies have shown that a MHC-linked HSP70 gene is linked with 
susceptibility to TIDM (Caplan et al., 1990). The RFLP investigations have revealed 
contradictory results. Pociot et al., in Denmark at 1993 have reported an association of 
Pstl-8.5 kb allele of with TIDM (Pociot et al., 1993) and that was supported by another 
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study in Taiwan (Chuang et al., 1996). In contrast, a Japanese study has demonstrated that 
the same allele was not associated with TIDM (Kawaguchi et al., 1993). 
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Conclusion 
There is no doubt that hyperglycaemia contributes to the pathogenesis of late diabetic 
microvascular complications (King et al., 1996; Nishikawa et al., 2000a; Brownlee, 200 I; 
Sheetz et al., 2002). The effect of hyperglycaemia may be mediated by activation of the 
polyol pathway and its subsequent metabolites, which are cofactors for many metabolic 
pathways. Other putative mechanisms such as PKC activation and AGEs will take part in 
the pathogenesis mechanism (Figure 1.2). 
Hyperglycaemia-activated polyol pathway induces ALR2 activation. The reduction of 
glucose to sorbitol by ALR2 has been linked to the development of diabetic vascular 
complications (Yabe-Nishimura, 1998). Recent evidence shows that ALR2 enzyme is 
upregulated by oxidative stress and is implicated in apoptotic cell death (Ramana et al., 
2003), mitogenic stimuli (Ramana et al., 2002) and vascular inflammatory diseases 
(Kasuya et al., 1999; Ruef et al., 2000). It is possible that ALR2 induce those effects 
through NFKB activation (Ramana et al., 2002 & 2003). 
The DAG-PKC pathway is activated in diabetes as a result of hyperglycaemia (King et al., 
1996). AGE and oxidative stress can enhance signalling pathways (PKC and MAPK) 
causing transcriptional changes as well as alterations in cellular survival. PKC and MAPK 
regulate many important factors such as cytokines, growth factors and NFKB, these factors 
affect vascular permeability, contractility and cellular proliferation (King et al., 1996; 
Koya and King, 1998; Ha et al., 2000). 
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Oxidative stress is the clearest example of interactions among these different pathways. 
The transcription factors NFKB and HSF-1 are upregulated by oxidative stress (Jacquier-
Sarlin et al., 1996; Mohamed et al., 1999). These factors bind to cognate DNA sequences 
on the target genes including ALR2 gene (lwata et al., 1999). It is possible that the 
increased flux of glucose through the polyol pathway provoke the tissue damage in the 
target organs through the alteration of the transcription factors-DNA binding activity, 
which may lead to an increase in the ALR2 transcription, more activation of polyol 
pathway and more production of oxidative stress. 
Intensive insulin treatment can slow the progression of diabetic microvascular 
complications (DCCT, 1993). However, it is difficult to keep the blood glucose level 
normal at all times throughout the life of patients with diabetes. Accordingly, chemical 
agents that reduce hyperglycemic injury would assist the insulin therapy. Previous studies 
have shown that the specific inhibition of the polyol pathway might limit the progress of 
microvascular diseases in chronic diabetes (Obrosova et al., 200 I; Okayama et al., 2002). 
AR!s (tolrestat, sorbinil, zopolrestat and ponelrestat) were studied to prevent diabetic 
complications and showed promising results. However, it is not clear how the AR!s work? 
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Hypothesis of this study 
This study addressed the following points: (a) Polymorphisms through the genes coding for 
proteins involved in glucose metabolism and immuno-regulatory mechanism may 
contribute to the susceptibility of TIDM and/or its late microvascular diseases. (b) The 
transcription factor-DNA binding activity is an important step in a complex program of 
transcriptional events; its importance confers to the target genes. Uncontrolled blood 
glucose level may influence the transcriptional regulation. (c) The pharmacological 
modulation of transcription factor activity represents an attractive therapeutic approach. 
Therefore, the treatment with ARts may influence the common signal transduction through 
the transcription factor- DNA binding activity. 
Aim of this study 
The aims of this study are outlined as follows: 
1- To identify genetic markers for the susceptibility to TlDM and its late 
microvascular complications. The candidate genes include the transcription factor 
NFKB gene (4q24), the HSP70 gene (14q22), the SORD gene (15q21) and the 
PKC-p gene (16pl2). 
2- To investigate the transcription factors, NFKB and HSF-1-DNA binding activity in 
response to high glucose concentration using cell lines and human PBMCs from 
patients with TIDM with and without microvascular complications. 
3- To assess the effect of aldose reductase inhibitors (ARis) on NFKB and HSF-1-
DNA binding activity in human PBMCs with and without microvascular 
complications. 
4- To study the MAPK p38 expression in relation to the NFKB and HSF-1-DNA 
binding activity. 
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Materials & Methods 
2.1 Entry criteria and subjects 
Eligible patients for this study were British Caucasoid patients. The study was restricted to 
patients with TIDM with and without microvascular complications. However, 24 patients 
with TIIDM were included at a later stage to support the studies on the role of NFKB. 
Classification was evaluated according to the clinical, physical and biochemical records. 
The subgroups of patients and normal controls (NC) were defined in previous studies 
(Heesom et al., 1997). 
The patients were classified as follows: 
-Uncomplicated diabetic controls (DC); patients who have had TIDM for at least 20 years 
but remain free of retinopathy, proteinuria, and neuropathy. 
-Nephropaths (ON); have had TIDM for at least I 0 years with persistent proteinuria (urine 
Albustix positive on at least three consecutive occasions over 12 months or three 
successive total urinary protein excretion rates more than 0.5 g/24h) in the absence of 
haematuria or infection on midstream urine samples. The presence of DN is commonly 
associated with diabetic retinopathy (DR) (Schwartz et al., 1998). 
-Retinopaths (OR); patients had retinopathy defined as more than 5 dots or blots per eye, 
hard or soft exudates, new vessels or flourescein angiographic evidence of maculopathy or 
previous laser treatment for pre-proliferative or proliferative retinopathy and maculopathy 
or vitrous haemorrhage. None of these patients had proteinuria. 
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-Neuropaths CDNU); this was defined by clinical and electro-physiology examination as 
damage to the nerve. The common symptoms and signs in this group are loss of sensation, 
hypotension (giddiness), sweating and joints problems. 
- Patients with short duration diabetes; have had diabetes for less than 10 years with or 
without complications. Patients with TIDM of short duration were included in this study as 
patients with TIDM irrespective of microvascular diseases. 
-Normal healthy controls CNC); are ethnically matched cord blood collected sequentially 
after normal obstetric delivery from the labour ward, Derriford Hospital, Plymouth, UK, 
schoolchildren aged between 5 and 16 years, and healthy adult donors with no family 
history of diabetes. 
2.2 Data collection 
Data were obtained from a diabetes register that includes patient number, sex, hospital 
number, date of birth, date of diagnosis, age at onset, diagnosis and classification. HbA 1c% 
data were re-called from the Derriford Hospital registers, Plymouth, UK. 
2.3 Statistical analysis 
Any differences in frequencies of alleles and genotypes were calculated by Statgraphics 
software (Statistical Graphics Corp. USA. 1996). The comparison between patient's 
subgroups and control subjects was made by 2x2 contingency tables using the x2 test. The 
p values were corrected for the number of comparisons made using the Bonferroni method 
(Tiwari 1985), and p values of <0.05 were considered to be significant. 
The protein assay study was performed to investigate the proteins -DNA binding activity 
in patients with diabetes mellitus compared to non-diabetic (healthy) controls. When 
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patients were classified according to the presence or absence of microvascular 
complications, some groups have a limited sample size that might reduce the power of the 
study and lead to a statistical error. To indicate a sufficient statistical power, all parameters 
have been standardized to reduce the intra-assay variation. Further, the intensity of the 
bands was expressed as means ± SE with each sample run in triplicate. The difference 
between means was calculated by student's t- test. The p value of <0.05 with 95% Cl was 
considered to be significant. Diabetic subgroups and control groups were compared by 
ANOVA to specify the difference between groups, p values of <0.05 were considered to be 
significant. Simple linear regression analysis was used to detect relationships among 
NFKB, HSF-1, age at onset and duration of the disease as the independent variables (SPSS 
version 9.0). Also, the expression of p38 was compared with the binding activity of NFKB 
and HSF-1 by using linear regression analysis. 
2.4 Hardy-Weinberg distribution 
Hardy-Weinberg equation confirms the relation between the expected alleles and 
genotypes frequencies with the observed frequencies. In case of random mating with two 
alleles, the expected frequencies of genotypes are (p2, 2pq, q2), where is the p and q are 
presenting alleles frequencies. Hardy-Weinberg equation can be extended to multiple 
alleles, frequency of any homozygote= square of allele frequency and frequency of any 
heterozygote= 2X product of allele frequencies (Hartl et al., 1999). 
2.5 Genotyping study 
2.5.1 Population 
The total number of the subjects included in the genotyping study is shown in Table 2.1. 
Clinical characteristics of patients' subgroups and NC are included with the results of 
genotyping studies. 
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Subjects NFICB 4q24 HSP70-A2 14q22 PKC-~ 16p12 
(CA) n 3' UTR (AAA TA) n 5' UTR T (+126) C 
NC Ill 94 88 
DC 38 44 34 
OR 76 55 60 
DN 48 38 39 
DNU 55 40 42 
SD 0 16 0 
TOTAL 328 287 263 
Table 2.1: Total number of the subjects included in the genotyping study 
Patients with TfDM were sub-grouped according to the presence or absence of 
microvascular complications. DC= those patients with no microvascular complications 
after 20 years duration of diabetes. DN= those patients with diabetic nephropathy. DNU = 
those patients with overt diabetic neuropathy. DR= those patients with diabetic 
retinopathy. SD= diabetes for less than 10 years with or without complications. NC= 
normal healthy controls. 
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2.5.2 Nucleon DNA Extraction 
Peripheral blood was collected into NaEDT A containing tubes. DNA was extracted using 
nucleon II DNA extraction kit following the manufacturer's instructions (Tepnel Life 
Science PLC, Manchester, UK). 3-l 0 ml of sample was transferred to a 50 ml Falcon tube. 
4x volume of nucleon A (which contains l 0 mM Tris-Hcl; 320 mM sucrose; 5 mM MgCb: 
I% Triton X-100; pH= 8.0) was added into the tube. The tube was shaken for 4 min and 
centrifuged at 1300 rpm for 4 min (MSE Mistral I 000- Sanyo, Park House Meridian East, 
Leicester, UK). The supematant was discarded and a 2 ml of nucleon B were added to the 
pellet and the tube vortexed and incubated at 37"C for I 0-15 min. The contents transferred 
to a 15 ml Falcon tube, and a 500Jll volume of 5 M Na percholate was added to the tube 
and the tube was inverted 10-15 times. A 2ml of chloroform (-20"C) were added into the 
tube, which was inverted I 0-15 times and centrifuged at 1300 rpm for 3 min. 200fll 
volume of silica suspension was added into the tube without distributing phases and the 
tube was centrifuged at 1300 rpm for 3 min. Upper aqueous phase was transferred to a 
fresh 15-ml Falcon and was spun for I min at 1300 rpm. The supematant was transferred 
to a fresh tube. 2x volumes of ethanol ( -20" C) were added into the tube and the tube was 
inverted a few times. Finally, the DNA was hooked with a glass rod and washed in 70% 
ethanol, then dissolved in I OOJ.!l double distilled water (ddH20) in an Eppendorf tube 
(Fisher Scientific, Leicestershire, UK). 
2.5.3 Optical density value of DNA 
Concentrations of DNA were determined by using spectrophotometer (Elegant technology, 
Cambridge, UK) at wavelengths of 260 nm. An optical density (OD) of l corresponds to 
approximately 50 Jlg/ml for double stranded (ds) DNA. 
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The range of DNA in samples can be calculated with the following equation: 
OD MxlOO x 50 = ng/ Jll 
1000 
N.B: 100 is the dilution factor and 50 is a fixed value for DNA quantitation. 
2.5.4 Design of primers 
Primers sets were designed as pairs of oligonucleotides to flank the interested areas (Figure 
2.1 ). They were 18-24 base pair (bp) in length and had GC contents of -50 %. All primers 
were supplied by MWG-BIOTECH UK LTD, Milton Keynes, UK. 
2.5.5 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) allows selective DNA sequences to be amplified 
using a set of two oligonucleotide primers (Figure 2.2). Extracted DNA (-I OOng) was 
subjected to PCR in a total volume of 30 111 containing a 0.5 111 of a suitably heat-stable 
DNA polymerase (2.5U) with 3 111 of I OX MgCh free PCR buffer (HT Biotechnology, 
Cambridge, UK), a 0.5 111 of DNA precursors lOOmM (dNTPs) (Amersham Pharmacia 
Biotech, Bucks UK), and the appropriate titration of 50 mM MgCh. PTC-200 
Thermocycler (MT-Research, Essex, UK) was used for all PCR. 
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(A) 
5' -
~~-..J~~AGGCAOAGCTTGCAOOAGCCOOA 
TCGCACACTOTACTCCAGCCTCGCOACAAACAAACAAACAAACAAAAAAACA 
GCOCGCTOCAOATOOAGCCAOCACCCOOGCTTCTCOCTCCCAOCCCCCTCCCO 
AAOCCCCGCCCCGCCTCCGGGTCTOOAGGAOOCTOGAAOCCCCGCCCCTCCAC 
OT -3' 
(B) 
5'-
(C) 
5'-
TCOATAAOTAATATTTATTTTATTTTATT 
~~~~===================TTT~T~A~T~TT~T~A~TTTOAOOCAOAOTCTAOC 
(D) 
5'-
OATCCTOAAOAAOOACOTTOTOATCCAA 
OATOATOACOTOOAOTGCACTATOOTOOAOAAGCGGGTOTTOGCCCTOCCT(C) 
GGGAAGCCGCCCTTCCTOACCCAGCTCCACTCCTOCTTCCAOACCATOOTAAC 
TTOTCCCATOGCCCTGGOTATTCCACCTCCAGGGCTTCACCAOGCTTTGGCCAA 
AGCTATCTTAGCAGCACCCAGCACAOAOATACCTOC 
Figure 2.1: Primers design 
(A) (CAAA) 5 repeats on the 5' UTR of the SORD gene on chromosome 15q21 
(Oenebank- L29249). (B) CA repeats on the 3' UTR of the NFKB gene on 4q24 (HOP 
working draft at UCSC Blat search). (C) the reverse strand shows the compatible 
nucleotides to AAA TA repeats, which are located at the 5' UTR of the HSP70 gene on 
14q22 at position 43133854- 43133813 (HOP working draft at UCSC Blat search). (D) 
The single nucleotide polymorphism (SNP) T (+126) Con exon 10 of the PKC-~ gene on 
16p12 (Oenebank- AC002299). The SNP (T) is in bald and (C) is the mutation nucleotide. 
CCCGGO sequence is recognised by Smal restriction enzyme (underlined). Primers are 
highlighted and the polymorphisms are underlined. 
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3' 
5' 5' 
3' 
Double strands DNA 
1 
5' 3' 
h a 5' 
3' .. 
1- Denaturation 
2- Annealing 
1 
3' 5' 5' 
3' 3' 5' 5' 
3' 3- Elongation 
Figure 2.2: Polymerase Chain Reaction 
PCR was performed with a starter step at high temperature of 94°C for 4 min followed by 
30 cycles with the following cycle profile: 1) denaturation of the double strands at 94°C for 
30 sec, 2) annealing stage at which the primers (a & b) join the main strand, the 
temperature varies according to the designed primers, 3) elongation at 72 °C for 30 sec. 
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Cycles basically involved a starter step at high temperature of 94"C for 4 min followed by 
30 cycles with the following cycle profile: denaturation at 94"C for 30 sec, annealing 
temperature, which is calculated for each primer separately for 10-45 sec, and elongation at 
72"C for 30 sec. Finally, a final elongation at 72" C for 10 min. PCR was performed with 
an annealing temperature of 70"C /45 sec, 53.5"C/30 sec, 54°C/10 sec, and 59.5"C /30 sec 
to amplify the wanted fragments of SORD, NFKB, HSP70-A2, and PKC-~ respectively. 
2.5.6 TBE buffer 
The stock solution (I Ox) of tris/borate EDT A buffer (TBE) was prepared from 108gm of 
trisma base, 55 gm of boric acid, 8gm of ethylyne-diamine-tetra-acetic acid (EDT A) 
(Sigma chemicals, Poole, UK) and made up to 1000 ml using double distilled water 
(ddH20). 
2.5.7 Agarose gel preparation and visualization of the PCR products 
The agarose gel was prepared (in different concentrations) by adding the appropriate 
amount of agarose (lnvitrogen, Paisley, UK) to I 00 ml volume of 0.5x TBE. lt was melted 
in a microwave (Super shower wave, Sanyo, Park House Meridian East, Leicester, UK). 
Agarose was mixed with I 0 !J-I of I 0 % ethidium bromide (Sigma chemicals, Poole, UK) 
for visualising the DNA bands. The PCR products were mixed with 1.5 !J-I of tracking dye 
and loaded into the gel along side a molecular weight ladder (lnvitrogen, Paisley, UK) and 
the gel was running in 0.5x TBE buffer at 150-200 v for 30 min. The gel was examined 
and visualised under the ultraviolet light (UV). 
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2.5.8 Restriction fragment length polymorphism (RFLP) genotyping 
This method was used to genotype the PKC-P gene according to the T ( + 126) C on ex on 
I 0. This is a single nucleotide polymorphism (SNP), at which one nucleotide can be 
mutated to different one. C is the mutated form that makes a restriction site for Sma I 
endonucleases (Roche diagnostic limited, East Sussex, UK), which recognizes CCCGGG 
sequence. Sma I restriction enzyme (I U/jll) was used in digesting the amplified region 
(282 bp) at 25"C for 3 hrs; the digested PCR was checked for quantifying the bands on a 
1.5 % agarose gel. The details are shown in Table 2.2. 
2.5.9 The 5'end labelling of microsatellite primers 
Forward pnmers for the microsatellites on the SORD, NFKB, and HSP70 A2 genes 
(Figure2.1) and 10 bp molecular weight marker were labelled with ATP [y32P] (20,000 
cpm) using ready to go.1M T4 polynucleotide kinase (T4PNK). Both chemicals were 
supplied by Amersham, Pharmacia, Biotech. Bucks, UK. 25 jll of ddH20 was added to one 
tube of ready to go"IM T4PNK and the tube was incubated at room temperature for 2-5 min. 
5 jll of the forward primer (I 0 pmol), 19 jll of ddH20, and Ijll of the radioactive ATP 
[i2P] were added into the tube. Next, the tube was centrifuged at 13000 rpm for 30 sec 
and incubated at 37°C for 30 min. Then the tube was incubated on ice for 2 min to stop the 
reaction. The neat 5 jll of sodium chloride (5M), 2111 of Quick precip (Edge Biosystem, 
Gaithersburg. MD) and 160 jll of I 00 % ethanol ( -20"C) were added into the tube and the 
tube spun at 13000 rpm for 3 min. The tube was vortexed and spun for another 30 sec. The 
supernatant was discarded and the pellet washed with 70 % ethanol. The tube was air dried 
at room temperature for 5 min. The pellet was dissolved in 50 jll of ddH20. 
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Contents Measures Conditions of Digestion 
PCR product 20 !11 25 °C /16 hrs 
H20 6j.tl 
Sma I buffer 3!11 
Sma I enzyme 1 j.tl (I U) 
Total volume 30 j.tl 
Table 2.2: PCR-based genotyping for the T (+126) Con exon 10 of the PKC-Il gene on 
16p12 using Smai restriction enzyme 
The amplified fragment (282 bp) flanking the T ( + 126) Con ex on I 0 of the PKC-P gene at 
16p 12 was digested with the endonuclease restriction enzyme (Sma I). The total volume of 
digestion was incubated at 25" C for 16 hrs. The digestion products were checked on 1.5 % 
agarose gel and visualised under UV light. 
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2.5.10 Polyacrylamide gel electrophoresis and microsatellite analysis 
PCR was performed with the radiolabelled forward primers to investigate the polymorphic 
dinucleotide (CA)" repeat at the regulatory region of the NFKB I gene (4q24) (Ota et al., 
1999), the pentanucleotid (AAAT A) " repeat at the promoter region of the HSP70-A2 gene 
(14q22) (Roux et al., 1994) and (CAAA) 5 repeat on the promoter region of the SORD 
gene ( 15q21) (lwata et al., 1995). The protocol of this method was illustrated in Figure 2.3. 
BIORAD sequi-gen GT electrophoresis system (BIORAD Laboratories, Hempstead UK) 
was used for this technique (Figure 2.3). The system contains 30x50 cm glass plates with 
0.25-cm spacers and a 40-space shark toothcomb. Before using, the glass plates and 
spacers were washed in detergent solution, rinsed thoroughly in tap water, followed with 
ddH20, and finally rinsed with 70 % ethanol. The inner surface of the back-glass plate was 
siliconised with a small amount of a repel saline for I 0 min (Amersham, Pharmacia, 
Biotech. Bucks, UK). The comb was inserted and the set was connected to the base. A 
polyacrylamide denaturing gel (6 %) was prepared by mixing 36 ml of concentrated 
Sequa-gel, 99 ml of diluted Sequa-gel, 15ml of Sequa-gel buffer, I 0 ml of formamide, 1.2 
ml of I 0 % ammonium persulphate (A.P.S) and 70 Jll of tetramethyl-ethylene-diamine 
(TEMED) (Sigma chemicals, Poole, UK). The mixture was cast to the set and left for 2 hrs 
to overnight at room temperature to allow complete polymerisation. The system was 
connected to a power pack (Biorad, Hempstead, UK). and the gel was running in I x TBE 
at 1800-2000 v for 1-2 hrs to allow the temprature to reach 50"C. 
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1- Genomic DNA extraction 2-Radiolabeled forward primer 
3-PCR 
4-6% PAGE 5- Developed X-ray film 
Figure 2.3: Protocol of polyacrylamide gel electrophoresis 
1-Genomic DNA was extracted. 2- Forward primer (a) was radiolabeled with y2P (b). 3-
PCR was performed. 4- 6~ of the PCR product was mixed with 3~ of stop solution and 
loaded to the polymerised 6% polyacrylamide denaturing gel (PAGE), the picture shows 
BIORAD sequi-gen GT electrophoresis system. The system contains 30x50 cm glass plates 
with 0.25-cm spacers, a 40-space shark toothcomb and sandwich clamps. The 
electrophoresis time was -2-3 hrs. 5- Gel was dried, exposed to X-ray film for 18 hrs at -
80°C and developed. The picture was adopted from BIORAD website. 
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Afterwards, the system was disconnected from the power; 6111 of the processed PCR with 
radiolabeled forward primer were loaded with 3)ll of stop solution (Amersham 
International plc, Buckinghamshire, England) and the gel electrophoresed for another 2-3 
hrs. 
2.5.11 Development of auto-radiographs 
The gel was placed on Whitman filter paper, dried and exposed to X-ray film (Kodak xls5) 
in a firmly closed cassette for 18hrs at -80"C. The film was developed using X-ray 
developer, stop- solution and liquid fixer (Kodak Ltd, Scientific imaging system UK). 
2.6 Cell culture and protein assay 
2.6.1 Isolation of peripheral blood mononuclear cells 
Patients with diabetes were recruited from the diabetic clinic, Derriford hospital, Plymouth, 
UK. They were classified according to the type of diabetes and type of microvascular 
complications as shown in Table 2.3. Clinical characteristics of patients' subgroups and 
NC are included with the results of the protein assay studies. 
The fresh whole blood (20 ml) was collected into 5 % EDT A vacutainers (Becton 
Dickinson, Oxford, UK). PBMCs were isolated by using histopaque following the 
manufacturer's instructions (Sigma chemical, Poole, UK). Every 5 ml blood was 
transferred into a fresh 14 ml polystyrene round-bottom tube, which contains equal volume 
of histopaque without disturbing the surface. The tubes were centrifuged at 2000 rpm for 
30 m in (MSE Mistral I 000). 
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Study NFICB-DNA 
Subjects HG HGZ 
NC 10 5 
TIDM-DC 7 3 
TIDM-DR 12 0 
TIDM-DN 5 0 
TIDM-DNU I I 
TIDM-SD 8 4 
TIIDM-DR 7 7 
TIIDM-DN 7 7 
TIIDM-SD 10 10 
TOTAL 77 37 
Materials & Methods 
HSF-1-DNA 
HG 
12 
6 
12 
6 
11 
8 
7 
7 
10 
79 
HGZ 
0 
0 
0 
0 
4 
7 
7 
10 
29 
Table 2.3: Total number of the subjects included in the protein study 
Patients with diabetes were sub-grouped according to the presence or absence of 
microvascular complications and type of diabetes. DC = those patients with no 
microvascular complications after 20 years duration of diabetes. DN = those patients with 
diabetic nephropathy. DNU = those patients with overt diabetic neuropathy. DR = those 
patients with diabetic retinopathy. SD = patients with diabetes for less than I 0 years 
without complications in both TlDM and TIIDM. NC =normal healthy controls. 
HG= hypeglycaemia stressed cells with 31 mM D-glucose. HGZ= hypeglycaemia stressed 
cells with 31 mM D-glucose and treated with 1 OJ.!M zopolrestat (ARO. 
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The white cell interface (PBMCs) was collected into a new polystyrene round-bottom tube 
with equal amount of phosphate buffers saline (PBS = 150 mM of NaCI, I 0 mM of sodium 
phosphate, pH7.4) (Invitrogen, Paisley, UK) and the tube was centrifuged at 1400 rpm for 
10 min. The cells were washed in 5 ml of RPMI-1640 medium with no supplement and 
were spun at 1400 rpm for 10 min. The pellet was resuspended in 2ml of RPMI-1640 
medium and counted by haemocytometer slide. A concentration of 0.5x I 06 was grown in 
culture flasks (200 ml) containing 20 ml of RPMI-1640 with 20 J..LI of phytohemagglutinin 
(PHA) (5J..lg/ J..Ll). PHA was supplied by Sigma chemicals, Poole, UK. The cells were 
incubated at 37°C and 5% C02 for 5 days in the incubator (Model GA 2SN- LEEC 
limited, Nottingham, UK). All Falcon equipments were supplied by Fahrenheit, Milton 
Keynes, UK. 
2.6.2 Cell lines 
2.6.2.1 Human Caucasoid hepatocyte carcinoma 
Hepatocyte carcinoma cells have epithelial morphology (Hep G2). Cells were obtained 
from European Collection of Cell Cultures (ECACC No: 85011430). 
2.6.2.2 Human Leukaernic T cell lymphoblast 
This cell line is IL-2 producing lymphocytes (Jurkat E6.1 ). Cells were obtained from 
ECACC No: 88042803. 
Both Hep G2 and E6.1 cell lines were supplied by centre for applied microbiology & 
research, Salisbury, Wiltshire. 
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2.6.3 Preparation of medium and culture 
Roswell Park Memorial Institute 1640 medium (RPMI-1640) was used for growing 
PBMCs and E6.1 cell line. Minimum Eagle medium (MEM) with earl's salts was used for 
growing the Hep G2 cell line. Both types of medium were supplied by Invitrogen, Paisley, 
UK. A volume of 500 ml of RPMI medium was supplemented·with 50 ml of foetal calf 
serum (FCS) (1 0 %), 5 ml of L-glutamine (200 mM) and Sml of penicillin/streptomycin 
(10 units/ml and 10 J.lg/ml respectively). MEM medium was supplemented with Sml non-
essential amino acids (1 OOX) (lnvitrogen, Paisley, UK). 
2.6.4 Preparation of the cell lines for culture 
Cell lines arrived from the company in a frozen tube. The tube was left for I m in at the 
room temperature and thawed in a water bath (37°C) as fast as possible. Cryopreserved 
cells were transferred to a culture flask (200 ml) containing 20ml of the recommended 
medium with supplements for growing. The flasks were placed in the incubator at 37" C 
and 5% C02 for 2-3 days. 
2.6.5 Cryopreservation 
A concentration of 500,000/ ml has been preserved in a plastic cryotubes containing a total 
volume of 1 ml of I 0% of Dimethyl Sulfoxide (DMSO), 30 % FCS and completed with the 
recommended medium and frozen gradually at -20"C for 2hrs and at -80"C overnight. The 
cryotubes were stored at the vapour phase of a liquid nitrogen freezer until required. 
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2.6.6 Hep G2 cells subculture 
Hep G2 cells were detached by using 5 ml of trypsine EDT A ( 1 X) for 20-30 min. The cells 
were scraped with a plastic scraper and neutralised with 5 m1 of FCS. The cells were 
harvested into a 50 ml Falcon tube and centrifuged at! 000 rpm for 4 min. The pellet was 
resuspended with 10 ml of PBS for washing and the tube was spun for another 4 min at 
1000 rpm. The pellet was resuspended with 2 m1 of medium with supplements, the cells 
were counted, divided, and placed into 2 culture flasks (200ml) and then were incubated at 
37 "C. 
2.6.7 E6.1 cells subculture 
E6.1 cells are suspended. The cells were harvested into a 50 ml Falcon tube and the tube 
was spun at 1400 rpm for 4 min. The pellet was re-suspended with I 0 ml of BPS for 
washing and the tube was centrifuged for another 4 min at 1400 rpm. The pellet was re-
suspended with a 2 ml of supplemented medium and divided into 2 culture flasks (200 ml) 
containing 19 ml of the medium with supplements then incubated at 37 "C. 
2.6.8 Cell count and viability 
The heamocytometer slide was used for cell counting. Equal volume of cell suspension and 
trypan blue dye was mixed gently. Trypan blue stains the dead cells. The counting chamber 
was filled by the capillary action with the cells I trypan blue solution. Cells were allowed 
to settle briefly. Viable cells (unstained) were counted in the four large corner squares 
(each large corner square contains 16 smaller squares). The average of the four large 
squares was used to determine the concentrations of cells. 
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The following equation was used to calculate the viable cells: 
n x 2 x 104 / ml of cell suspension. 
Materials & Methods 
N.B. n =number of cells, 2 is a dilution factor and 104 is a constant factor. 
2.6.9 Incubation of cells with stress factors 
Cells were stressed, grown in the 'recommended medium and incubated at 37"C for 5 days 
as shown in Table 2.4 for the following investigations: l) NF-KB-ONA binding activity in 
response to high glucose concentration in PBMCs isolated from patients with TIOM and 
TIIOM, 2) HSF-1-0NA binding activity in response to high glucose concentration in 
PBMCs isolated from patients with diabetes, 3) the effect of ARI on hypeglycaemia-
induced NF-KB and HSF-1-0NA binding activity in PBMCs isolated from patients with 
diabetes, 4) NF-KB and HSF-1-0NA binding activity in response to hypeglycaemia and 
HO in cell lines for optimisation and supportive investigation, 5) the expression of the 
MAPK p38 in response to hypeglycaemia and HO in cell lines. 
Experiments were set as following: l) Normal condition, medium without stress factors, 2) 
hypeglycaemia, medium with high glucose concentration. A final concentration of 21 mM 
and 31 mM of 0-glucose were studied on the protein activity for optimisation. Afterwards, 
the concentration of 31 mM 0-glucose was fixed in all experiments, 3) HO stress of 
IIOmM of NaCl for 16 hrs. 
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Stress Concentration Time Cells 
N Medium without stress 5 days PBMCs 
factors HepG2 
E6.1 
D-glucose 3lmM 5 days PBMCs 
HepG2 
E6.1 
NaCI llOmM 16 hrs HepG2 
E6.1 
Zopolrestat 10 llM 5 days PBMCs 
Sorbinil 51lM 5 days PBMCs 
Table 2.4: Stress conditions and incubation time 
Cells were stressed according to the type of experiments, grown in the recommended 
medium and incubated for 5 days at 37°C and 5% C02. Hypeglycaemia-stressed cells were 
stimulated with a final concentration of 31 mM 0-glucose. Hyperosmolar-stressed cells 
were exposed to 110 mM NaCl for 16 hrs then washed and grown in the recommended 
medium to complete the incubation time of 5 days at 37"C. N = unstressed -control cells. 
Cells were treated with zopolrestat and sorbinil for a complete time of 5 days. 
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For ARI study, at the beginning, the dose effect of zopolrestat (Pfizer, Groton, USA) on 
the protein-ONA binding activity was adjusted by using different doses of 0, 5, I 0, 15 
JlM/ml zopolrestat. According to EMSA results, a final concentration of I 0 JlMiml of 
zopolrestat was used in this study. PBMCs were isolated from patients with diabetes and 
NC and divided into 3 groups as following: NG, hypeglycaemia-stressed PBMCs with and 
without zopolrestat. A different ARI, sorbinil (Pfizer, Groton, USA) was used to confirm 
whether zopolrestat has a specific inhibitory effect on hypeglycaemia-increased protein 
activity. The dose of sorbinil was adjusted to a final concentration of 5 JlM!ml. 
2.6.10 Protein extraction 
2.6.10.1 Buffers for protein extraction 
Buffer A (cell membrane lysis buffer) contains IOmM of hydroxy-ethyl-piprazine-ethane-
sulfonic acid (HEPES, pH 7.9), 10 mM of KCI, 1.5 mM of MgCh. 0.5 mM of di-thio-
threiotol (OTT), 0.2 % of NP40 (Tergitol). 
Buffer C (nuclear membrane lysis buffer) contains 20mM of HEPES (pH 7.9), 25% of 
glycerol, 0.42 M of NaCI, 1.5 mM of MgCh. 0.5 mM of OTT, 0.2 mM of EOT A. 
To I ml of either buffer we added a 5 Jll of I 00 mM of amino ethyl benzo-sulfonyl fluoride 
(AEBSF), 10 Jll of 18.4 mg/ml sodium orthovanadate, I 0 Jll of 42 mg/ml sodium fluoride, 
and I Jll of 2.2 mg/ml aprotinin. 
Sodium dodecyle sulphate (SOS) gel-loading buffer contains 3 ml of ddH20, I ml of 0.5 
M of tris-Hcl pH6.8, 1.6 ml of glycerol, 1.6ml of I 0% SOS, 0.4 ml of ~-mercapten and 0.4 
ml of 0.5% bromophenol blue. 
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2.6.10.2 Nuclear protein extract 
Cells were harvested into a 50 ml Falcon tube. The tube was spun at 1400 rpm for 4 min, 
the pellet was resuspended with 1 ml of PBS buffer and transferred into a 1.5 microfuge 
tube and spun for 30 sec at 7000 rpm. The cells were lysed in 300f!l of buffer A, and 
incubated on ice for 10 min. Then the tube was centrifuged at 12000 rpm for 10 min. The 
supematant (cytoplasmic protein) was kept at -80" C. The pellet was resuspended in 50f!l 
of buffer C and incubated on ice for 10 min. The tube was spun at 13000 rpm for 3 min. 
The supematant (nuclear protein) was kept at-80" until required for EMSA. 
2.6.10.3 Whole cellular protein extract 
E6.1 cells were harvested into a 50 ml Falcon tube, which spun for 4 min at 1400 rpm. The 
pellet was resuspended with 10 ml of PBS and the tube spun for a further 4 min at 1400 
rpm. The pellet (cells) was lysed in 500 f!l of SOS loading buffer and transferred into a 
microfuge tube. The cells were sonicated at 20,000 cpm for 15 sec by using an ultrasonic 
processor (Vibra cell T.M- VC 70, Newtown CT. U.S.A). The lid of the tube was pierced 
and the tube was incubated in a water bath at 95"C for 5 min and cooled on ice. The protein 
was kept at -80"C. 
Hep G2 are adhesive cells. The medium in the flask was discarded and the cells were 
washed with PBS in the flask. The buffer was discarded, cells were lysed in 500 1-11 of SOS 
buffer in the flask and then the lysate was transferred into a microfuge tube following the 
same protocol as mentioned for E6.1 cells. 
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2.6.10.4 Determination of Protein concentration 
Concentration of protein extracts were determined by using a coomassie plus protein assay 
reagent kit (Pierce, Rockford, UK) following the manufacturers instructions. Bovine serum 
albumin (BSA) solution used as a standard (2mg/ml). BSA was mixed with ddH20 up to 
50 Jll in a set of test tubes with different concentrations. The dilutions of BSA (Ill): H20 
(Jll) started with a blank (0: 50) and increased gradually as following: (5: 45), (10: 40), (15: 
35), (20: 30), and (25: 25). The amount of protein in a tube with 5Jll of BSA equals IOJlg 
and so on. Then 1.5 ml of Coomassie dye was added to each tube and the tubes were 
vortexed carefully. The changes in absorbance were measured at 595 nm with a 
spectrophotometer. Data was plotted on the X coordinate with the corresponding OD 
values on the Y -axis. Standard curve was established (Figure 2.4). The curve was used to 
determine sample's protein concentrations. To determine concentration of protein extracts 
in the study's samples, a dilution of I: I 0 of the protein (5 Jll of protein + 45 Jll ddH20) 
was mixed with 5 ml of Coomassie dye and the tubes were vortexed carefully. The 
absorbance was measured at 595 nm with a spectrophotometer and the protein 
concentrations were determined by using the standard curve shown on Figure 2.4. 
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Figure 2.4: Protein standard curve 
The concentration of BSA used as a standard is 2mg/ml (2Jlg/Jll). BSA was homogenized 
with ddH20 in a total volume of 50Jll. The amount of protein was increased gradually 
from 0 (no protein= blank) to 10, 20, 30, 40, and 50Jlg. O.D. was measured with 
spectrophotometer at wavelength of 595nrn. Data was scattered on X and Y -axis . The line 
was determined via linear regression. 
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2.6.11 Labelling of the oligonucleotide probes for EMSA 
The reaction mixture was prepared from 2j..LI of T4 polynucleotide kinase (T4 PNK) !Ox 
buffer, 2j..Ll of T4 PNK (I 0 U/ j..Ll) (Promega, Delta House, Southampton, UK), 4j..Ll of 
ddH20 and lj..Ll of A TP [ i 2P] (20,000 cpm). The tube was incubated at 37"C for 20 min. 
2j..Ll of consensus oligonucleotides [NFKB: 5' TGA GGG GAC TIT CCC AGO C 3' 
(Promega, Delta House, Southhapton, UK) and HSF1: 5' GCC TCG AA T OTT CGC GAA 
OTT T 3' (Goldenberg et al., 1988) (MWG-BIOTECH UK LTD, Milton Keynes, UK)] 
were added into the tubes and incubated at room temperature for 10 min. The reaction was 
stopped with 1j..Ll of 0.5M EDT A, diluted in 89 j..Ll of TE buffer and was kept at -20°C. 
2.6.12 Electrophoresis Mobility Shift Assay (EMSA) 
This method was used to assess the translocation and activation of the transcription factors 
that bind to specific consensus DNA sequences (Mercie et al., 2000). In this study EMSA 
was performed to give us an estimate on NFKB and HSF-1 activation in PBMCs of patients 
with diabetes in response to stimulation with high D-glucose level. The protocol for this 
method was illustrated in Figure 2.5. BIORAD ProteanR Il Xi cell (BIORAD Laboratories, 
Hempstead UK) was used for assessing the protein binding activity (Figure 2.5). The 
system contains glass plates, spacers, and a toothcomb. Before using, the glass plates and 
spacers were washed in detergent solution, followed by 70 % ethanol, rinsed thoroughly in 
tap water, and finally rinsed with ddH20. The comb was inserted and the set was 
connected to the base. 
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A- CeU culture 
B-Nuclear protein extraction 
C-Radiolabeled oligos 
Room temperature /20 min 
D- Non-denaturing polyacrylamide (5%) 
4 
3 E- Developed X-ray film 
6 
Figure 2.5: Protocol of electrophoresis mobility shift assay 
A- Cells were grown in the recommended medium with and without stress factors. 
B- Nuclear proteins were extracted and measured. C- DNA probes (a) were radiolabeled 
with ATP y2P (b). An adequate volume of 10 ~-tg of nuclear protein was processed with 
2~-tl of gel shift binding buffer (5x), 1 ~-tl of radiolabelled oligonucleotide probe and loaded 
with 1~ of the loading dye to a 5% non-denaturing polyacrylamide gel. D- Gel was 
electrophoresed for 2-3 hr in BIORAD ProteanR IT Xi cell. The system contains tank and 
lid (1), central cooling core (2), casting stand (3), sandwich clamps (4), alignment card (5), 
and combs (6). E- Gel was transformed to Whatman filter paper and exposed to X-ray film 
for 18 hrs at -80°C and developed. ProteanR 11 Xi cell picture was adopted from BIORAD 
website. 
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5% nondenaturing polyacrylamide gel was prepared by mixing 5 ml ofTBE 10x, 2.5 ml of 
2 % bisacrylarnide, IOml of 40% acrylamide, 3.1 ml of 80% glycerol, 79.5 ml of ddH20, 
750 !11 of I 0 % of APS and 50 !11 of TEMED. The mixture was cast to the set and left 
overnight at room temperature to allow complete polymerisation. The gel was run in O.Sx 
TBE at 1 OOv for I hrs for warming up. An adequate volume of 10 11g of nuclear protein 
was measured and mixed with 2 ~-tl of gel shift binding buffer (Sx) and incubated at room 
temperature for 10 min, then mixed with I ~-tl of radio-labelled oligonucleotides probes and 
incubated for another 20 min at room temperature. The samples were loaded with I !11 of 
the loading dye and the gel was electrophoresed for another 2-3 hr. Gels were transferred 
to Whatman filter paper (Arnersham, Pharmacia, Biotech. Bucks, UK), dried and exposed 
to X-ray film overnight at -80" C. 
2.6.13 Super-shift assay for NFKB 
The identity of the subunit proteins bound to the NFKB probe was determined by super-
shifting with antibodies to the rei-family members p50 and p65, which have recently beeri 
shown to be the most common NFKB heterodimmer (Ghosh et al., 1998). EMSA was 
performed with four tubes as shown in Table 2.5. HelaScribe Th1 nuclear extract was 
supplied with EMSA kit as a positive control protein. Antibodies, p50 and p65 were used 
as specific antibodies for p50/p65 NFKB heterdimer. Antibodies were supplied by New 
England Bio labs, Herts, UK. 
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Mixutre Reaction I Reaction 2 Reaction 3 Reaction 4 
(-ve control) ( +ve control) pSO antibody p65 antibody 
dd H202 7fll 5fll 4 jll 4fll 
GS-binding buffer 2jll 2fll 2 jll 2 jll 
Hela extract 0 jll 2fll 2fll 2jll 
pSO antibody 0 jll 0 jll I jll 0 jll 
p65 antibody 0 jll 0 jll Ofll I Ill 
32P labelled NFKB oligo I Ill I jll lfll I Ill 
Total volume 10 JJ.I 10 JJ.I 10 JJ.I 10 JJ.I 
Table 2.5: Super-shift assay for NFKB 
The table shows the measurements of the reagents, which were used in the super-shift 
mobility electrophoresis for the NFJCB heterodimer (p50/p65). ddH202 + GS-buffer + 
Hela + antibody were mixed and incubated at room temperature for 10 min. Then I jll of 
32P labelled NFICB oligo was added and incubated at room temperature I 20 min. GS- = gel 
shift binding buffer 5 X. 1 jll of the loading dye buffer was added into the reaction tubes 
and the mixture was loaded onto 5% nondenaturing gel. The gel was electrophoresed for 2-
3 hr. 
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2.6.14 Competition shift assay 
To confirm the specificity of the protein DNA complex, competition experiments were 
performed by a set of 4 tubes as shown in Table 2.6. The unlabeled APl oligonucleotide 
was used as a non-specific competitor that was supplied with EMSA kit. Unlabeled NFKB 
and HSF-1 oligonucleotides (50-fold excesses) were used as specific competitors. 
2.6.15 Western Blot 
8 !ORAD ProteanR ll Xi cell was used in this method to assess the expression of p38 in 
hypeglycaemia and HO-stressed Hep G2 and E6.1 cells following the protocol outlines in 
2.6.12. The SOS-PAGE gel was used for separating the proteins. The stack gel (4 % 
PAGE) and the resolving gel (12% PAGE) were performed as shown in Table 2.7. The 
whole protein extracts (20 f!g) were run through 12% polyacrylamide gels for 3 hrs and 
transferred to enhanced chemilumine scene (ECL) membrane (Amersham, Pharmacia, 
Biotech. Bucks, UK) by running the system at I volt overnight in the transfer buffer. The 
membrane was incubated with 5% milk buffer for I hr to block non-specific bands. 
Afterwards, phospho-active antibody of p38 (rabbit lgG anti-human) in a dilution of 
I: I 000 was incubated with the blot for 2 hrs on the shaker and then washed. The 
membrane was incubated with conjugated secondary antibody (anti rabbit-lOg) m a 
dilution of 1/5000 for I hr. Antibodies were supplied by New England Bio labs, Herts, UK. 
Super signal detection system was used to visualise the reactions (Pierce, Chester, UK). 
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Mixutre Reaction 1 Reaction 2 Reaction 3 Reaction 4 
( -ve control) ( +Ve control) Specific Nonspecific 
dd H202 7J.LI SJ.LI 4J.LI 4J.LI 
GS-binding buffer 2111 2 IJ.I 2111 2111 
Hela extract 0 Ill 2 Ill 2Jll 2 IJ.I 
Unlabeled oligo 0 Ill OJ.ll IJ.ll 0 IJ.I 
Unlabeled APt oligo 0 Ill 0 Ill 0 Ill I IJ.I 
32P labelled oligo I 111 I Ill I IJ.I IJ.ll 
Total volume 10 J.LI 10 J.LI 10 J.LI 10 J.LI 
Table 2.6: Competition shift assay 
The table shows the measurements of the reagents, which were used in the competition 
experiments. ddH202 + GS-buffer + Hela + unlabeled oligos (50 fold) were mixed and 
incubated at room temperature for I 0 min. Then I IJ.I of 32P labelled NF!CB oligo was added 
and incubated at room temperature for 20 min. GS-binding buffer = gel shift binding 5 X 
buffer. 
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Reagent Resolving Stack 
12% PAGE 4% PAGE 
30% acrylamide IBis 40ml 3.9 ml 
1.5 M Tris-HCI pH 8.8 25 ml 
0.5 M Tris-HCI pH 6.8 7.5 ml 
10%SDS 1.0 ml 300 J.ll 
H20 33.5 ml 18.3 ml 
TEMED 50 J.ll 30 J.ll 
10%A.P.S 500 J.ll 150 J.ll 
Total volume 100 ml 30 ml 
Table 2.7: SDS-Polyacrylamide gel for Western Blot 
SDS-P AGE gel for Western Blot was performed from two layers, the resolving (running 
gel) is 12% PAGE to separate the p38 (MW=38KD) and the stack (high porosity gel) is 4% 
PAGE. The mixture was cast to the set and left overnight at room temperature to allow 
complete polymerisation. 
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2.6.15.1 Buffers for Western blot 
Tris-Glycine electrophoresis buffer is the running buffer. The stock (5 x) buffer contains 
45.0 g of Tris-Base, 216.0 g of glycine, and 15.0 g of SOS in a total volume of 3 litre were 
completed with ddH20. For using, dilute 300 ml of 5x with 1.2 litre of ddH20. 
Transfer buffer contains 15.1g of Tris-base and 72g of glycine in 5 litres of ddH20. 
10% SDS buffer was made by dissolving lOg of SOS were dissolved in 60 ml dH20 and 
completing with ddH20 to 100 rnl. 
Washing buffer (TBS-Tween) contains 1900 ml of ddH20, I 00 mM of NaCI (80 ml of 
2.5 M), 20 mM of Tris (20 ml of I M) and 0.1% of Tween 20 (2 ml). 
Blocking buffer was made by mixing 5 gm of non-fat milk in I 00 rni of Tween-20 buffer. 
2.6.16 Quantification of bands 
Phosphor-imager soft ware program was used for quantifying the bands in autoradiographs 
(Bio-Rad Multi-Analyst TM; PC version 1.1 ). 
2.7 Autoclaving 
All solutions, glassware, and plastic ware used in the techniques of DNA analysis were 
autoclaved at a temperature of 121 "C, and pressure of IS-pressure specific index (p.s.i) for 
30 min in a steam autoclave (Prior Clave Limited, London, UK). 
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3.1 Results of genotyping 
3.1.1 Result of the (CA)n micosatellite genotyping of the NFICB gene on 4q24 
Microsatellite analysis for the NFICB gene was performed in 217 patients with TIDM and 
Ill NC. Clinical characteristics of these groups are shown in Table 3 .I. In our population, 
18 alleles (A 1-A 18) of the (CA) repeat microsatellite in the regulatory region of the NFKB 
gene were detected. The size of the alleles ranged from 120 to 154 bp (Al-Al8) (Figure 
3.1 ). The frequencies of the alleles in the patients and controls are shown in Table 3.2. The 
A8 and A14 alleles were the most prevalent in the NC (19.8% and 28.4% respectively). In 
contrast, in those patients with TIDM there was a highly significant decrease in the 
frequency of both the A8 as well as the A 14 allele compared to the NC (6.2% vs 19 .8%, 
2 2 X= 26.75, p=0.000004, OR= 3.7 and 3.9% vs 28.4 %, X= 79.80, p=0.000017, OR= 9.7 
respectively). In those patients with TlDM, there was a highly significant increase in the 
frequency of the A I 0 (138 bp) allele compared with the NC ( 17.5% vs 2.7% respectively, 
X2= 32.8, p = 0.00002, OR= 9.4) (Table 3.2). 
More than 70 genotypes were identified in our population. Table 3.3 shows the frequency 
of the common genotypes. In NC population, the most common genotype was A8/ A 14 but 
this was only found in I of the 217 patients with TlDM (12.6 % vs 0.5%, x2= 22.1, p= 
0.00014). The second most prevalent genotype in NC group was A14/Al4 and this was 
completely absent from the patient group (9.9% vs 0.0%, -l= 19.3, p=0.0007). Similarly, 
the A8/ A 11 genotype was found in 6.3% of the NC but was absent from the patient 
population (6.3% vs 0.0%, X2= 11.1 ). However, this difference was not significant after 
correction of the p-value (p=0.06). 
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In the patient group, the A9/ A I 0 genotype was the most common genotype and was 
present in 4 of the Ill NC (11.9 % vs 3.6%, X2= 5.2, OR= 3.3, p=ns). The A 10/ A 11 
genotype was found in 9.2% of the patients but was absent from the NC group (X2= 9.3, p= 
ns). No difference was found between observed and expected frequency of the alleles in 
both the patient and the normal populations (Table 3.4). 
Table 3.5 shows the frequency of the NF!d3 genotypes with respect to age at onset of 
TIDM and gender. The patients were categorised into <10, 10-20 or >20 years age at onset 
of diabetes. There were no significant differences in the frequency of the genotypes with 
age at onset although the A9/Al0 genotype was found in only 4.8% of those diagnosed 
before the age of 10 years compared to 13.2% and 14.0% in the 10-20 years and >20 years 
age at onset respectively. There were no significant differences in the frequency of the 
NFKB genotypes with gender. Table 3.6 shows the frequency of the common NFKB 
alleles with respect to the presence or absence of diabetic microvascular disease after 20 
years duration of diabetes. Whilst A9 was more common in those with diabetic 
microvascular disease compared to those with no complications after 20 years of diabetes, 
these differences were not significant. All the other frequencies of the alleles were similar 
between the patient sub-groups. 
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Patient subgroup DC DN DNU DR NC 
(n=38) (n=48) (n=55) (n=76) (n=lll) 
Male: Female 14:24 22:26 26:29 37:39 58:53 
AAO (years) 17.8±10.7 16.4±10.4 19.1 ±11.3 18.1 ±10.5 
Duration of 29.2±10.5 34.5±11.5 31.5±10.8 32.1±11.7 
diabetes (years) 
Table 3.1: Clinical characteristics of the patient sub-groups in the microsatellite 
analysis of NFKB 
DC, those patients with no microvascular complications after 20 years duration of diabetes; 
DN, those patients with diabetic nephropathy; DNU, those patients with overt diabetic 
neuropathy; DR, those patients with diabetic retinopathy and NC, normal healthy controls. 
Data is shown as mean of years ± s.d. AAO= age at onset of diabetes. 
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Figure 3.1: NFkB microsatellite analysis 
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Results 
Autoradiograph is showing some of the CA dinucleotide repeats polymorphisms in the 
human NFkB gene. Lane 1: A8/Al4, Lane 2: Al3/A14, Lane 3: A8/A14, Lane 4: 
All/A16, Lane 5: A8/A13, Lane 6: A14/Al4, Lane 7: A13/A14, Lane 8: A8/All. 
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Allele Patients with TIDM Normal healthy controls 
% (n=434) % (n=222) 
Al 0.0 (0) 0.5 (1) 
A2 1.6(7) 0.5 (1) 
A3 1.2 (5) 0.0 (0) 
A4 6.2 (27) 0.0 (0) 
AS 4.8 (21) 0.0 (0) 
A6 5.8 (25) 0.0 (0) 
A7 5.8 (25) 0.5 (I) 
A8 6.2 (27) 19.8 (44) 8 
A9 14.9 (65) 9.9 (22) 
AlO 17.5(76) h 2.7 (6) 
All 10.6(46) 9.9 (22) 
A12 7.6(33) 2.3 (5) 
Al3 5.3 (23) I 1.3 (25) 
A14 3.9 (17) 28.4 (63) c 
A15 6.7 (29) 7.2 (16) 
Al6 1.6(7) 5.4 (12) 
Al7 0.2 (I) 0.9 (2) 
A18 0.0 (0) 0.9 (2) 
Table 3.2: Frequency (%) of NF AB microsatellite alleles in patients with TIDM and 
normal healthy controls 
Allele frequencies are expressed as percentage of the total number of chromosomes. The 
numbers in the top parentheses is the number of chromosomes. 
u vs patients with TIDM, p = 0.000004 
h vs normal healthy controls, p = 0.00002 
c vs patients with TIDM, p = 0.000017 
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Genotypes Patients with TIDM Normal healthy controls 
% % 
(n=217) (n= 111) 
A8/A9 3.2 4.5 
(7) (5) 
AS/All 0.00 6.3 
(0) (7) 
A8/A14 0.5 12.6. 
(I) (14) 
A9/A10 11.9 3.6 
(26) (4) 
A9/A15 4.2 0.9 
(9) (I) 
AlO/All 9.2 0.0 
(20) (0) 
A14/A14 0.00 9.9 b 
(0) (11) 
XIX 70.9 62.2 
(154) (69) 
Table 3.3: Frequency (%) of NF .dJ genotypes in patients with TIDM and normal 
healthy controls 
The table shows the frequency of genotypes with prevalence >3%. X= all other genotypes. 
• and b vs patients with TIDM, p = 0.00014 and p = 0.0007 respectively. X/X = other 
genotypes. 
122 
Patients with TIDM (n=217) Normal healthy controls (n=lll) 
Genotype Expected Expected Observed Expected Expected Observed 
frequency number number frequency number number 
AS/X 0.07 17 21 x2 = 13.02 0.3 38 40 x2= 3.64 
A9/X 0.18 38 42 p = 0.07 0.2 21 16 p=0.8 
AlO/X 0.1 24 30 0.02 2 2 
All/X 0.04 8 8 0.11 13 12 
A12/X 0.03 6 14 0.01 2 
A13/X 0.03 6 12 0.11 ll 12 
Al4/X 0.005 4 0.22 22 19 
Others 0.5 117 86 0.03 3 8 
Table 3.4: Hardy-Weinberg equation and NF KB genotypes in patients with TIDM and normal healthy controls 
Hardy-Weinberg principle was compared with the observed results of the most common genotypes in patients with TlDM and normal healthy 
controls. Frequency of any heterozygote= 2X product of allele frequencies (Hart! et al., 1999). The observed numbers fit the predicted 
numbers in patients with TIDM and normal healthy controls. 
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Age at Onset (years) 
<10 10-20 >20 
Genotype (n=42) (n=68) (n=107) 
% % % 
Male: Female Male: Female Male: Female 
A9/A10 4.8 13.2 14.0 
0:2 4:5 8:7 
AlO/All 16.7 8.8 6.5 
I :6 2:4 4:3 
AlO/X 14.3 16.2 12.2 
2:4 7:4 5:8 
XIX 64.2 61.8 67.3 
15:12 20:22 34:38 
Table 3.5: Frequency(%) of the most common NF ~genotypes with respect to age at 
onset of TIDM and gender 
Patients were classified into three groups according to the age at onset of TIDM: <I 0, I 0-
20, >20 years. No difference was found in the frequency of the genotypes with either age at 
onset or gender. X/X = other genotypes 
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Allele DC DN DNU DR 
% % % % 
(n=76) (n=96) (n=110) (n=152) 
AlO 19.8 17.7 16.4 17.1 
(15) (17) (18) (26) 
A9 9.2 16.7 16.4 15.8 
(7) ( 16) ( 18) (24) 
All 11.8 10.4 9.1 11.2 
(9) (10) (10) ( 17) 
X 59.2 55.2 58.1 55.9 
(45) (53) (64) (85) 
Table 3.6: Frequency (%) of the most common NF KB alleles with respect to presence 
or absence of diabetic microvascular complications 
There were no significant differences in the frequency of the NFKB alleles between any of 
the patient subgroups. DC, those patients with no nephropathy, retinopathy or overt 
neuropathy after 20 years duration of diabetes. DN, those patients with nephropathy. DNU, 
those patients with overt neuropathy. DR, those patients with retinopathy. X= other alleles. 
125 
Results 
3.1.2 Results of the (AAA TA) microsatellite analysis of the HSP70-A2 (14q22) 
Microsatellite analysis of the HSP70-A2 gene was perfonned in I93 patients with TIDM 
and 94 NC. Clinical characteristics of these groups are shown in Table 3.7. In our 
population, li alleles (HI-HII) were detected, their size ranged from 124 to I74 bp with a 
difference of 5 bp (Figure 3.2). The frequency of the alleles in the patients and controls are 
shown in Table 3.8. The HI and H5 alleles (124 and I44bp) were the most prevalent in NC 
(19.7% and 39.9% respectively). In contrast, in those patients with TIDM there was a 
highly significant decrease in the frequency of both the HI as well as the H5 allele 
compared to NC group (2.6% vs 19.7%, x2= 46.9, p < 0.01, OR= 9.2I and 9.8% vs 39.9%, 
x2= 70.3, p < 0.01, OR= 6.08 respectively). In those patients with TIDM, there was a 
highly significant increase in the frequency of the H3 and H7 ( 134 and 154 bp) alleles 
compared with the NC (17.6% VS 8.0%, X2= 8.7, p= O.Q3, OR= 2.5 and 29.5 VS 3.7, X2 = 
49.1, p <0.01, OR= 9.8 respectively) (Table 3.8). 
The results revealed 28 genotypes in this population. Table 3.9 shows the frequency of the 
common genotypes. In the NC group, the most common genotype was H5/H5 but this was 
found in only 11 of the 193 patients with TIDM (21.3% VS 5.7%, x2= I4.3, p= 0.006, OR= 
4.47). The second most prevalent genotype in NC group was H I/H5 and this was 
completely absent from the patient group (11.7% vs 0.0% x2= 20.4, p = 0.00008). In the 
patient group, the H7/H7 genotype was the most common genotype and was present in 2 of 
the 94 NC (14.5% VS 2.1 %, x2= 9.I, p = ns). The H3/H7 genotype was found in 10.4% of 
the patients but was 3.2% in NC group (/= 4.4, p= 0.06). The observed and predicted 
frequency of the alleles was similar in patients with TIDM and NC population (Table 
3.10). 
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Table 3.11 shows the frequency of the common HSP70 alleles with respect to the presence 
or absence of diabetic microvascular complications after 20 years duration of diabetes. 
There was no difference was observed between any of the diabetic complications and the 
DC group. Patients with TIDM were divided into three groups according to the age at onset 
of the disease: <I 0 (n=57), 10-20 (n=63), and >20 years (n= 73). There were no significant 
differences in the frequency of the genotypes with either age at onset or gender (Table A. I, 
appendix). 
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DC DN DNU DR SD NC 
Patient subgroup (n=44) (n=38) (n=40) (n=55) (n= 16) (n=94) 
Female: Male 29:15 21: 17 18:22 30:25 9:7 48:46 
AAO (years) 15.7±9.4 17.1±11.2 19.2±10.04 18.6±11 4.5±3.3 
Duration (years) 30.4 ±9.5 32 ±11.6 31.8 ± 9.9 31.1 ±JI 6.6 ± 3.8 
Table 3.7: Clinical characteristics of the patient sub-groups in the microsatellite analysis of HSP70-A2 
DC, those patients with no microvascular complications after 20 years duration of diabetes; DN, those patients with diabetic nephropathy; 
DNU, those patients with overt diabetic neuropathy; DR, those patients with diabetic retinopathy and NC, normal healthy controls. Data is 
shown as mean of years ± s.d. AAO= age at onset. 
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Figure 3.2: HSP 70-A2 microsatellite analysis 
6 7 
H8= 159bp 
H7= 154bp 
H6= 149bp 
HS= 144bp 
H4= 139bp 
H3 =l34bp 
Results 
Autoradiograph is showing some of the 11 alleles (Hl-Hl1 ) of the (AAATA) 
pentanucleotide repeat polymorphism in the human HSP70-A2 gene. Their size ranged 
from 124 to 174 bp with a difference of 5 bp. Lane 1: H3/H3, Lane 2: H5/H6, Lane 3: 
H3/H7, Lane 4: H5/H6, Lane 5: H3/H7, Lane 6: H3/H3, Lane 7: A molecular weight (10 
bp). 
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Allele Size Patients with TIDM Normal healthy controls 
(H) (bp) % (n=386) % (n =188) 
Hl 124 2.6 (10) 19.7 (37) a 
H2 129 0.0 (0) 0.5 (1) 
H3 134 17.6 (68) b 8.0 (15) 
H4 139 9.8 (38) 7.5 (14) 
HS 144 9.8 (38) 39.9 (75) c 
H6 149 12.1(47) 3.2 (6) 
H7 154 29.5 (114) d 3.7 (7) 
H8 159 6 (23) 0.5 (I) 
H9 164 3.6 (14) 12.2 (23) 
HlO 169 I (4) 4.8 (9) 
Hll 174 7.8 (30) 0.0 (0) 
Table 3.8: The frequency (%) of HSP70-A2 microsatellite alleles in patients with 
TIDM and normal healthy controls 
a and c vs patients with TIDM, p < 0.01 for both 
b VS NC, p = 0.03 
d VS NC, p < 0.0 I. 
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Genotypes Patients with TIDM Normal healthy controls 
% % 
(n=193) (n =94) 
Hl/111 2.1 7.5 
(4) (7) 
Hl/115 0.0 11.7 u 
(0) ( 11) 
H3/H3 9.3 3.2 
(18) (3) 
H3/H7 I 0.4 3.2 
(20) (3) 
H5/H5 5.7 21.3h 
(11) (20) 
H7/H7 14.5 2.1 
(28) (2) 
XIX 55.4 51.0 
(112) (48) 
Table 3.9: The frequency (%) of the most common genotypes of HSP70 gene in 
patients with TIDM and normal healthy controls 
X/X=all other genotypes. 
• vs patients with TIDM, p= 0.00008 
h vs patients with TIDM, p= 0.006 
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Patients with TIDM (n= 193) Normal healthy controls (n= 94) 
Genotype Expected Expected Observed Expected Expected Observed 
frequency number number frequency number number 
Hl/X 0.008 2 6 x2 =30.1 0.295 28 29 x2 =4.98 
H3/X 0.26 50 50 p < 0.05 0.025 2 5 p = 0.4 
HS/X 0.058 12 23 0.438 41 34 
H7/X 0.26 50 65 0.001 0 2 
H8/X 0.02 4 I I 
H9/X 0.001 0 4 0.01 3 
Others 0.4 75 34 0.23 22 21 
Table 3.10: Hardy- Weinberg equilibrium and HSP70-A2 genotypes in patients with TIDM and normal healthy controls 
Hardy-Weinberg principle was compared with the observed results of the most common genotypes in patients with TIDM and normal healthy 
controls. Frequency of any heterozygote= 2x product of allele frequencies (Hart! et al., 1999). The observed numbers fit the predicted numbers 
in normal healthy controls but not in patients with TIDM. X= other alleles. 
132 
Results 
Allele DC DN DNU DR 
% % % % 
(n=386) (n=88) (n=76) (n=80) (n=llO) 
HI 0.0 2.6 2.4 1.8 
(0) (2) (2) (2) 
H3 12.5 13.2 8.8 11.8 
(11) (10) (7) (13) 
us 3.5 11.8 8.8 11.8 
(3) (9) (7) (13) 
H7 40.9 26.3 25 28.2 
(36) (20) (20) (31) 
X 43.1 46.1 55 46.4 
(38) (35) (44) (51) 
Table 3.11: Frequency (%) of the most common HSP70 alleles with respect to the 
presence or absence of diabetic microvascular complications 
No difference was observed between any of the diabetic complications and diabetic 
controls. DC, those patients with no microvascular complications after 20 years duration of 
diabetes; DN, those patients with diabetic nephropathy; DNU, those patients with overt 
diabetic neuropathy and DR, those patients with diabetic retinopathy. X= other alleles 
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Results of the (CAAA) 5 microsatellite analysis of the SORD gene (15q21) 
PCR-based microsatellite analysis was performed to detect the repeats in the promoter 
region of the SORD gene. A total number of 48 genomic DNA samples were randomly 
chosen. The PCR-amplified fragment size was 258 bp. PAGE results have revealed that the 
(CAAA) 5 microsatellite was not polymorphic. Figure 3.3 is an autoradiograph, which 
shows no difference in the fragment size of the genotyped group. Three PCR products have 
been sequenced by MWG-Biotech, UK LTD to confirm our results. The sequencing results 
showed that the (CAAA) microsatellite was five repeats in all samples (Figure 3.4 A, B, 
and C). 
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Figure 3.3: SORD microsatellite analysis 
Autoradiograph shows the rnicrosatellite (CAAA) 5 of the SORD gene. Lane 1 is a 10 bp 
molecular weight ladder. Lanes 2-9 demonstrate the fragment size of 258bp in 8 subjects. 
135 
Results 
A (MWG-order number VIII-73, template 1) 
GAGCCGGGATCGCACCACTGTACTCCAGCCTCGGCGACAAACAAACAAACAA 
ACAAAAAAAACAGCGCGCTGCAGATGGAGCCAGCACCCGGGCTTCTCGCTCCC 
AGCCCCCTCCCGAAGCCCCGCCCCGCCTCCGGGTCTGGAGGAGGCTGGGAAGC 
CCCGCCCCTCCACGCTAGCGCCGCCCAGGCTGGCACAAAGGAGGAAGCCTA 
B (MWG-order number VIII-73 template 2) 
CAGTGAGCCGGGATCGCACCACTGTACTCCAGCCTCGGCGACAAACAAACAAA 
CAAACAAAAAAAACAGCGCGCTGCAGATGGAGCCAGCACCCGGGCTTCTCGC 
TCCCAGCCCCCTCCCGAAGCCCCGCCCCGCCTCCGGGTCTGGAGGAGGCTGGG 
AAGCCCCGCCCCTCCACGCTAGCGCCGCCCAGGCTGGCACAAAGGAGGAAGC 
CTAGTCA 
C (MWG-order number V -423 template SORD) 
GCCGGGATCGCACCACTGTACTCCAGCCTCGGCGACAAACAAACAAACAA 
ACAAAAAAAACAGCGCGCAGAGATGGAGCCAGCACCCGGGCT 
Figure 3.4: Results of sequencing the amplified region of the (CAAA) 5 on the S'UTR 
of the SORD gene (15q21) 
The figure shows the 5' noncoding region of the SORD gene. The amplified fragment 
presents (CAAA) 5 repeats. A, B, and Care the sequences of three different samples. The 
underlined nucleotides are microsatellite's repeats, which are equal in all subjects. 
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3.1.3 Results of the T ( + 126) C polymorphism of the PKC-~ gene (16p12) 
PCR-based RFLP analysis was developed and applied to type PKC-~ in 175 patients with 
TJDM and 88 NC. Clinical characteristics of subjects are shown in Table 3.12. The PCR 
product was a fragment size of 282 bp. Figure 3.5 demonstrates the results of RFLPs using 
Smal endonuclease that revealed three genotypes, homozygous CC, TT and heterozygous 
CT. The frequency of the alleles and genotypes in patients with TIDM and NC groups are 
shown in Table 3.13. There was no significant difference in the frequency of either the T 
(wild) or the C alleles in patients with TJDM compared with NC (0.72 vs 0.68 and 0.27 vs 
0.31 respectively). The frequency of genotypes TT, TC and CC in patients with TIDM was 
54.3%, 36.6% and 9.1% respectively that were not significantly different from those of NC 
group (45.5%, 45.5% and 9.1% respectively). Hardy-Weinberg equation was applied, the 
predicted frequencies and numbers fit to the observed results (Table 3.14). 
When patients were divided into subgroups according to the presence of complications 
(DC, DN, DNU, and DR). There was no significant difference in the frequency of either 
the alleles or genotypes in patients with complications compared with those in patients 
with DC (Table 3.15). Our results suggest that the T ( + 126) C polymorphism of the PKC-
~ gene is not associated with the susceptibility to TIDM or any of the late micro vascular 
complications. 
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DC DN DNU DR NC 
n=34 n=39 n=42 n=60 n=88 
Male: Female 13: 21 20: 19 26: 16 33:27 44:44 
AAO (years) 15±10.6 18.8 ± 12.4 21.5±11.9 20.6 ± 12.1 
Duration (years) 30 ± 9.1 30.1 ± 12 29.3 ± 10 29.7 ± 10.9 
Table 3.12: Clinical characteristics of the patient sub-groups in RFLP analysis of 
PKC-~ 
DC, those patients with no microvascular complications after 20 years duration of diabetes. 
DN, those patients with diabetic nephropathy. DNU, those patients with overt diabetic 
neuropathy. DR, those patients with diabetic retinopathy. NC= normal healthy controls. 
Data is shown as mean of years± s.d. AAO= age at onset. 
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Figure 3.5: RFLP analysis of the C (+126) Ton exon 10 of the PKC-~ gene 
Results 
A total volume of 20~ of the PCR product (282bp) was incubated with 1~ of Srna I 
restriction endonucleases for at least 3 hrs . A 2 % agarose gel electrophoresis was used for 
polymorphisms detection. Lane 13 is the molecular weight ladder. Lane 1, 5,6,8, 10 are 
heterozygous (TC). Lane 2, 3, 4, 7, 11 and 12 are homozygous wild type (TT). Lane 9 is a 
homozygous mutant (CC). 
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Normal controls Patients with TIDM Normal controls Patients with TIDM 
Allele % % Genotype % % 
(n=176) (n= 350) (n= 88) (n= 175) 
T 68.2 72.6 TT 45.4 54.3 
(120) (254) (40) (95) 
c 31.8 27.4 TC 45.4 36.6 
(56) - (96) (40) (64) 
cc 9.2 9.1 
(8) (16) 
Table 3.13: Frequencies of alleles and genotypes ofT (+126) C polymorphism in exon 10 of the PKC-JJ gene in TIDM and normal 
healthy controls 
T allele (wild type) and C allele did not show a significant difference in either patients with TlDM or normal healthy controls. Genotypes did 
not show any difference between patients and normal healthy controls. 
140 
Patients with TIDM Normal healthy controls 
Genotype Expected Expected Observed Expected Expected Observed 
frequency number number frequency number number 
TT 0.52 91 95 x2 = 0.21 0.47 41 40 
TC 0.4 68 64 p =0.9 0.43 38 40 
cc 0.08 16 16 0.1 9 8 
Table 3.14: Hardy-Weinberg equation and PKC-~ genotypes in patients with TIDM and normal healthy controls 
Hardy-Weinberg principle was compared with the identified genotypes in patients with TIDM and normal healthy controls. 
The observed numbers fit the predicted numbers in patients with TIDM and normal healthy controls. 
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x2 = 0.12 
p=0.9 
Allele DC DN DNU DR Genotype DC DN DNU DR 
% % % % % % % % 
(n=68) (n=78) (n=84) (n=120) (n=34) (n=39) (n=42) (n=60) 
T 76.5 70.5 72.6 71.7 TT 55.9 51.3 57.1 53.3 
(52) (55) (61) (86) (19) (20) (24) (32) 
c 23.5 29.5 27.4 28.3 TC 41.2 38.4 31 36.7 
( 16) (23) (23) (34) (14) ( 15) (13) (22) 
cc 2.9 10.3 11.9 10 
(I) (4) (5) (6) 
Table 3.15: Frequencies of alleles and genotypes ofT ( + 126) C polymorphism in exon 10 of the PKC-P gene in patients subgroups 
No difference in the frequency of either alleles or genotypes was observed between diabetic subgroups. DC= uncomplicated diabetic patients, 
DN= diabetic pateints with nephropathy, DNU= diabetic pateints with neuropathy and DR= diabetic pateints with retinopathy. T is the wild 
allele and C is the modified nucleotide. TT is a homozygous (wild type) genotype, TC is heterozygous, and CC is the modified homozygous. 
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3.2 Results of cell culture and protein assay 
3.2.1 NFICB-DNA binding activity 
3.2.1.1 Super-shift experiment 
The identity of the subunit proteins bound to the NFK:B probe was demonstrated by super-
shifting with antibodies to the rei-family members p50 and p65, which have been shown to 
be the most common NFKB heterodimmer (Ghosh et al., 1998). Figure 3.6 is an 
autoradiograph, which demonstrates the binding of the protein complex (p50/p65) with the 
radiolabelled DNA-oligonucleotide. Hela protein extract was used as a positive control as 
shown in lane 2 while no band was developed in lane I as this was the negative control 
with no protein. Lane 3 shows that an antibody to p50 did not affect the shift of the 
complex while the antibody to p65 in lane 4 delayed the migration of unit 65 as being the 
efficient part in the NFKB complex, leaving the lower band (p50) unaffected. 
3.2.1.2 Competition experiment 
To confirm the specificity of the protein DNA complex for NFKB sequence, we have 
performed competition experiments. Competition assays contained 50-fold excesses of 
unlabeled NFKB oligonucleotide as a specific competitor, which blocked all of DNA 
binding, while the non-specific competitor (API) failed to block the DNA binding in 
DNA-protein complex (Figure 3.7). 
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Figure 3.6: Super-shift assay for NFlCB 
Super-shift assay for the heterodirner NFKB (p65&p50) protein: Lane 1: Negative control, 
Lane 2: positive control, Lane3: p50 antibody in combination with NFKB hetrodimer, 
Lane4: p65 antibody in combination with NFKB hetrodimer. ns= non-specific band. 
p50/p65 
ns 
1 2 3 4 
Figure 3.7: Competition shift assay for NFlCB-DNA binding activity 
Competition assays were performed with binding reaction mixtures containing 50-fold 
excesses of unlabeled NFKB oligonucleotide (lane 3). Lane 1: Negative control (no 
protein), Lane2: positive control (Hela extract). Lane 4: non-specific competitor APl. 
ns=non-specific band. 
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3.2.1.3 NF!CB-DNA binding activity in cell lines 
3.2.1.3.1 Hyperglycaemia and NF!CB -DNA binding activity in different cells 
To simulate the diabetic state and the effect of uncontrolled chronic hyperglycaemia, cells 
were stimulated with increased D-glucose level and grown in RPMl-1640 medium for 5 
days at 37° C. EMSA results have shown that hyperglycaemia induced NFJCB-DNA 
binding activity. Arbitrary units (AU) quantitation showed a significant increase in 
hyperglycaemia -stressed Hep 02 with 21 and 31 mM D-glucose compared with unstressed 
(NO) (0.3 ± 0.01 and 0.5 ± 0.01 vs 0.2 ± 0.01, p= 0.002 and 0.001 respectively). The 
NFJCB-DNA binding activity was correlated with glucose concentration since a 
concentration of 31 mM D-glucose induced approximately a two-fold increase in NFKB-
DNA binding activity compared with a concentration of 21 mM (0.3 ± 0.01 vs 0.5 ±0.01, 
p=0.006) (Figure 3.8). 
The concentration of 31 mM D-glucose was fixed in all experiments in this study. 
hyperglycaemia-induced NFKB-DNA binding activity in different cell types was assessed 
by phospho-imager quantitation (Figure 3.9). Results have revealed a 2.5 fold increase in 
basal activity in hyperglycaemia-stressed Hep 02 relative to NO (0.5 ± 0.1 vs 0.2 ± 0.04, 
p= 0.001) while no difference was observed in hyperglycaemia -stressed E6.1 compared 
with that in NO group (0.25 ± 0.05 vs 0.2 ± 0.02, p=ns). No significant increase in NFKB-
DNA binding activity was observed in hyperglycaemia-stressed human PBMCs from NC 
individuals compared with unstressed cells (0.1 ± 0.09 vs 0.2 ± 0.1, p=ns) (Figure 3.10). 
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Figure 3.8: NFKB binding activity under different D-glucose concentration 
A bar graph shows the results of three experiments. Arbitrary units quantitation (AU) 
revealed a significant increase in response to 21& 31 mM 0-glucose. NG= 
normogl ycemia. 
a vs stressed Hep 02 with 21 and 31 mM, p= 0.002 and p= 0.001 respectively 
b vs Hep 02 stressed with 21 mM, p= 0.006 
146 
Results 
p65/p50 
os 
1 2 3 4 5 6 7 8 9 
Figure 3.9: NFKB-DNA binding activity in stressed-cell lines 
An autoradiograph, which depicts the binding of equal amounts of nuclear protein extracts 
from Hep 02 and E6.l cells to an oligonucleotide containing NFKB motif. The 
heterodimer NFKB complex (p65/p50) is the upper band while the lower band is a non-
specific (ns =free protein). Lane 1& 2:E6.1 cells contols, lane 3: hyperglycaemia -stressed 
E6.1 cells, lane 4: HO-stressed E6.1 cells, lane 5: hyperglycaemia -stressed HepG2 cells, 
Lane 6,7 HepG2 cells with HO stress, lane 8: unstressed-HepG2 cells, Lane 9: negative 
control. 
Hyperglycaemia= a concentration of 31 mM D-glucose 
HO= hyperosmolar stress with a final concentration of 110 mM NaCl 
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Figure 3.10: Hyperglycaemia -induced NFKB-DNA binding activity in different cell 
types 
A bar graph shows the hyperglycaemia-induced NFJCB-DNA binding activity in human 
PBMCs from normal healthy controls, Hep G2 and E6.l cell Lines. Cells were stressed with 
31 mM D-glucose and grown in the recommended medium and incubated at 37 ° C for 5 
days. Experiments were repeated for 3 times. Results are the means of AU ± SE. NG= 
normoglycernia, HG= hyperglycaemia. AU= arbitrary units. 
a vs Hep G2 controls, p= 0.001 
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3.2.1.3.2 HO and NFICB -DNA binding activity in cell lines 
The EMSA results showed that HO stress of 110 mM NaCI did not induce NFKB-DNA 
binding activity either in Hep 02 or E6.1 cell lines. The autoradiograph (Figure 3.9) shows 
NFKB-DNA binding activity in HO-stressed E6.1 in lane 4 compared with that in E6.1 
controls in lanes 1 and 2. The bands in lane 6 and 7 shown NFKB-DNA binding activity in 
HO-stressed Hep 02 while that in lane 8 for control cells. AU quantitation was illustrated 
in the bar graph (Figure 3.11). No change in the density of the bands was observed in HO-
stressed Hep 02 compared with unstressed cells (0.2 ± 0.01 vs 0.2 ± 0.01) while HO-
stressed E6.1 cells have shown a significant inhibition in the protein activity compared 
with controls (0.1 ± 0.02 vs 0.2 ± 0.0 I, p= 0.04). 
3.2.1.4 NFICB-DNA binding activity in patients with diabetes 
·PBMCs were isolated from ten NC and sixty-seven patients with diabetes. Forty-three of 
the patients had TIDM, and 24 had TIIDM. The 43 patients with TIDM included 7 without 
complication (DC), 28 with microvascular complications (TIDM-Comp) and 8 with SO 
(TIDM-SD). Patients with TIIDM included 2 groups: 14 patients with microvascular 
complications (TIIDM-Comp) and SO (n=IO). Herein, SO group in either TIDM or TIIDM 
are patients with less than I 0 years without complications. The characteristics of the 
patients are shown in Table 3.16. Cells were stressed with 31 mM 0-glucose and incubated 
for 5 days at 37" C then EMSA was performed to investigate NFKB-DNA binding activity. 
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Figure 3.11: NFKB-DNA binding activity in HO-stressed cell lines 
The bar graph shows arbitrary units (AU) quantitation in HO-stressed Hep G2 and E6.1 
cell lines. Cells were stressed with 110 mM NaCl for 16 hrs then incubated at 37 ° C to 
complete 5 days. Experiments were repeated for 3 times. NO= normal osmolarity and HO= 
hyperosmolarity. The results are the means of AU ±SE. 
a vs E6.1 NO, p= 0.04. 
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Subjects 
TIDM (n-43) 
TIDM-DC 
(n= 7) 
TIDM-Comp 
(n= 28) 
TIDM-SD 
(n=8) 
TIIDM (n=24) 
TIIDM-Comp 
(n=14) 
TIIDM-SD 
(n= 10) 
NC 
(n=10) 
Total 
Results 
Male: Female Age at onset Duration 
2:5 8.25 ± 4.8 31.8 ± 6.8 
21:7 26.8± 15.5 29.8 ± 8.9 
2:6 26.3 ± 16.3 8.2 ±4.2 
8:6 56±4 5±3 
8:2 66 ± 10 5±2 
4:6 
45:32 
Table 3.16: Subjects included in the study of hyperglycaemia and NFICB-DNA binding 
activity 
A total number of 67 patients and I 0 NC were included in this study. Patients were sub-
grouped according to the presence or absence of microvascular complications and type of 
diabetes. DC = those patients with no microvascular complications after 20 years duration 
of diabetes. TIDM & TIIDM-Comp = those patients with microvascular complications 
including ON, DNU and DR. TIDM& TIIDM-SD = patients with short duration diabetes 
for less than 10 years without complications. NC = normal healthy controls. The table 
presents the classification according to sex, age at onset, and duration of the disease. Data 
are presented in means of years ± s.d. 
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AU quantitation showed a significant increase in the NFteB-DNA binding activity in 
hyperglycaemia -stressed PBMCs compared with the unstressed cells from patients with 
iabetes (0.5 ± 0.04 vs 0.3 ± 0.07, p= 0.003). hyperglycaemia induced a significant NFteB 
activation compared toNG in those patients with TIDM and those with TIIDM (0.3 ± 0.05 
vs 0.2 ± 0.05, p= 0.009 and 0.7 ± 0.07 vs 0.5 ± 0.07, p= 0.03 respectively). Further, NFteB-
DNA binding activity was significantly increased in hyperglycaemia-stressed cells 
compared with unstressed cells in patients with microvascular complications irrespective 
of type of diabetes (TfDM, 0.2 ± 0.09 vs 0.1 ± 0.09, p= 0.001 and TllDM, 0.7 ± 0.2 vs 0.5 
± 0.2, p= 0.047). Hyperglycaemia did not induce NFteB activation in cells of NC, DC, and 
all patients with SD (n= 18) (0.2 ± 0.1 vs 0.1 ± 0.09, 0.4 ± 0.1 vs 0.2 ± 0.1, and 0.6 ± 0.08 
vs 0.5 ± 0.08 respectively) (Table 3.17). 
Patients with diabetes (n=67) showed a significant increase in the hyperglycaemia-
induced NFK:B ratio (fold) compared with NC group (n= I 0) (2.1 ± 0.2 fold vs 1.65 ± 0.3 
fold, p= 0.01) (Figure 3.12). When all patients were divided into groups based on the 
type of diabetes, a significant difference in the hyperglycaemia-induced NFKB ratio was 
observed between patients with TIDM (n=43) and TllDM (n=24) (2.2 ± 0.12 vs 1.7 ± 0.17, 
p= 0.02) (Figure 3 .12). Further patients were divided into subgroups based on the 
presence of complications. In patients with TIDM, those with complications (n=28) have 
shown a significant increase in the hyperglycaemia-induced NFKB ratio compared with the 
DC (n=7) (2.5 ± 0.15 vs 1.9 ± 0.3, p= 0.047) and those with SD (n=8) (2.5 ± 0.1 vs 1.6 ± 
0.3, p= 0.003) (Figure 3.13). Patients with TIDM-comp (n=28) did not show a difference 
when compared with those with TIIDM-comp (n=14) (2.5 ± 0.15 vs 1.95 ± 0.24, p=ns) 
(Figure 3.13). Also, no difference was observed between TIDM-SD (n=8) and TIIDM-SD 
(n= 10) groups ( 1.6 ± 0.3 vs 1.3 ± 0.3, p=ns) (Figure 3.13). 
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NC DM TIDM TIIDM DC AIISD TIDM-Comp TIIDM-Comp 
M±SE 
(n=10) (n= 67) (n=43) (n=24) (n=7) (n=18) (n=28 ) (n= 14) 
NG 0.1 ± 0.09 0.3 ± 0.07 0.2 ± 0.05 0.5± 0.07 0.2 ± 0.1 0.5± 0.08 0.1 ± 0.09 0.5 ±0.2 
HG 0.2 ± 0.1 0.5 ± 0.04 0.3 ± 0.05 0.7 ± 0.07 0.4 ± 0.1 0.6 ± 0.08 0.2 ± 0.09 0.7 ±0.2 
p ns 0.003 0.009 0.03 ns ns 0.001 0.047 
Table 3.17: Results of hyperglycaemia and NFICB-DNA binding activity 
Patients were sub-grouped according to types of diabetes and the presence or absence of microvascular complications. OM =all patients with 
diabetes, NC = non-diabetic controls, all SD= all patients with short duration diabetes without complications, TIDM & TIIDM= type I & 2 
diabetes mellitus. Comp= microvascular complications. ns= non-significant p value. NO= unstressed PBMCs, HO= stressed PBMCs with 
31 mM D-glucose. Results are in means of arbitrary units± S.E and compared by student t-test. 
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Figure 3.12: - Hyperglycaemia-induced NFlCB in patients with diabetes compared 
with normal healthy controls 
Hyperglycaemia-induced NFKB-DNA binding activity was calculated in folds in different 
groups. DM = all patients with diabetes, NC = non-diabetic controls, TIDM& TIIDM= 
type 1& 2 diabetes mellitus. Results are in means of folds± S.E and compared by student 
t-test. 
a vs NC, p= 0.01 
b vs those patients with TIIDM, p= 0.02 
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Figure 3.13: Hyperglycaemia-induced NFlCB binding activity in diabetic subgroups 
The bars represent the ratio of hyperglycaemia -induced NFKB binding activity in folds . 
The patients were classified to four groups according to the presence and absence of 
complications. TIDM-comp and TIIDM-comp are patients with both types of diabetes with 
microvascular complications. DC= patients with TIDM for at least 20 years with no 
complications. TIDM-SD and TIIDM-SD =patients with TIDM and TIIDM for less than 
10 years without complications. Results are in means of the folds± S.E and compared with 
student t-test. 
a vs DC, p=0.047 and TIDM-SD, p=0.003 
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Patients with TIIDM with complications (n=14) have shown an increase in the 
hyperglycaemia-induced NFKB ratio compared with the TIIDM-SD (n=lO), however it 
was not significant (I. 95 ± 0.2 vs 1.3 ± 0.3, p = ns) (Figure 3.13). 
When the patients in the TIDM-Comp group were divided into the following groups, DN 
(n=5), OR (n= 12) and DNU (n= 11 ), there was no significant difference in hyperglycaemia 
-induced NFKB binding activity between complication subgroups (2.4 ± 0.3, 2.4 ± 0.2, and 
2.5 ± 0.2 respectively, p=ns). However, all patients with complications irrespective of 
type of diabetes were combined and classified into three groups including all ON (n= 12), 
all DR (n= 19), and all DNU (n= 11 ). These groups were compared with SD (n= 18) in both 
TJDM and TIIDM. The results revealed a significant difference in the ratio (p= 0.009) 
(Table 3.18). Further analysis has shown that the fold was significantly higher in PBMCs 
of patients with both DR and DNU compared with those of SD group (p= 0.04 and 0.016 
respectively). 
The Pearson correlation was used to define the extent of the linear relationship between the 
ratios of hyperglycaemia -induced NFKB, duration of the disease, age at onset and 
HbA 1c%. Data analysis revealed a significant correlation with the duration of the disease (r 
= 0.291, p= 0.035) (Figure 3.14 A). A positive correlation was observed between 
hyperglycaemia-induced NFKB-DNA binding activity and HbA 1c% in patients with 
diabetes, however it was not significant (r= 0.255. p=ns) (Figure 3.14 B). No correlation 
was observed between age at onset and hyperglycaemia -induced NFKB-DNA binding 
activity (Figure 3.14 C). 
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All DN All DR AIIDNU AIISD ANOVA 
(n=12) (n=19) (n=ll) (n=18) 
Fold 2.2 ± 0.24 2.3 ±0.19 2.5 ± 0.25 1.5 ± 0.19 0.009 
Table 3.18: Hyperglycaemia -induced NFKB-DNA binding activity in complication subgroups 
Hyperglycaemia induced approximately a two-fold increase in NFKB-ONA binding activity in patients with different microvascular 
complications compared with all patients with SO. All =the complication subgroup in both TIDM and TllOM. Results are in means of folds± 
S.E. ON, those patients with diabetic nephropathy; ONU, those patients with overt diabetic neuropathy and OR, those patients with diabetic 
retinopathy. SO= all patients with TlOM and TIIDM for less than I 0 years without complications. 
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Figure 3.14: Hyperglycaemia-induced NFKB binding activity in PBMCs of patients 
with diabetes in relation to duration of diabetes, HbA1c %, and age at onset 
(A): Pearson correlation revealed a significant pos1t1ve correlation between 
hyperglycaemia -induced NFKB-DNA binding activity and the duration of diabetes (r = 
0.291 , p= 0.035). (B) Shows a non-significant positive correlation with HbA1c% (r= 0.255, 
p> 0 .05). HbA1c%= blood glucose level. Figure C shows no correlation with age at onset. 
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3.2.2 HSF-1-DNA binding activity 
3.2.2.1 HSF-1-DNA binding activity in different cells 
3.2.2.1.1 Hyperglycaemia and HSF -1-DNA binding activity in different cells 
To confirm the specificity of the protein DNA complex for HSF-1 sequence, we have 
performed competition experiments. Competition assays contained 50-fold excesses of 
unlabeled HSF-1 oligonucleotide as a specific competitor, which blocked all of DNA 
binding, while the non-specific competitor (API) failed to block the DNA binding in 
DNA-protein complex. To assess HSF-1-DNA binding activity in response to high glucose 
concentration, cells were stressed with 31 mM D-glucose and grown for 5 days at 37" C. 
Cells were harvested, nuclear protein was extracted and EMSA was performed. A typical 
autoradiograph was shown in Figure 3.15, which shows two bands. The upper band is the 
complex of HSF-1 protein with the responsive element (GAA) (HSF-1 I HSE) while the 
lower band is non-specific band (free protein). 
High concentration of D-glucose did not induce HSF-1-DNA binding activity in Hep G2. 
Phospho-imager quantitation revealed that HSF-1-DNA binding activity was 0.26 ± 0.03 in 
hyperglycaemia -stressed Hep G2 vs 0.15 ± 0.03 in unstressed cells, p=ns (Figure 3.16). 
While the protein-DNA binding activity was significantly increased in E6.1 cells compared 
with unstressed cells (1.09 ± 0.02 vs 0.65 ± 0.02, p= 0.004) (Figure 3.16). With respect to 
human PBMCs, there was a 1.2 fold increase in HSF-1-DNA binding activity in response 
to a 31 mM D-glucose concentration compared to NG (0.5 ± 0.07 vs 0.6 ± 0.08, p> 0.05) 
(Figure 3.16). 
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Figure 3.15: HSF1-DNA binding activity in HepG2 and E6.1 cell lines 
An autoradiograph shows the binding of equal amounts of nuclear protein from Hep G2 
and E6.1 cells to the HSF-1 probe. The upper band was the complex of HSF-1 protein with 
the responsive element (HSF-11 HSE) while the lower band was non-specific (ns). Lane 1 is a 
positive control, lane 2 is a negative control, and lane 3 presents unstressed-HepG2. No 
bands were observed in hyperglycaemia -stressed HepG2 cells in lanes 4 and 5. Lane 7 
shows HSF-1 in unstressed E6.1 cell while lane 8 and 9 are for hyperglycaemia -stressed 
cells. Lane 6 presents HO-stressed HepG2 cell while lane 10 presents HO-stressed E6.1 
cells. Hyperglycaemia = a final concentration of 31mM 0-glucose. HO= hyperosmolar 
stress 
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Figure 3.16: Hyperglycaemia-increased HSF-1-DNA binding activity in different cell 
types 
A bar graph shows the hyperglycaemia -induced HSF-1-DNA binding activity in human 
PBMCs Hep 02 and E6.1 cell lines . Cells were incubated at 37°C for 5 days. The densito-
metric quantitation of the bands was obtained from 3 experiments. Results are in means ± 
SE. 
a vs unstressed E6.1, p = 0.004 
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3.2.2.1.2 HO and HSF -1-DNA binding activity in cell lines 
Figure 3.15 is an autoradiograph; the bands represent equal amounts of nuclear protein 
combined with the radiolabelled HSF-1 DNA probe. Lane 3 demonstrates the HSF-1-DNA 
binding activity in Hep G2 controls and lane 6 is HO-stressed Hep G2. Lane 7 is a band for 
E6.1 controls and lane 10 demonstrates the binding activity in HO-stressed E6.l. Densito-
metric quantitation of the bands obtained from 3 experiments in both cell types has shown 
that HO stress may induce HSF-1-DNA binding activity. There was a 1.3 fold increase in 
HO-stressed E6.1 cells compared with unstressed cells; t-test has revealed a significant 
increase in the mean of AU quantitation (0.8 ± 0.02 vs 0.65 ± 0.02, p= 0.01). No 
difference was observed in HO stressed-Hep G2 compared with controls (Figure 3.17). 
3.2.2.2 Hyperglycaemia and HSF-1-DNA binding activity in patients with 
diabetes 
This study included 67 patients with diabetes mellitus (TIDM= 43 and TIIDM=24) and 12 
NC. The clinical characteristics of the patients are shown in Table 3.19. The 43 patients 
with TIDM included 6 patients with DC. 29 patients with TlDM-comp and 8 patients with 
TIDM-SD. The ratio of men to women was 6.25 among patients with microvascular 
complications while it was 0.33 among patients with SD. Patients with TllDM included 2 
groups: TIIDM-comp (n=l4), and TIIDM-SD (n=IO). The ratios of men to women were 
1.3 among patients with complications and 4 among SD. PBMCs were isolated from 
patients with TIDM and TIIDM, stressed with 31 mM D-glucose and grown for 5 days at 
37"C then EMSA was performed. 
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Figure 3.17: HSF-1-DNA binding activity in DO-stressed cell lines 
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fCNO ~ 
The bar graph shows arbitrary units (AU) quantitation in HO-stressed Hep G2 and E6.1 
cell lines. Cells were stressed with 110 mM Na Cl for 16 hrs then incubated at 37 ° C to 
complete 5 days. Experiments were repeated for 3 times. NO= normal osmolarity and HO= 
Hyperosmolarity. The results are the means of AU ±SE. HSF-1-DNA binding activity was 
increased in response to HO in E6.1 but not in Hep G2. 
a VS E6.1 NO, p= 0.01 
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Subjects 
DC 
(n= 6) 
TIDM-Comp 
(n= 29) 
TIDM-SD 
(n= 8) 
TIIDM-Comp 
(n= 14) 
TIIDM-SD 
(n=10) 
NC 
(n=12) 
Total 
Male: Female 
2:4 
25:4 
2:6 
8:6 
8:2 
5:7 
50:29 
Results 
Age at onset Duration 
8.25 ± 4.8 25 ± 5 
23.2± 11.9 22.2 ±7.4 
26.3± 16.3 8.2 ±4.2 
56±4 5±3 
66± 10 5±2 
Table 3.19: Subjects included in the study of hyperglycaemia and HSF-1-DNA 
binding activity 
The table presents the classification according to sex, age at onset, and duration of the 
disease. Data are presented in means of years ± SO. A total number of 67 patients and 12 
NC were included in this study. Patients were sub-grouped according to the presence or 
absence of microvascular complications and types of diabetes. DC= those patients with no 
microvascular complications after 20 years duration of diabetes. TIDM-Comp & TIIDM-
Comp = those patients with microvascular complications including ON, DNU and DR. 
TIDM-SD& TIIDM-SD = patients with short duration diabetes for less than 10 years 
without complications. NC =non-diabetic controls. 
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Quantitation of the bands showed a significant increase in HSF-1 activity in 
hyperglycaemia -stressed PBMCs relative toNG in patients with diabetes (0.5 ± 0.03 vs 0. 
39 ± 0.03, p= 0.017) while no difference was observed in NC group (0.6 ± 0.08 vs 0.5 ± 
0.07, p= ns) (Table 3.20). No difference in the ratio was observed between patients with 
diabetes (n=67) and the NC group (n=12) (1.3± 0.07 vs 1.2 ± 0.1, p= ns) (Figure 3.18). 
With respect to type of diabetes, there was a significant increase in HSF-1 binding activity 
in hyperglycaemia -stressed PBMCs compared with unstressed cells in patients with TIDM 
(0.4 ± 0.04 vs 0.3 ± 0.04, p = 0.0 I) while no difference was observed in patients with 
TIIDM (0.6 ± 0.05 vs 0.5 ± 0.05, p=ns) (Table 3.20). Further, no difference in the ratio was 
observed between TIDM (n= 43) and TIID~ (n=24) ( 1.4 ± 0.09 vs 1.2 ± 0.1, p=ns) (Figure 
3.18). 
With respect to the presence of complications, HSF-1-DNA binding activity was 
significantly increased in response to hyperglycaemia-stressed PBMCs from patients with 
TIDM-comp compared with unstressed cells (0.44 ± 0.09 vs 0.3 ± 0.09, p= 0.008). No 
difference was observed in hyperglycaemia-stressed PBMCs from patients with DC 
compared with unstressed cells (0.26 ± 0.1 vs 0.24 ± 0.1, p=ns) (Table 3.20). Further, no 
difference in the ratio was observed between TIDM-complications (n= 29) and those 
patients with either DC (n = 6) or TIDM-SD (n = 8) (1.4 ± 0.1 vs 1.3 ± 0.1 and 1.2 ± 0.2 
respectively, p=ns) (Figure 3.19). 
No difference was observed in hyperglycaemia stressed cells of patients with TIIDM-comp 
compared with unstressed cells (0.7 ± 0.08 vs 0.5 ± 0.08, p= ns) (Table 3.20). 
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TIIDM-
NC DM TIDM TIIDM DC TIDM-Comp 
M±SE Comp (n=12) (n= 67) (n=43) (n=24) (n=6) (n=29 ) 
(n= 14) 
NG 0.5 ± 0.07 0.39 ± 0.03 0.3 ± 0.04 0.5 ± 0.05 0.24±0.1 0.3 ± 0.09 0.5 ± 0.08 
HG 0.6 ± 0.08 • 0.5 ± 0.03 b 0.4 ± 0.04 0.6 ± 0.05 0.26 ± 0.1 c 0.44 ± 0.09 0.7 ±0.08 
Table 3.20: Results of hyperglycaemia and HSF-1-DNA binding activity 
The table shows the HSF-1-DNA binding activity in hyperglycaemia -stressed and unstressed PBMCs. Patients were divided according to the 
types of diabetes. Data presents the mean of the AU ± SE. Student t-test was used in the comparison of densito-metric quantitation. DC = 
those patients with no microvascular complications after 20 years duration of diabetes. TlDM-Comp & TIIDM-Comp = those patients with 
microvascular complications including DN, DNU and DR. NC = normal healthy controls. DM= all patients with diabetes. HG= = a final 
concentration of 31 mM D-glucose. NG= unstressed cells 
" vs NG of total diabetes, p= 0.017 
b vs NG of TIDM, p= 0.01 
c vs NG of patients with TlDM-Comp, p= 0.008. 
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Figure 3.18: Hyperglycaemia -increased HSF-1-DNA binding activity in patients with 
diabetes compared with normal healthy controls 
The graph shows the ratio of the HSF-1-DNA binding activity in patients and NC. Patients 
were divided according to the type of diabetes. Data presents the mean of the AU ± SE. 
DM=all patients with diabetes, NC= normal healthy controls, TIDM& TIIDM= type 1 &2 
diabetes mellitus. The values are the mean of the folds ± SE. One-way ANOV A did not 
show a significant difference in HG/NG between groups (p> 0.05). HG= = a final 
concentration of 31 mM 0-glucose. NG= unstressed cells. 
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Figure 3.19: Hyperglycaemia -induced HSF-1-DNA binding activity in patients with diabetes mellitus 
T2DM-SD 
(n=10) 
The graph shows the increased HSF-1-DNA binding activity in patients with diabetes mellitus with and without complications. 
a vs all patients with all SD, p=O.OOl 
b vs TIIDM-SD, p = 0.005 
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No difference was observed in the ratio between patients with TIDM-comp and those with 
TIIDM-comp (Figure 3.19). Patients with TIIDM-complications (n= 14) showed a 
significant increase in the ratio compared to the TIIDM-SD group (n= I 0) (1.4 ± 0.1 vs 
0.95 ± 0.1, p=0.005) (Figure 3.19). Further, no difference was observed between patients 
with TlDM-SD and those with TIIDM-SD (1.2 ± 0.2 vs 0.9 ± 0.1, p=ns) (Figure 3.19). 
Patients with complications (n=43) were compared to the SO patients (n= 18), a significant 
increase in ratio was observed in the former group (1.5 ± 0.08 vs 1.08 ± 0.2, p= 0.001) 
(Figure 3.19). 
Patients were divided into the following groups ON (n=13), OR (n= 19), DNU (n= 11) and 
SO group (n=18). No difference in ratio was observed between any of these groups (Table 
3.21 ). Further analysis revealed that there was no correlation between hyperglycaemia -
induced HSF-1-DNA binding activity in patients with diabetes, age at onset, and duration 
of the disease or the level of HbA~c%. 
When we compared hyperglycaemia -induced NFKB to hyperglycaemia -induced HSF-1 
DNA binding activity in response to 31 mM D-glucose in PBMCs of patients with diabetes, 
a highly significant positive correlation between both proteins has been identified by the 
Pearson correlation test (r = 0.915, p < 0.01) (Figure 3.20). 
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NG 
HG 
All DN 
(n=13) 
0.4 ± 0.1 
0.6 ± 0.1 
HG/NG 1.5± 0.1 
(Fold) 
All DR 
(n=19) 
0.35 ± 0.1 
0.53 ± 0.1 
1.6 ± 0.1 
AIIDNU 
(n=ll) 
0.35 ± 0.1 
0.46 ± 0.1 
1.4 ± 0.1 
AIISD 
(n=18) 
0.46 ±0.1 
0.49 ± 0.1 
1.08 ± 0.1 
Results 
ANOVA 
ns 
Table 3.21: Hyperglycaemia and HSF-1-DNA binding activity in diabetic 
microvascular complications 
ANOV A test was used to compare (fold) between complication groups. All= patients with 
either TIDM or TIIDM with the complication. ON, those patients with diabetic 
nephropathy. DNU, those patients with overt diabetic neuropathy. OR, those patients with 
diabetic retinopathy. All SO = all patients with short duration diabetes without 
complications Data is shown as means± s.d. 
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Figure 3.20: NFlCB-DNA binding activity in correlation with that of HSF-1 
2.5 
NFKB and HSF-1 DNA binding activity were induced in response to a high concentration 
of 31 mM D-glucose in patients with both TIDM and TIIDM with and without 
microvascular. Pearson correlation has revealed a highly significant positive correlation 
between proteins activities (r = 0.915, p < 0.01). 
171 
Results 
3.2.3 Aldose reductase inhibitor and transcription factors binding activity 
3.2.3.1 ARI and hyperglycaemia -increased NFlCB-DNA binding activity 
Samples from 5 NC and 32 patients with diabetes were investigated for the effect of ARI 
on hyperglycaemia -induced NFKB-DNA binding activity. Eight of the patients had TIDM 
and 24 had TIIDM. Patients with TIDM included 3 with DC, I with DNU and 4 with SD. 
There are 7 patients with TIIDM with DN, 7 with DR and 10 with SD. The characteristics 
of the patients are shown in Table 3.22. 
In order to optimize the dose of zopolrestat on the protein activity, NG and hyperglycaemia 
-stressed cells were treated with different doses of zopolrestat (0, 5, I 0, and 15 J.!Miml). 
EMSA results showed that zopolrestat significantly inhibited the hyperglycaemia -
increased NFKB activity in a dose-dependent fashion. Densito-metric quantitation of the 
bands showed that hyperglycaemia stress without ARI treatment induced NFKB-DN A 
binding activity in human PBMCs (1.6 ± 0.2). When PBMCs were stimulated with 
hyperglycaemia and treated with doses of 5 11M, I 0 J1M and 15 11M of zopolrestat, AU 
quantitation of the protein activity was reduced to 1.06 ± 0.15, 0.8 ± 0.1, and 0.4 ± 0.05 
respectively (p= 0.0 I, 0.04, and 0.004 respectively vs hyperglycaemia stressed cells 
without ARO (Figure 3.21 A). NG-PBMCs did not show any difference in the protein 
activity when compared to treatment with ARI (0.3 ± 0.1 vs 0.3 ± 0.2) (Figure 3.21 B). 
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DC TIDM- TIDM- TIIDM- TIIDM- NC 
Comp SD Comp SD 
(n= 3) (n=l) (n=4) (n=l4) (n= 10) (n= 5) 
Male: Female I :2 I: 0 0:4 8:6 8:2 4: I 
Age at onset 26.5 ± 0.7 7 22 ± 9.5 56±4 66± 10 
Duration 20.5 ± 4.9 35 9 ± 5.8 5±3 5±2 
Table 3.22: characteristics of patients included in the study of zopolrestat and 
hyperglycaemia -induced NFKB-DNA binding activity 
A total number of 32 patients included in the study of hyperglycaemia -induced NFKB-
DNA binding activity in response to the treatment with zopolrestat. DC = those patients 
with TIDM with no microvascular complications after 20 years duration of diabetes. 
T!DM-Comp& TIIDM-Comp those patients with TIDM or T!IDM with microvascular 
complications. SO = those patients with diabetes for I 0 years or less without 
complications. NC = non-diabetic controls. Data is shown as means of years ± s.d. 
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Figure 3.21: Zopolrestat and hyperglycaemia -increased NFlCB-DNA binding activity 
(A): The graph shows the NFICB-DNA binding activity in PBMCs in response to a high 
concentration of 31mM D-glucose (HG) without ARI and with 5, 10, 15~ of 
zopolrestat/mJ respectively. a vs HG, p= 0.01. b vs HG+ 5~, p= 0.04. c vs HG+lO~, p= 
0.004. (B) The bar graph presents the mean of NFICB-DNA binding activity in unstressed 
cells (NG) with and without ARI. The densito-metric quantitation of the bands obtained 
from 3 experiments are in means of arbitrary units ± SE. 
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To investigate the treatment with ARI on the hyperglycaemia -induced NFICB-DNA 
binding activity, isolated PBMCs from patient with diabetes as well as the NC were 
classified into three groups. The first was a control group (NG) grown with no 
hyperglycaemia stress. The second was stressed with 31 mM D-glucose without 
zopolrestat. The third was stressed with hyperglycaemia and 10 j.lM of zopolrestat/ml 
(HGZ). All groups were incubated at 37° C for 5 days. Figure 3.22 (A) is an 
autoradiograph, which represents the DNA-binding activity of NFKB protein in the three 
groups. The phospho-imager quantitation showed that zopolrestat reduces hyperglycaemia 
-induced NFICB-DNA binding activity. 
In the NC group (n=5), there was no significant effect of the zopolrestat on 
hyperglycaemia -induced NFKB binding activity (0.4 ± 0.04 vs 0.6 ± 0.09, p=ns) whilst a 
significant inhibitory effect was found in patients with diabetes (n= 32) (0.35 ± 0.05 vs 0.7 
± 0.05, p=0.000002) (Table 3.23). The inhibition ratio was significantly decreased in 
patients with diabetes compared with NC (0.4 ± 0.05 fold vs 0.6 ± 0.09, p= 0.04) (Table 
3.23). 
The patients were categorized into two groups according to the type of complications: 15 
with complications (DR, DN and DNU) and 17 with no complications (SD + DC). The 
quantitation showed significant inhibition of NFKB-DNA binding activity by zopolrestat in 
patients with or without complications (0.25 ± 0.07 vs 0.7± 0.07 and 0.4 ± 0.06 vs 0.8 ± 
0.06 respectively, p < 0.05) (Table 3.23). Further, the (fold) was significantly reduced in 
patients with complications compared to those patients without complications (0.3 ± 0.06 
vs 0.5 ± 0.05, p= 0.01) (Table 3.23). 
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Figure 3.22: ARI-inhibited hyperglycaemia -increased NFKB-DNA activity 
Autoradiographs show the NFKB-DNA binding activity in response to a concentration of 
31 mM D-glucose (HG) with and without ARI treatment. Each three lanes present NG, HG 
and HG with ARI respectively for each individual. (A): Zopolrestat (lO~ml) and HG-
induced NFKB-DNA binding activity. (B): Sorbinil (5 J.l.M/rnl) and HG-induced NFKB-
DNA binding activity. Lanes 1-9 for three patients with diabetes. ns=non-specific band 
(free protein). 
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NC DM All with comp All without comp 
(n=5) (n= 32) (n= 15) (n= 17) 
HG 0.6 ± 0.09 0.7 ± 0.05 0.7± 0.07 0.8 ± 0.06 
HGZ 0.4 ± 0.0.04 "0.35 ± 0.05 h0.25 ± 0.07 C0.4 ± 0.06 
HGZJHG 0.6 ± 0.09 d0.4 ± 0.05 "0.3 ± 0.06 0.5 ± 0.05 
(Fold) 
Table 3.23: Zopolrestat and hyperglycaemia-increased NFKB-DNA binding activity in patients with diabetes and normal healthy 
controls 
The densito-metric quantitation of the bands obtained from each group of patients. Data present the mean of the AU ± SE. hyperglycaemia-
stressed cells with zopolrestat show a significant decrease in NFKB binding activity compared with hyperglycaemia -stressed PBMCs without 
zopolrestat. DM= all patients with diabetes, HG= hyperglycaemia (31 mM), HGZ= HG-stressed PBMCs +I OjlM/ml zopolrestat and NC= 
normal healthy controls. 
• vs HG in all patients with OM, p= 0.000002 
h vs HG in all patients with complications, p= 0.0008 
c vs HG in all patients without complications, p= 0.0008 
d vs NC, p= 0.04 
• vs all without comp, p= 0.01 
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To confirm whether the effect of the ARI was specific the hyperglycaemia -stressed 
PBMCs were treated with a second class of ARI, sorbinil to study whether it has the same 
effect on the hyperglycaemia- induced NFJCB activation. The dose of sorbinil was adjusted 
to 5 j.l.M. NFJCB-DNA binding activity in PBMCs of three patients was inhibited in 
response to treatment with sorbinil compared with hyperglycaemia -stressed cells without 
sorbinil (0.01 ± 0.02 vs. 0.2 ± 0.05, p= 0.001) (Figure 3.22 (B). However, sorbinil was 
used for a confirmatory purpose and it was not investigated in patients' subgroups. 
3.2.3.2 ARI and hyperglycaemia -induced HSF-1-DNA binding activity 
The effect of the zopolrestat on the hyperglycaemia -increased HSF-1-DNA binding 
activity was investigated in 29 patients with diabetes. Five of the patients had TlDM and 
24 had TllDM. The characteristics of the patients are shown in Table 3.24. 
Overall, the HSF-1-DNA binding activity was lower in response to treatment of 
hyperglycaemia -stressed PBMCs with zopolrestat compared with the hyperglycaemia-
stressed PBMCs without zopolrestat. Figure 3.23 is an autoradiograph, which shows the 
HSF-1-DNA binding activity in unstressed-PBMCs, hyperglycaemia -stressed PBMCs 
with 31 mM 0-glucose, and HGZ-stressed PBMCs. In patients with diabetes, the phospho-
imager quantitation revealed a significant inhibition in HSF-1-DNA binding activity in 
response to treatment with zopolrestat compared with hyperglycaemia-stressed PBMCs 
without zopolrestat (0.3 ± 0.05 vs 0.58 ± 0.05, p= 0.00 I) (Table 3.25). 
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DC 
(n= 1) 
Male: Female 0:1 
Age at onset 6 
Duration 32 
TIDM-
SD 
(n=4) 
0:4 
21.25±4 
10 ± 5.8 
TIIDM-
comp 
(n=14) 
8:6 
56±4 
5±3 
TIIDM-
SD 
(n= 10) 
8:2 
66± 10 
5±2 
Results 
Table 3.24: characteristics of patients included in the study of zopolrestat and 
hyperglycaemia -induced HSF-1-DNA binding activity 
A total number of 29 patients included in the study of hyperglycaemia and HSF-1-DNA 
binding activity in response to the treatment with zopolrestat. DC = those patients with 
TIDM without microvascular complications after 20 years duration of diabetes. TIDM-
comp & TIIDM-comp those patients with TIDM or TIIDM with nephropathy, overt 
neuropathy, and retinopathy. SO= those patients with diabetes for 10 years or less without 
complications. NC =normal healthy controls. Data is shown as means of years± s.d. 
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Figure 3.23: HSF-1-DNA binding activity in human PBMCs 
An autoradiograph shows the HSF-1-DNA binding activity in PBMCs stressed with 
hyperglycaemia with and without zopolrestat. Each three lanes present nonnoglycemia, 
hyperglycaemia (31rnM D-glucose), hyperglycaemia-stressed PBMCs +10 J..lM/ml 
zopolrestat DM=diabetes mellitus. ns =non-specific band (free protein). HSF-1/HSE is a 
complex of HSF-1 protein with the responsive element (GAA). 
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HG 
HGZ 
HGZ/HG 
(folds) 
Total DM 
(n= 29) 
0.58 ± 0.05 
a 0.3 ± 0.05 
0.6 ± 0.3 
All comp 
(n=14) 
All no comp 
(n= 15) 
0.7 ± 0.08 0.4 ± 0.05 
b 0.37 ± 0.08 0.3 ± 0.05 
0.55 ± 0.07 0.7 ± 0.08 
Table 3.25: Zopolrestat and HSF-1-DNA binding activity 
Results 
The table shows AU quantitation of HSF-1-DNA binding activity in hyperglycaemia-
stressed PBMCs with and without zopolrestat. DM=diabetes mellitus, all comp = patients 
with either TIDM or TIIDM with complications. All no comp= patients with either TlDM 
or TIIDM without complications. HG= hyperglycaemia (31 mM), HGZ= HG-stressed 
PBMCs + lOjJ.M/ml zopolrestat. Densito-metric units of HSF-1-DNA binding activity were 
compared with t-test. ANOY A test was used to compare HGZIHG (fold). Results are in 
means± SE. 
a VS HG in all patients with diabetes, p= 0.001 
h vs HG in patients with complications, p=0.003 
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When patients were divided according to the presence of complications, the HSF-1-DNA 
binding activity was significantly lower in hyperglycaemia-stressed PBMCs with 
zopolrestat in patients with complications (n= 14) (0.37 ± 0.08 vs 0.7 ± 0.08, p= 0.003) but 
not in those without complications (n= 15) (0.3 ± 0.05 vs 0.4 ± 0.05, p=ns). However, no 
difference in the folds was observed between patients with and without complications 
(Table 3.25). 
3.2.4 Mitogen activated protein kinase p38 in cell lines 
Hep G2 and E 6.1 cells were stressed with high D-glucose concentration of 31 mM and 
grown in the recommended medium for 5 days at 37° C. Whole cellular proteins were 
extracted by SDS-buffer. Western blot was performed and autoradiographs were visualised 
by phosphor-imager soft ware program (Figure 3.24). The p38 was two-four folds 
increased in response to hyperglycaemia stress. AU quantitation was 0.25 ± 0.02 in 
hyperglycaemia stressed-Hep G2 vs 0.15 ± 0.02 in unstressed Hep G2, p= 0.045. Whilst 
E6.1 cells have shown a significant increase in p38 expression in response to 
hyperglycaemia compared with controls (0.2 ± 0.05 vs 0.05 ± 0.05, p= 0.02) (Figure 3.25). 
Hep G2 and E 6.1 cells were stressed with a concentration of 110 mM NaCl for 16 hours in 
the recommended medium and washed by PBS and grown for a complete time of 5 days at 
37" C. Whole cellular proteins were extracted by SDS-buffer and Western blot was 
performed (Figure 3.24). Results have shown that HO stress did not induce p38 either in 
Hep G2 or E6.1 cells. AU quantitation was 0.1 ± 0.02 vs 0.15 ± 0.02 in HO stressed-Hep 
G2 compared with unstressed Hep G2. In E6.1 cells, HO stress did not induce MAPK p38 
expression compared with controls (0.1 ± 0.05 vs 0.05± 0.05) (Figure 3.25). 
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Figure 3.24: Western Blot assay and MAPK p38 expression 
The autoradiograph depicts the binding of equal amounts of whole nuclear protein extracts 
from Hep 02 and E6.1 cells to phospho-active antibody ofp38 (1:1000). 
Lanes 1,2: HepG2 control, Lane 3, 4: HO-stressed HepG2, Lanes 5,6: hyperglycaemia-
stressed HepG2 Lane 7: E6.1 cell control, Lanes 8, 9: hyperglycaemia-stressed E6.1 cell 
and lane 10: HO-stressed E6.l. 
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Figure 3.25: Mitogen activated protein kinase p38 in cell lines 
To investigate MAPK p38 in response to hyperglycaemia, Hep 02 and E6.l cell lines were 
stressed with 31 mM D-glucose for 5 days at 37 ° C. For HO study, cells were stressed 
with 110 mM NaCl for 16 hrs then washed with PBS and grown in the recommended 
medium to complete incubation time of 5 days. N= normal control cells, HG = 
hyperglycemis, and HO= hyperosmolar stress. The bar graph demonstrates the means of 
arbitrary units (AU) quantitation ±SE. 
a vs Hep 02 controls, p= 0.045 
b vs E6.1 controls, p= 0 .02 
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4.1 Genotyping 
This is the first study to look at the NFKB (4q24) and HSP70-A2 (14q22) genes in patients 
with TIDM. The results suggest that the A I 0 allele of the NFK:B gene and H3 and H7 
alleles of the HSP70-A2 gene are risk markers for the susceptibility to TIDM, whilst the 
Al4 allele of the NFKB gene and HI and H5 alleles of the HSP70-A2 gene may be 
protective markers and may reduce the risk of developing TIDM. 
The polymorphism of the NFKB gene is located within the 3'UTR while that of the 
HSP70-A2 gene is located within the S'UTR, suggesting that these polymorphisms may 
modify expression of the genes. It has previously been shown that polymorphisms in the 
non-coding regions of IL-6 (Fishman et al., 1998) and IFN-y (Pravica et al. 1999) genes are 
linked to their expression. The regulatory machinery for a gene is different. For instance, 
enhancer elements have been found up to 50 Kb from the coding region and these can 
directly affect the expression of the genes (Rim et al., 1998). Consequently, the results of 
this study could be attributed to differences in the expression of the NFKB and HSP70 
genes. They may determine the direction and magnitude of the cell response to an external 
stress and whether it is channelled towards apoptosis, inflammation or necrosis (Figure 
4.1). 
There is currently very little information on the mechanisms of islet P-cell death during the 
pre-diabetic period in man. It remains to be determined whether the (CA) polymorphism of 
NFKB and the (AAAT A) polymorphism of the HSP70-A2 are associated with P-cell 
damage and the pathogenesis of TIDM. 
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11 Ill IV 
Genetic Response Effects Diabetes susceptibility loci 
& Pro-inflammatory Apoptosis, Mellitus 
Environmental Anti-inflammatory inflammation and Pro-apoptotic necrosis + 
risk factors Anti-apoptotic Complications 
Mediators 
Stress factors 
Figure 4.1: Algorithms of the course of diabetes mellitus and its late complications 
Genetic and environmental factors could direct and magnify the effect of signals (mediators), which contribute to the development of the 
disease. 
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The association of the AIO allele of the NFteB gene with susceptibility to TIDM in this 
study may be linked with enhanced rate of transcription compared with the protective 
allele (Al4). NFteB has both proinflammatory and anti-inflammatory effects (Tak et al., 
200 I) and it is possible that the A 10 allele is associated with proinflammatory responses 
whilst the Al4 allele is anti-inflammatory (Figure 4.2). This might be related to variable 
amounts of NFteB protein, which would have a detrimental effect allowing intracellular 
proteins and other molecules to be exposed to the immune system thereby, provoking an 
autoimmune response. It is possible that the polymorphism of the NFteB gene may affect 
the binding affinity of the p65/p50 dimer with the response element. It may also affect the 
efficacy of the p65 subunit (the functional unit of the NFteB dimer). However, further 
studies are needed to investigate whether this polymorphism linked to the NFKB-DNA 
binding activity and the p65 expression. 
The (CA) polymorphism of the NFKB gene has been suggested to be a useful marker in 
inflammatory diseases (Ota et al., 1999). The investigation carried at part of this thesis was 
the first study of NFKB gene polymorphisms with susceptibility to TIDM (Hegazy et al., 
2001 ). Recently, in Denmark, Gylvin et al. have investigated the same microsatellite 
marker (CA) in highly selective multiplex families. However, no association was observed 
with TIDM in this Danish population (Gylvin et al., 2002). It is well known that multiplex 
family studies do not always replicate the association in sporadic populations of non-MHC 
genes with susceptibility to TIDM (Davis et al., 1994, Hashimoto et al., 1994). This could 
be due to sampling, ethnic, environmental variation, or due to combination of all these 
factors. This is also possible to be due to an incomplete (low) penetrance between the 
genotypes and phenotype of TTDM in family studies. 
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Genotyping of candidate genes 
NFlCB & HSP70 A2 
Oxidative 
1- inhibit ALR2 
stress 
Hypothesis 
Risk alleles 
NFlCB AlO & HSP70 H3 + HS 
t NFKB 
HSF-1 
Results 
Figure 4.2: Illustration of hypothesis and results of the study 
1-Mediate proinftammatory responses, 
atherogenic molecules, ET-1, VEGF, ECM, 
PKC, cytokines. 
2- Abnormalities in blood flow, vascular 
permeability, apoptosis of microvascular 
ceUs and progressive caplllary occlusion, 
oedema, ischaemia, and proliferation and 
neovasularization 
Decrease the damage of vascular 
homeostasis 
Possible effects and outcomes 
The study included genotyping of the candidate genes and investigating the role of hyperglycaemia (HG) with and without aldose reductase 
inhibitor (ARI) on the transcription factors-DNA binding activity. 
? =Unknown further effects, whkh might need further studies. 
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With respect to HSP70-A2, the association of H3 and H7 with the susceptibility to TIDM 
may be explained in two ways. Firstly, these markers could be associated with decrease in 
the level of HSP70 leading to a deficiency in the cytoprotective mechanism, which may in 
turn accelerate ~-cell autoimmune destruction. It has been suggested that HSPs in general 
and HSP70 in particular are a protective line of defence, which has been correlated to 
tissue damage (Bellmann et al., 1995; Eizirik, 1996; Burkart et al., 2000). Secondly, HSP-
70 and HSF-1 are known to have an auto-regulation mechanism (Morimoto 1993; Schett et 
al., 1998; Schafer et al., 2000). It is possible that the risk alleles H3 and H7 of the HSP70 
gene are associated with alteration of the HSF-1-DNA binding activity. HSF-1 may bind to 
the specific response element on proinflammatory genes, including cytokines, which 
contribute to ~-cell destruction. Conversely the HI and HS alleles may direct HSF-1 to 
bind to the anti-inflammatory genes (Figure 4.2). This may be related to variable amounts 
of HSP protein, which would have a detrimental effect on the autoimmune response. 
Previous studies have shown that MHC-Iinked HSP70 gene linked with susceptibility to 
TIDM in British Caucasoid population (Caplan et al., 1990). However, the following 
studies have revealed contradictory results in different populations (Pociot et al., 1993; 
Kawaguchi et al., 1993; Chuang et al., 1996). These studies and our study suggest that HSP 
genes may have susceptible loci to TIDM. 
In this study, the risk markers of both NFteB and HSP70-A2 genes are associated with 
patients with TlDM compared with non-diabetic healthy controls. However, when patients 
were classified according to the presence or absence of microvascular complications, no 
difference was observed in the distribution of risk alleles between DC group and any of the 
complications groups. 
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The duration of the disease, age at onset, sex or age of the patients with TIDM could help 
to define subtypes of TIDM. However, no association was observed between these factors 
and the risk alleles of either NFKB or HSP70-A2 genes. This was the first time that NFKB 
and HSP70-A2 loci have been investigated to the susceptibility to TIDM and its late 
microvascular complications. More studies are needed to confirm these results with further 
examination of the molecular mechanisms and the protein expression underlying these 
findings. This may provide an insight into the pathogenesis of diabetic complications. 
However, several candidate genes have been previously suggested to confer susceptibility 
to TIDM and its microvascular complications but they have yielded inconclusive results 
and require further confirmation. 
Our results revealed that the microsatellite (CAAA) 5 on the 5' SORD gene is not 
polymorphic. That has been confirmed by sequence analysis. The results suggest that 
screening for this polymorphism is unlikely to be a useful tool for risk assessment. In 
addition, no evidence of association was obtained between PKC-13 gene T ( + 126) C 
polymorphism on ex on I 0 and TIDM or any of its late complications. Similarly, the same 
marker has been investigated previously in patients with TIDM with nephropathy and no 
association was observed (Araki et al., 2000). However, genotyping of one polymorphism 
on any gene is not enough to confirm the presence or absence of risk marker to the disease. 
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4.2 NFJCB-DNA binding activity in patients with diabetes 
In diabetes, there are a variety of different stressors such as hyperglycaemia, HO, oxidative 
stress, AGEs, hypoxia cytokines and growth factors. All of these stress factors either alone 
or in combination have the potential to induce the proinflammatory and heat shock 
responses. This study focused on the role of uncontrolled hyperglycaemia in the 
development of diabetic microvascular complications (Figure 4.2). The hypothesis was that 
uncontrolled hyperglycaemia might influence the transcriptional regulation of many genes. 
This study examined whether NFKB and HSF-1 activity is increased in the cells of patients 
with diabetes, whether this activity is responsive to hyperglycaemia and whether the 
response is polyol-dependent. 
Elevated D-glucose concentration (31 mM) significantly increased NFKB-DNA binding 
activity in PBMCs from patients with diabetes but not in those from the NC population 
(Figure 3.12). This result suggests that PBMCs of patients with diabetes were pre-stressed 
with hyperglycaemia and other stress factors in diabetes for long time. Therefore, more 
risk factors in diabetes magnified the effect of hyperglycaemia stress and induced NFKB 
activation. It is known that the effect of hyperglycaemia remains for a period of time even 
after the treatment with hypoglycaemic drugs (DCCT, 2000; Sheetz et al., 2002). 
Hyperglycemic memory may cause functional alteration such as formation of AGEs, 
stimulation of growth factors and enhanced proinflammatory processes. These factors 
induce NFKB activity. Previous studies have shown that NFKB up regulates VEGF and 
AGEs (Marumo et al., 1999; Tanaka et al., 2000). 
Hyperglycaemia induces NFKB-DNA binding activity in most cell types. In this study, 
hyperglycaemia induced a significant increase of NFKB-DNA binding activity in Hep G2 
cells but not in E6.1 cells (Figure 3.10). 
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NFICB has also been found to be active in response to hyperglycaemia in VSMC (Yemeni 
et al., 1999) and retinal pericytes but not retinal endothelial cells (Romeo et al., 2002). 
Therefore, these findings suggest that NFICB is implicated in the pathogenesis of 
endothelial dysfunction in diabetes. It is also possible that hyperglycaemia-induced polyol 
pathway in diabetes induces NFICB activation in PBMCs from patients with diabetes since 
hyperglycaemia itself did not induce significant activation in PBMCs from healthy 
individuals (Figure 3.1 0). The polyol pathway is implicated in the pathogenesis of 
microvascular complications in diabetes (Yabe-Nishimura 1998; Nishikawa et al., 2000a; 
b; Brown lee 2001 ). Both hyperglycaemia and the polyol pathway are important sources of 
oxidative stress, which induce NFKB activation (Williamson et al., 1993; Mohamed et al., 
1999; Obrosova et al., 1999). Therefore, hyperglycaemia and diabetic-induced polyol 
pathway may induce their diverse effects through NFICB activation. 
Hyperglycaemia-induced NFKB-DNA binding activity was pronounced in patients with 
TIDM (Figure 3.12). It is well known that the proinflammatory cytokines such as TNF-a 
and IL-l are implicated in the pathogenesis of TIDM and they are upregulated by NFK:B 
(Green et al., 1999; Kukreja et al., 1999; Eizirik et al., 2001 a and b; Cardozo et al., 2001). 
This may explain the higher activation of NFICB in patients with TIDM. Results showed a 
significant increase in hyperglycaemia-induced NFKB-DNA binding activity in PBMCs 
from patients with diabetic microvascular complications. No difference was observed 
between patients with TIDM-comp and those patients with TITDM-comp (Figure 3.13). 
The result suggests that the role of NFKB in the underlying molecular mechanisms of 
microvascular complications is similar in both types of diabetes. Clinically, most of 
patients with diabetic microvascular complications have hypertension, long duration of the 
disease with uncontrolled blood glucose levels. These are major risk factors, which induce 
endothelial dysfunction and contribute to the development of diabetic microvascular 
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diseases (DCCT, 1993; 1995; Rossing et al., 1996; Weidmann et al., 1997; UKPDS 33, 
1998; Gabir et al., 2000; Perin et al., 2001; NIH, 2002). 
Hypertension potentially increases the mechanical load onto VSMC (Donnelly, 2000; 
Calles-Escandon et al., 2001) and triggers a number of biochemical changes including 
NFKB (Brand et al., 2001) and HSP (Pockley et al., 2000). 1n this study, most of the 
patients with microvascular complications had TIDM for more than 20 years. Therefore 
cells were exposed for a long period to cumulative hyperglycaemia, which induces the 
proinflammatory response and initiates endothelial dysfunction, which in turn induces 
more tissue damage. Microvascular diseases are associated with endothelial dysfunction. 
EC activation is associated with transcriptional induction of ET-I, E-selectin, VCAM-1, 
ICAM-1 and cytokines (Pieper et al., 1997; Guha et al., 2000; Quehenberger, 2000), most 
of these factors are up regulated by NFKB. Previous studies have also shown that NFKB 
activation is linked to increased MCP-1 and monocytes infiltration (Rovin et al., 1995). 
Therefore, the results suggest that NFKB is implicated in the pathogenesis of late diabetic 
complications. Further data analysis has revealed a significant positive correlation between 
the duration of diabetes and hyperglycaemia-induced NFKB- DNA binding activity in our 
population (Figure 3.14 (A)). 
In this study, patients with TIIDM developed microvascular complications with a mean of 
5 years after diagnosis. This may be due to strong hyperglycaemia exposure or due to other 
environmental factors such as insulin resistance, obesity, and hyperlipidaemia that could 
accelerate the development of microvascular complications in TIIDM. However, the 
intensity of hyperglycaemia as well as the duration of the disease is a major risk factor to 
diabetic complications (DCCT, 1993; Gabir et al., 2000). The results showed that 
hyperglycaemia-induced NFKB was positively but not significantly correlated with HbA 1c 
levels (Figure 3.14 (B)). However, another study did find a significant correlation between 
protein activity and HbA le levels in patients with TIDM (Hofmann et al., 1998). 
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Interestingly, no increase in NFKB- DNA binding activity was observed in response to 
31 mM D-glucose in patients who had TIDM for a mean duration of 31.8 ± 6.8 years and 
have remained free of microvascular complications. The results suggest that glucose alone 
is not enough to lead to the development of microvascular complications and support the 
role of genetic factors. Those patients may be genetically protected. It is possible that they 
have the protective allele of any of the genes, which contribute to the development of 
diabetic microvascular complications such as ALR2 and VEGF. It is known that these 
factors could modulate the NFKB activity (Marumo et al., 1999; Ramana et al., 2002& 
2003). 
In this study, there was no association between the identified risk markers of the NFKB 
gene and patients with diabetic complications while hyperglycaemia-induced NFKB-DNA 
binding activity was pronounced in PBMCs from those patients. The results suggest that 
the proteins-DNA binding activity is unlikely to be linked with the investigated 
polymorphisms. Therefore, it is possible that increased glucose levels interferes with IKB 
phosphorylation and stimulate its degradation or it might enhance the p65 subunit activity. 
More studies are needed to investigate the expression of IKB and p65 in response to 
hyperglycaemia and their relation with NFKB-DNA binding activity. Hyperglycaemia-
induced NFKB- DNA binding activity was significantly increased in patients with DR and 
DNU but not DN. Supporting these observations; it has previously been shown that NFKB 
activity was increased in retinal cells in response to hyperglycaemia (Romeo et al., 2002). 
However, a previous study also showed raised NFKB-DNA binding activity in the PBMCs 
of TlfDM patient with DN; although in this instance the cells were not cultured in vitro 
(Hofmann et al., 1999). It is shown that polyol pathway and its derivatives including 
oxidati ve stress are active in lens and neural tissues (Mizuno et al., 1999; Obrosova et al., 
1999; 2001 ). The polyol pathway may induce its devastating effects in those tissues 
through the activation of the proinflammatory NFKB. 
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4.3 HSF -1-DNA binding activity in patients with diabetes 
Hyperglycaemia induced HSF-1-DNA binding activity m PBMCs from patients with 
diabetes but not in those of the NC group (Table 3.20). The protein activity was 
pronounced in patients with microvascular complications (Figure 3.19) suggesting that 
increased flux through the polyol pathway in diabetes in general and in diabetic 
complications in particular may induce HSF-1-DNA binding activity. The polyol pathway 
induces redox and osmolarity imbalances, previous studies have shown that both factors 
can increase HSF-1-DNA binding activity (Jacquier-Sarlin et al., 1996; Caruccio et al., 
1997). Hyperglycaemia may also have a direct effect on the HSF-1-DNA binding 
mechanism since hyperglycaemia induced the protein-DNA binding activity in E6.1 
lymphocytes in this study (Figure 3.16). However there is no published data to support this 
observation. 
Hyperglycaemia-stressed PBMCs showed a significant increase in HSF-1 binding activity 
compared with unstressed cells from patients with TIDM (Table 3.20). The results showed 
that both NFKB and HSF-1-DNA binding activity was more pronounced in patients with 
TIDM. These observations suggest that TIDM as an autoimmune disease may affect cell 
viability and therefore magnify the response to stress factors. The increase of HSF-1-DNA 
binding activity in diabetes may be linked to the level of HSPs, which are known to play a 
role in the aetiology of TIDM such as HSP-60, HSP-65, and HSP-70 (Eiias et al., 1990; 
1995; Caplan et al., 1990; Pociot et al., 1993; Birk et al., 1996; Figueredo et al., 1996; 
Yamagishi et al., 2001). Further investigation is needed to study whether any relation 
between HSF-1-DNA binding activity and the expression of these proteins. However, high 
glucose concentration induced the activation of both factors in PBMCs isolated from 
patients with diabetes along with the cell lines. Therefore we believe our results correlate 
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with increased NFJCB and HSF-1 in circulating mononuclear cells in patients with poorly 
controlled diabetes. Similarly, the activation of these factors has been described in other 
inflammatory diseases such as RA, Alzheimer's disease and arteriosclerosis (Schett et al., 
1998; Bijur et al., 1999; Brand et al., 200 I). 
The results showed a highly significant positive correlation between the NFJCB-DNA 
binding activity and that of HSF-1. This result suggests that HSF-1 may have 
proinflammatory effects. It might enhance the activation of NFJCB. Previous studies have 
shown that heat shock response can modulate cellular proinflammatory signalling through 
their phosphorylation of the IJCB gene (Malhotra et al., 2002), activation of hcB means an 
activation of NFJCB and its subsequent proinflammatory effects. Therefore, it is possible 
that HSF-1 together with NFJCB activation may accelerate the development of late diabetic 
microvascular complications through transcription of proinflammatory genes such as 
cytokines, adhesion molecules, and growth factors. 
Phosphorylation of IJCB and subsequent translocation of NFKB into the nucleus is auto-
regulated by the level of NFK:B and usually terminates within a short time (Baeuerle et al., 
1991 & 1996; Bames et al., 1997; Ghosh et al., 1998). HSF-1-DNA binding activity is also 
auto-regulated by HSP70 (Morimoto 1993; Schafer et al., 2000; Kim et al., 2000). In 
diabetes, chronic hyperglycaemia and activated polyol pathway may induce persistent 
transcription factor activation, which may disturb the auto-regulation mechanisms of these 
factors. Prolonged activation of the transcription factors in vivo may induce expression of 
adhesion molecules. Such molecules recruit inflammatory cells and initiate angiopathy 
(Guha et al., 2000; Calles-Escandon et al., 2001). 
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4.4 Aldose reductase inhibitor and transcription factors-DNA binding activity 
In this study, it remains unclear whether the protein activation observed in response to high 
glucose levels is derived from the direct effect of hyperglycaemia or is dependent on the 
generation of other hyperglycaemia-induced products such as excessive polyol pathway 
flux and its subsequently biochemical products. However, the data presented here indicate 
that hyperactive polyol pathway plays an important role since ARls such as zopolrestat and 
sorbinil reduced the DNA-binding activity of both NFKB (Table 3.23) and HSF-1 (Table 
3.25) in hyperglycaemia-stressed PBMCs isolated from patients with diabetes. The effect 
was more pronounced in patients with microvascular complications. 
Hyperglycaemia may contribute to the pathogenesis of diabetic complications via rapid 
increases in ALR2 transcription and expression. ALR2 is found in many tissues 
susceptible to diabetic complications such as kidney, nerve cells, the eye, and cells lining 
blood vessels (Yabe-Nishimura 1998). It catalyses the NADPH-mediated conversion of 
glucose to sorbitol, which escapes slowly from cells and can cause tissues damage. In 
addition, it has a pro-oxidant effect. Studies have shown that the expression of cytoplasmic 
anti-oxidant genes decrease in response to excess glucose in patients with diabetes 
(Ceriello et al., 2000; Hodgkinson et al., 2003). These observations detect the detrimental 
effect of excess polyol pathway flux on the induction of antioxidant enzymes in response 
to high glucose. Since exposure to hyperglycaemia has been shown to result in excess 
ROS generation that is largely polyol pathway dependent, it may be that excess ROS 
interferes with induction of protective antioxidant genes. This likely reflects the increase in 
NFKB and HSF-1 binding activity in cells exposed to high glucose is most likely pan of a 
generalized response to oxidative stress and redox imbalance. The results also suggest that 
ARI (zopolrestat) may reduce the production of oxidative stress, which induces both 
NFKB and HSF-1 (indirect effect). ALR2 activity may be linked with an activation of the 
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transcription factors NFJCB and HSF-1 as a part of signalling pathways. Studies have 
shown that the promoter region of the ALR2 gene contains binding sites for many 
transcription factors including NFKB (Aida et al., 1998; Fazzio et al., 1999; Iwata et al, 
1999), it is also possible that there is a binding site for HSF-1. Therefore, ARis may have a 
direct inhibitory effect on the binding sites of NFKB and HSF-1; this in turn reduces the 
proteins-DNA binding activity. It is also possible that the ARI (zopolrestat or sorbinil) 
competes with the effect of hyperglycaemia on the proteins activity. With respect to 
NFKB, ARI could interfere with NFKB pathway by reducing the IJCB phosphorylation; 
therefore it will prevent its degradation. It is previously shown that anti-inflammatory 
drugs negatively modulate NFJCB pathway by specific inhibition of IJCB phosphorylation 
(Peirce et al., 1996). Furthermore, ARI could interfere with hyperglycaemia-induced 
phosphorylation of the functional subunit (p65). Studies have shown that ALR2 is 
involved in mediating mitogenic and apoptotic signalling (Ramana et al., 2002& 2003). It 
has also been shown that ALR2 activity links to an increase in VSMC growth and 
proliferation (Kasuya et al., 1999; Ruef et al., 2000). So ALR2 is a good target for 
potential medicines for diabetic complications. Inhibition of ALR2 has been shown to 
prevent the pathological changes related to diabetic complications in several target tissues 
(Yabe-Nishimura 1998). 
However, the effect of ARI might be more useful than the specific inhibition of either 
NFKB or HSF-1 since specific inhibition may disturb the functional balance. It is known 
that NFKB has both pro and anti-inflammatory as pro and anti-apoptotic (Taylor et al., 
1998; Yamamoto et al., 2001). So specific inhibition of NFKB may inhibit the 
proinflammatory but in the same time it will block the anti-inflammatory. [During this 
study, the NFKB and HSF-1-DNA binding activity has been investigated in LPS-stressed 
human umbilical vein endothelial cells (HUVEC). LPS is a strong stimulator for 
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NFteB activity (Schulze-Osthoff et al., 1997). The treatment with specific NFteB inhibitor 
(SN50) revealed a highly significant inhibition of the NFteB. This result indicates that 
SN50 has a specific inhibition on the NFteB-DNA binding activity since it blocked the 
binding activity of NFteB but not HSF-1-DNA (Figure AI and Table A.3)]. 
The results suggest that pharmacological modulation of NFteB and HSF-1-DNA binding 
activity could be useful as potential therapeutic targets to slow the progress of long-term 
diabetic microvascular diseases. Inhibition of NFKB pathway by both aspirin and salicylate 
has been shown to prevent leukocyte recruitment (Peirce et al., 1996) and NFteB inhibition 
reduced the progress of RA (Bondeson et al., 2000) and p cell apoptosis (Heimberg et al., 
2001). 
Metabolic flux through the polyol pathway is very sensitive and it is important to define 
the degree of inhibition needed for maximum efficacy for maintaining cytosolic coenzyme 
balance. Despite recent clinical, experimental and pharmacological data has shown that 
ARis slow the progression of diabetic complications, no ARI is on the worldwide market 
(Cameron et al., 1997; Oates et al., 1999; Mizuno et al., 1999; Obrosova et al., 1999, 200 I; 
Okayama et al., 2002). It is shown that inhibition of polyol pathway has recently yielded a 
dose dependent efficacy on nerve structure and function (Cameron et al., 1997; Mizuno et 
al., 1999; Obrosova et al., 200 I). However, there was no detectable impact on retinal or 
renal dysfunction (Juhl et al., 1997; Mcauliffe et al., 1998). On the other side, clinical trials 
have been disappointing because treatment with ARI (zopolrestat) produces short term 
optimistic therapeutic approach (Arezzo et al., 1996). In addition, many ARis (sorbinil and 
tolrestat) have an inadequate safety and efficacy (Pfeifer et al., 1997; Kubo et al., 1999). 
So, more understanding of the natural history and molecular mechanism of diabetic 
microvascular complications are needed to demonstrate that slowing the progress of 
diabetic complications is not rapid reversal of symptoms. 
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4.5 Cell lines 
The protein assay study was mainly conducted to investigate NFKB and HSF-1-DNA 
binding activity in response to hyperglycaemia in PBMCs from patients with TIDM. 
However, Hep 02 and E6.1 cell lines were used for optimising and supportive 
investigation, which was difficult to perform on patients due to limited amounts of cells. In 
this study, NFKB and HSF-1-DNA binding activity was significantly activated by 
hyperglycaemia. The proteins activity seems to be a cell dependent mechanism (Figure 
3.1 0& 3.16 respectively). However, distinct forms of stress can differentially trigger the 
protein activation. When cells were simulated with 110 mM NaCI, no activation was 
observed in NFKB-DNA binding activity in any of the cell types (Figure 3.11). Supporting 
this result, recently, an in vitro study has shown inhibition of NFKB activation in response 
to hypertonicity in smooth muscle cells (Pingle et al., 2003). These observations indicate 
that hypertonic solutions may prove useful as anti-inflammatory agents. On the other side, 
hyperglycaemia and HO induced HSF-1 DNA binding activity in E6.1 cells but not Hep 
02 (Figure 3.16 and 3.17 respectively). There is no published data to support these 
observations. However, the results showed that the mode of the proteins activation is 
different in response to HO stress, supporting that signal and cell type can generate 
qualitative differences in gene expression (Hill et al., 1995). 
The transduction of extra-cellular signals to the nucleus often involves phosphorylation 
cascades that allow rapid transmission and amplify the signal by activating multiple 
factors. It is previously shown that MAPK p38 is involved in the activation pathways of 
both NFKB and HSF-1 (Haire et al., 1988; Schulze-Osthoff et al., 1997; Kim et al., 1997). 
Results have shown that p38 expression was significantly increased in response to 31 mM 
D-glucose in both Hep 02 and E6.1 cells. The expression of p38 was linked but not 
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correlated with NFKI3 activation m Hep G2 cells and with HSF-1 activation in E6.1. 
Previous studies have shown that MAPK p38 is implicated in the pathogenesis of diabetic 
microvascular complications (Schaffler et al., 1998). Therefore, these findings suggest that 
MAPK p38 may contribute to the development of diabetic complications through the 
activation of these factors. 
MAPK p38 is viewed as an osmotic response element (lgarashi et al., 1999; Karin 2001). 
However, in this study the HO stress of 11 OmM NaCl did not induce p38 expression in 
either Hep G2 or E6.1 cells. This observation suggests that under normal conditions the 
protein has a specific functional role that could change due to the disturbance of 
homeostasis within the cell. However, in vitro studies have a time-limited course from 
hours to days that may induce a transient response, while the chronicity of stress in the 
intact organism could produce a sustained activation. 
4.6 Methodological aspects of the project 
At the beginning of the study, the plan was to follow the genotyping of the NFKB and 
HSP-70A2 genes by an investigation of transcription factor-DNA binding activity and the 
protein expression of NFKI3 (p65) and HSP-70 in PBMCs of patients with TlDM with and 
without microvascular complications. However, for practical reasons and limited flexibility 
the initial plan of investigation was changed to include cell line and patients with TlfDM to 
allow the completion of the study. 
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Patients and design of the studies 
This study is a case-control study. Matching between normal and patients populations has 
been proposed to improve the power of the study. In the genotyping study, 100% British 
Caucasoid patients with TIDM were included. The combination of genotype information 
with functional data gives important information about the role of certain susceptibility 
loci. Therefore, the binding activity of the transcription factors NFK:B and HSF-1 was 
investigated in relation to identified susceptibility alleles in few numbers of patients but the 
results were inconclusive. This was a disadvantage in this study. Larger patients numbers 
may have been an advantage, however, the recruitment of patients was difficult to 
complete this stage. It was also difficult to genotype same DNA samples for all the 
candidate genes due to lack of samples and degradation of DNA. Most of samples were 
used in other studies. 
The protein assay study was conducted to investigate NFKB and HSF-1-DNA binding 
activity in response to hyperglycaemia in PBMCs of patients with TIDM with and without 
microvascular complications. However, 35% of the patients included were TIIDM to 
complete the study of treatment with zopolrestat on the hyperglycaemia-induced proteins 
activity. The pathogenesis of TIDM is different from that of TIIDM however; it is 
suggested that the underlying molecular mechanisms of microvascular complications in 
both types are similar (OCCT, 1993; UKPDS 33, 1998; Calles-Escandon et al., 2001). 
Patients with either TlDM or TIIDM of short duration are included in this study as patients 
with diabetes mellitus irrespective of the duration of the disease. Patients with TIDM of 
short duration without microvascular complications present 8.3% and 11% of patient's 
population in the genotyping study of HSP70-A2 and protein assay study respectively. 
They have been included as an unbiased sample of patients with Tl OM and act as controls 
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for diabetes itself while other diabetic subgroups such as nephropaths, retinopaths, and 
neuropaths have all been specifically chosen for their complication phenotype. Sometimes, 
the frequency of the polymorphisms seems the same in normal controls as a complication 
group, but short duration patients give a better idea of association with the autoimmune 
disease itself. However, data analysis of HSp70-A2 alleles and genotypes excluding this 
group did not affect the association of the identified alleles in either patients or normal 
control populations. 
With respect to the protein assay study, approximately 24% of patients had short duration 
diabetes (11% with TIDM without microvascular complications and 13% with TilDM with 
microvascular complications). This group showed that the duration of the disease as an 
environmental risk factor is implicated in the pathogenesis of micovascular diseases in 
diabetes as well as hyperglycaemia. 
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Summary and Conclusions 
1- A strong association between polymorphisms in close proximity to the NFKB 
(4q24) and HSP70 A2 (14q22) genes and susceptibility to TIDM but not with the 
long- term microvascular complications of this disease. At the present time, the 
influence of these microsatellites on the expression of either NFKB or HSP70 
proteins is unknown. 
2- Hyperglycaemia induces a marked increase in the NFKB and HSF-1-DNA binding 
activity, which was more pronounced in patients with TlDM, those patients with 
microvascular complications in particular. 
3- HSF-1-DNA binding activity correlates with NFKB-DNA binding activity m 
patients with diabetes. 
4- NFKB-DNA binding activity was correlated with the duration of the disease. 
5- The ARis, zopolrestat and sorbinil reduce the hyperglycaemia-induced 
transcription factors binding activity-particularly in diabetes that may either be 
competing with hyperglycaemia or, interfere with the binding mechanism of the 
transcription factor. 
6- The transcription factor-DNA binding activity may be cell and stress specific 
mechanism. 
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Further studies 
The AlO allele of the NFKB gene, H3 and H7 alleles of the HSP70-A2 gene were 
identified as risk markers of TIDM in general population. Further, future efforts are aimed 
to confirm the association of these markers in a family-based study. During this study, the 
number of patients with TIDM with microvascular complications was relatively small and 
limited for practical reasons. It remains possible that with large numbers of patients to 
study these polymorphisms may be shown to be related to the presence or absence of 
microvascular complications rather than to diabetes itself. 
Gene's transcription is a complicated mechanism. The binding of transcription factor to 
DNA (response element) is the start point of the transcription mechanism. It either inhibits 
or assists RNA polymerase in initiation and maintenance of transcription. In this study, 
investigation has shown that high glucose concentration increased NFKB-DNA binding 
activity in PBMCs of patients with TIDM with microvascular complications. However, the 
expression of p65, the functional part of the NFKB heterodimer in response to 
hyperglycaemia is not clear. Future work is now required to ascertain whether the 
hyperglycaemia-induced NFKB-DNA binding activity is combined with an increase in the 
p65 expression in human PBMCs. 
The down-regulation of NFKB activity m PBMCs needs to be clarified. It could be 
difficult to find a treatment which does not completely inhibit the NFKB-DNA binding 
activity. Inhibition of polyol pathway by ARI has shown a promising effect on the protein 
activity. Treatment of PBMCs with ARI (I 0 IJ.mol zopolrestat) reduced but did not block 
the effect of hyperglycaemia on NFKB-DNA binding activity. However, more studies are 
needed to investigate the effect of different classes of polyol pathway inhibitors or 
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specific NFKB inhibitors on NFKB-DNA binding activity in human PBMCs. 
Further, it is a point of interest to investigate the phosphorylation of IKB in response to 
hyperglycaemia with and without treatment by ARI, since IKB is the main regulator of 
NFKB activation. Different techniques such as Western Blot and immuno-cytochemistry 
will be used to investigate the phosphorylation of proteins for comparison purposes and 
more accuracy. 
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A.l Re: HSP-70 A2 results 
Age at Onset (years) 
<10 10-20 >20 
Genotype (n=57) (n=63) (n=73) 
% % % 
Male: Female Male: Female Male: Female 
HI/X 0.02 0.05 0.03 
0: I 3:0 1:1 
H3/X 0.3 0.1 0.3 
9: 11 I :6 6:17 
US/X 0.08 0.1 0.1 
0:5 2:6 5:5 
H7/X 0.3 0.4 0.3 
I: 14 16:10 18:6 
XIX 0.3 0.3 0.2 
. 4:12 9:10 11:3 
Table A.l: Frequency (%)of the most common HSP70-A2 genotypes with respect to 
age at onset of TlDM and gender 
Patients were classified into three groups according to the age at onset (AAO) of Tl OM: 
<10,10-20, >20 years. No difference was found in the frequency of the genotypes with 
either AAO or gender. 
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A.2 Specific-NFKB inhibitor and transcription factors -DNA binding activity 
A.2.1 Human Umblical Vein Endothelial Cells 
Human umbilical vein endothelial cells (HUVEC) were derived from a newborn, male 
donor. Cells were obtained from Totam Biologicals, Northampton, UK No: C-003-5C. 
A.2.2 Preparation of medium for culture 
The HUVECs were grown in medium 200, which supplemented with low serum growth 
supplement (LSGS). Cells, medium and LSGS were supplied from Totam Biologicals, 
Northampton, UK. Medium 200 contains essential and non-essential amino acids, 
vitamins, trace minerals, and inorganic salts and dose not contains antibiotics, 
antimycotics, hormones, growth factors, or proteins. The HUVECs were stressed with LPS 
(specific stimulant for NFICB activation). Furthermore, LPS-stressed HUVECs have been 
treated with SN-50 (specific-NFKB inhibitor) and sodium arsenite (Na As), which induce 
the heat shock response and is suggested to inhibit NFICB-DNA binding activity. Table A.2 
shows the stress conditions and the duration of exposure. Cells were stressed and incubated 
for 5 days at 37 °C and 5% C02. 
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Stress Concentration Time 
N 5 days 
NaAs 0.1 IJ.M 30 min 
SNSO 50Jlg/m1 30 min 
LPS 10 Jlg/ml 18 hrs 
Table A.2: Stress conditions and the duration of exposure of the growing cells 
Cells were stressed according to the type of experiments, grown in the recommended 
medium and incubated for 5 days at 37 °C and 5% C02. N= control (unstressed cells). 
NaAS =sodium arsenite, SN50 = specific-NFKB inhibitor, and LPS = lipopolysacharride. 
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A.2.3 Results 
Figure A.2 is an autoradiograph shows the NFKB and HSF-1 DNA binding activity in 
HUVEC. LPS induced more than two fold increase in the NFKB-DNA binding activity 
(2.5 fold) (Table A.3). When LPS- stressed HUVEC were treated with SN-50 (100 !lg/ml), 
there was a significant inhibition of the NFKB-DNA binding activity compared with LPS-
HUVEC with no SN-50 (0.09 ± 0.008 vs 0.13 ± 0.008, p=0.025). Also, Na As reduced the 
NFKB-DNA binding activity in LPS-stressed HUVEC (0.02 ± 0.008 vs 0.13 ± 0.008, p= 
0.0008). LPS induced HSF-1-DNA binding activity compared with unstressed HUVEC 
(p= 0.017) (Table A.3). No inhibition was observed in the HSF-1-DNA binding activity in 
LPS-stressed HUVEC with SN-50. 
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(A) 
NFKB-DNA complex 
ns 
1 2 3 4 5 
(B) 
HSF-1/HSE 
1 2 3 4 5 
Figure A.1: Autoradiograph shows the NFKB and HSF-1-DNA binding activity in 
HUVEC 
(A) NFKB-DNA binding activity, lane 1: LPS-stressed HUVEC with SN50 (NFKB 
inhibitor), lane 2: LPS-stressed HUVEC+ NaAS, lane 3, unstressed HUVEC, lane 4& 5: 
LPS-stressed HUVEC. (B) HSF-1-DNA binding activity, lane 1: unstressed HUVEC, lanes 
2, 3, 4 : LPS-stressed HUVEC+ NS 50 (100, 75, 50 ~g/ml respectively), and lane 5: LPS-
stressed HUVEC. NaAS = sodium arsenite and LPS = lipopolysacharride. ns= non-specific 
bands. 
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NFJCB-DNA binding activity HSF-1 DNA binding activity 
Stress 
N 
LPS 
LPS+ SN 50 
LPS+ NaAs 
0.05 ± 0.008 
*0.13 ± 0.008 
**0.09 ± 0.008 
***0.02 ± 0.008 
0.29 ±0.01 
•0.37 ± 0.01 
0.39 ± 0.01 
Table A.3: Results of EMSA for NFJCB and HSF -1-DNA binding activity 
HUVEC cells were stressed with LPS with or without NFKB inhibitors. Cells were 
incubated at 37 "C for 5 days. Experiments were repeated for 3-4 times. The results are the 
means ± SE. N= control (unstressed cells). NaAS = sodium arsenite, SN50 = specific-
NFKB inhibitor, and LPS = lipopolysacharride. 
*vs HUVEC controls, p= 0.008, **vs LPS-stressed HUVEC, p= 0.025, 
*** vs LPS-stressed HUVEC, p= 0.0008. 
• vs HUVEC controls, p= 0.017. 
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ABSTRACT 
Diabetes is associated with considerable metabolic abnormalities leading to oxidative stress 
and redox imbalance within the cell. The redox-sensitive transcription factor, nuclear factor 
kappa B (NFKB) is activated in patients with microvascular complications. Gel~shift assays 
were used to investigate the NFKB DNA binding activity in peripheral blood mononuclear 
cells (PBMCs) of 67 patients with diabetes 45 with type 1 and 23 with type 2 diabetes 
mellitus (TlDM and T2DM) and 10 normal healthy controls (NC). PBMC were exposed to 
high glucose (31mM D-glucose, HG) for 5 days. NFKB activity was more than two-fold 
higher in PBMC exposed to HG compared to normal glucose (NG). The increased activity 
was more pronounced in PBMC from patients with diabetes compared with NC (2.1 ± 0.9 vs 
1.6 ± 0.4, p=O.Ol). The binding activity was significantly higher in cells from TIDM patients 
with microvascular disease compared to those with none after 20 years duration of diabetes 
(uncomp) (2.2 ± 0.8 vs 1.9 ± 0.6 p=0.04). When the PBMCs were cultured in the presence of 
10 JlM of the aldose reductase inhibitor (ARI) zopolrestat there was a highly significant 
reduction in NFKB-DNA binding activity (0.1-1 fold, p= 0.000006). Similar results were 
obtained using sorbinil, a structurally distinct ARI. This was more pronounced in PBMC 
from patients compared to the NC group (0.4 ± 0.2 vs 0.7 ± 0.3, p= 0.04). In conclusion, 
these results suggest that inhibition of the polyol pathway can directly influence diabetes-
induced NFKB activation. Although the underlying biochemical mechanisms for this 
response remain to be elucidated, these data suggest that HG-induced activation of redox-
sensitive NFKB results from cytoplasmic redox alteration resulting from enhanced metabolic 
flux through the polyol pathway. 
? 
INTRODUCTION 
Chronic exposure to diabetes inevitably leads to diabetic microvascular complications · 
in a proportion of patients with type 1 as well as type 2 diabetes mellitus (TlDM and T2DM 
respectively). Whilst the underlying mechanisms responsible for the development of diabetic 
microvascular complications have still to be elucidated there is compelling evidence for the 
involvement of oxidative stress and the polyol pathway [1-6]. 
Aldose reductase (AKR1B1 or ALD2) is the first and rate-limiting enzyme of the 
polyol pathway and reduces glucose to sorbitol in a NADPH dependent reaction; sorbitol is 
then metabolised to fructose by the enzyme sorbitol dehydrogenase and the co-factor NAD+. 
Increased flux through the polyol pathway due to diabetes has been linked with a network of 
metabolic perturbations including increased osmotic stress, reductive stress and oxidative 
stress [5-7). Although there is in vitro evidence in some cell types to suggest that ALR2 
(along with other aldo-ketoreductases) may play a role in cell defence against noxious insults 
[8], it has become clear that ALR2 and members of the aldo-keto reductase family are 
involved in mediating cytokine-initiated mitogenic signalling and apoptosis in a variety of 
cell types including vascular smooth muscle cells (VSMC)[9], lens epithelial cells [10], 3T3 
fibroblasts [ 11] and inner retinal neurons [ 12]. 
Many of the cytokine responses will involve the activation of NFKB, a redox-
sensitive transcription factor NFKB whose activation is thought be triggered by oxidative 
stress [13-15]. NFKB promotes the expression of over 150 target genes including those 
coding for cytokines such as tumour necrosis factor-a (TNF-a), and interleukin-1 p (IL-l p); 
chemokines, adhesion molecules and endothelin-1 (ET-I) [14-17]. Previous studies have 
shown increased activity of NFKB in patients with TlDM as well as T2DM who have 
microvascular disease [18-22]. Further, the promoter region of ALR2 contains an NFKB 
.. response elementand the gene.can be.activated.directly-by TNE-a-[9,23]. -
The aim of this study was to investigate the link between aldose reductase and NFKB 
activity using peripheral blood mononuclear cells (PBMC) obtained from patients with 
diabetes and exposing them to hyperglycaemia in the presence or absence of two structurally 
distinct aldose reductase inhibitors (ARI). 
MATERIALS AND METHODS 
Subjects 
Caucasoid patients with either TlDM or T2DM (defmed by the National Diabetes Data 
Group, [24]) were recruited from the Diabetic Clinic, Derriford Hospital, Plymouth, UK). 
Local ethical committee approval was obtained. The criteria for defining the presence of 
microvascular complications has been defined previously [25]. Briefly, uncomplicated 
patients with TlDM have had Tl DM for at least 20 years but remain free of retinopathy, 
microalbuminuria, proteinuria, and overt neuropathy. Patients with short duration diabetes 
(SD) have had diabetes for less than 10 years and remain free of nephropathy, retinopathy or 
neuropathy. Patients with complications have the following: 
Diabetic nephropathy: persistent proteinuria (urine Albustix positive on at least three 
consecutive occasions over 12 months or three successive total urinary albumin excretion 
rates more than 0.5 g/24h) in the absence of haematuria or infection on midstream urine 
samples. The presence of nephropathy is always associated with diabetic retinopathy. 
Retinopathy: defined as having more than 5 dots or blots per eye, hard or soft exudates, new 
vessels or flourescein angiographic evidence of maculopathy or previous laser treatment for 
preproliferative or proliferative retinopathy and maculopathy or vitrous haemorrhage. None 
of these patients had microalbuminuria or protienuria. The clinical characteristics on of the 
patients are shown in Tables I and 3. 
Preparation of peripheral blood mononuclear cells (PBMC) 
The fresh whole blood (20ml) was collected into 5% ethylenediaminetetraacetic acid 
(EDTA) Vacuainers (Becton Dickinson, Oxford, UK). PBMCs were isolated using 
Histopaque according to the manufacturer's instructions. A concentration of 0.5x 106 cells 
were grown in culture flasks (200ml) containing 20 ml of RPMI-1640 (Invitrogen, Paisley, 
UK) with 20J.1l ofphytohemagglutinin (PHA) (Sigma Aldrich, UK). According to the type of 
the experiment, cells were grown under normal conditions (NG) or, high glucose conditions 
(HG) where the medium was supplemented with 28 mmol/L D-glucose. For the ARI studies, 
the PBMC were grown in the presence of 10 J.1M of either zopolrestat or sorbinil (Pfizer, 
Groton). To investigate the dose effect of zopolrestat on NF!CB-DNA binding activity the 
PBMC were exposed to either NG or HG and divided into four flasks containing either 0, 5, 
10, or, 15 J.1M of zopolrestat. To confirm the inhibitory effect of zopolrestat, PBMCs were 
· stressed with 10 J.lg/ml of lipopolysacharride (LPS) for 18 hrs which is known to be a strong 
activator ofNF!CB. The PBMCs were incubated at 37° C with 5% C02 for 5 days and then 
harvested. 
Nuclear Protein Extraction 
The PBMCs were harvested by centrifugation. The cell pellets were lysed by adding 300J.1l of 
buffer A containing 15mM of HEPES pH7.9, 10mM KC!, 1.5mM MgCh, 0.5mM 
dithiothreiotol, O.SmM phenylmethylsulfonyl fluoride (PMSF), 1J.1g/ml each ofleupeptin and 
pepstatin, 0.01 U/ml aprotinin) before incubating on ice for 15 min. The lysate was 
centrifuged at 12000 rpm for 10 min, resuspended in 50J.1l of buffer C (containing 15mM 
HEPES (pH 7.9), 20% glycerol, 0.42M NaCI, 1.5mM MgCh, 0.5mM iodoacetamide, 0.2mM 
EDTA, O.SmM PMSF, 1J.1g/ml each of leupeptin and pepstatin, and O.OIU/ml of aprotinin) 
and incubated.on ice.for.JO min. Then_the lysate was centrifuged at.13000.rpm.foc3 min. __ 
The supematant containing the nuclear protein was kept at -80° until required for GSA. The 
concentrations of the extracts were determined by Coomassie protein assay reagent (Pierce, 
Chester, UK) following the manufacturers instructions. A standard curve using ? human 
serum albumin ? was established by measuring the Coomassie protein assay reagent in a 
spectrophotometer at OD600 that was then used to determine protein concentrations of the 
extracts. 
Gel Shift Assay 
A 5% non-denaturing polyacrylamide vertcial gel was prepared and left to set overnight at 
room temperature. 10 Jlg of nuclear protein was mixed with 21-11 of gel shift binding buffer, 
incubated at room temperature for 10 min, mixed with 1 J.ll of radiolabelled oligonucleotide 
probe and incubated at room temperature for 20 min. The probe used was NFJCB consensus 
oligonucleotide: 5' TGA GGG GAC TTT CCC AGO C 3' (Promega, Delta House, 
Southampton, UK) labelled with ['f2P] ATP by using T4 polynucleotide kinase. At the end 
of the incubation, 11-11 of loading buffer was added and the mixture loaded on to the gel and 
electrophoresed in O.Sx TBE at 100v for 2-3 hrs. The gel was then transferred onto filter 
paper, dried and exposed to X-ray film for 18 hrs at -80°C. Autoradiography was performed 
and a phosphor-imager software program used for quantify the bands (Bio-Rad Multi-
Analyst, Hertfordshire, UK). 
Statistical Analysis 
The intensity of the bands was expressed as means ± SD with each sample run in 
triplicate. The fold change in binding activity in cells exposed to high glucose compared to 
normal glucose was calculated for each sample. Statistical analysis was performed using 
student's /-test. p value less than 0.05 was considered to be significant. 
A 
RESULTS 
Ten nonnal healthy controls and sixty-seven patients (45 with TlDM) were 
investigated for HG-induced NFKB-DNA binding activity. The characteristics of the patients 
are shown in Table I. In cells from nonnal controls and diabetics exposed to high glucose the 
activity of NFKB was increased two-fold when compared to cells cultured under nonnal 
condition (nonnals controls, 0.2 ± 0.08 vs 0.5 0 ± 0.08 and diabetics, 0.5 ± 0.07 vs 0.3 ± 
0.07, p = 0.004)(Table 2). This fold increase in binding activity was significantly higher in 
patients compared to the nonnal healthy controls (2.1 ± 0.9 vs 1.6 ± 0.4, p= 0.01) When the 
patients were separated according to their type of diabetes, there was a significant increase in 
binding activity between the patients with TlDM and nonnal controls but not with those with 
T2DM (2.2 ± 0.8 vs. 1.6 ± 0.4, p= 0.001 and 1.1 ± 0.9 vs. 1.6 ± 0.4, p=ns respectively)(Table 
2). When the patients with TlDM were separated according to either the presence or, absence 
of microvascular complications, the fonner had a significant increase in binding activity 
compared to the latter (2.4 ± 0.8 vs 1.9 ± 0.6, p= 0.04). However, this difference was not 
apparent with patients with T2DM with. complications (n=ll) and vs 2.1± 1.1, p=ns 
respectively) (Figure 3). No difference was observed between the other groups. 
When the tissue culture media was supplemented with an ARI there was a marked 
and consistent reduction in NF-KB binding activity in a dose-dependent manner. (Figure 1) .. 
A further 34 patients and 5 nonnal controls were studied for the effect of ARI on NFKB 
binding activity (Table 3). Zopolrestat, reduced the HG-induced protein binding activity by 
more than 50% compared to HG-stressed cells without zopolrestat (0.3 ± 0.1 vs 0.7 ± 0.4, p= 
0.000006). PBMCs cultured in nonnal media in the presence or absence of zopolrestat 
·showed no difference in the protein binding·activity'(0;3 ± 0.1 vs 0:3 ± 0.2; p= ns). When the 
PBMCs were stimulated with the NFKB activator LPS, there was a marked increase in 
NFKB-DNA binding activity that was inhibited by zopolrestat (data not shown). 
The reduction ofNFKB activity by zopolrestat was greater in patients when compared 
to nonnal controls (0.4 ± 0.2 vs 0.7 ± 0.3, p= 0.04). When the patients were categorised 
according to the presence or absence of complications, NFKB activity was found to be 
significantly reduced by zopolrestat in those with complications compared to either patients 
to nonnal controls (0.3± 0.1 vs 0.7 ± 0.3, p= 0.03). Whilst the reduction ofNFKB activity in 
the uncomplicated patients was less marked, this was still significantly different from the 
nonnal controls (0.5 ± 0.2 vs 0.7 ± 0.3, p= 0.04) (Table 4). Similar results were obtained in 
PBMC from nonnal controls exposed to HG in the presence of sorbinil, a second, structurally 
distinct ARI (0.2±0.05 vs 0.01±0.02, p=O.OOI). 
DISCUSSION 
This study examined whether NFKB activity is increased in the cells of patients with 
. diabetes, whether this activity is responsive to hyperglycaemia and whether the response is 
polyol-dependent. In our study, PBMCs from patients with diabetes had threefold higher 
NFKB binding under nonnal glucose conditions compared to cells from nonnal controls and 
nonnal healthy controls cultured with a high glucose concentration demonstrated an increase 
of NFKB-DNA binding activity. Previous studies have shown that NFKB-DNA binding 
activity was increased in response to elevated glucose in cultured porcine VSMCs [26] and 
that activity was correlated to the glycaemic control in PBMCs of patients with TlDM [19). 
In the present study, PBMCs from patients with TlDM had a higher increase in 
glucose-induced NFKB activity than PBMCs from patients with T2DM and nonnal healthy 
controls. This effect was more apparent in PBMCs from patients with microvascular 
complications than in those without or normal controls. A previous study also showed raised 
NFKB-DNA binding activity in the PBMCs of T2DM patient with diabetic nephropathy, 
although in this instance the cells were not cultured in vitro [20]. We found a clear increase 
in NFKB activity in response to high glucose, and this was prevented by treatment with two 
structurally distinct ARls. Another ARI, epalrestat, has been shown to inhibit platelet-
derived growth factor [27] and inhibition of the polyol pathway causes decreased TNF-a.-
induced NFKB-DNA binding activity in the neointima of rat carotid arteries and cultured 
VSMCs [9]. In the present study we have to our knowledge demonstrated for the first time 
that inhibition of the polyol pathway can have a marked effect on NFKB-DNA binding 
activity in the human cells, including patients with or without microvascular complications. 
These findings together with those recently reported in cell lines and other species [6,7,9,10] 
strongly suggest that increased flux through the polyol pathway causes activation of the pro-
inflammatory transcription factor NFKB. · 
We have previously shown that PBMC of patients with nephropathy have increased 
expression of ALR2 and SORD genes following exposure to high glucose when compared to 
cells from patients with no complications after 20 years of diabetes. The induction is tightly 
linked to the Z-2 'susceptibility' marker in the promoter region of ALR2 [28]. In addition, 
PBMC of patients with nephropathy have decreased expression of cytoplasmic anti-oxidant 
genes in response to excess glucose, whilst those from patients with no complications have a 
marked increase in expression of these genes [29,30]. All of these disturbances in gene 
expression can be ameliorated by inhibition of the polyol pathway [28,29]. These 
observations are consistent with a detrimental effect of excess polyol pathway flux on the 
induction of key antioxidant enzymes in response to high glucose. Since exposure to HG has 
been shown to result in excess ROS generation that is largely polyol pathway dependent 
_ ·-- ·-- ... [31 ,32],.it may. be that excess ROS.interferes with induction ofprotective antioxidant genes. 
This likely reflects The increase in NFKB binding activity in cells exposed to high 
glucose is most likely part of a generalized response to oxidative stress and redox imbalance 
[32]. 
In conclusion, we have shown that NFKB activity is elevated in cells that have been 
exposed to high glucose. The effect was particularly apparent in patients with TIDM and 
microvascular complications and could be reversed by treatment with two structurally 
distinct ARls. 
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Table 1: Clinical Characteristics of the Patients 
Sex (M/F) Age at onset Duration of diabetes 
of diabetes(Ys) (Yearss) 
Uncomplicated (n= 7) 2:5 8.3 + 4.8 31.8 + 6.8 
TlDM -Comp (n= 28) 21:7 26.8± 15.5 29.8 ± 8.9 
T1-SD (n=8) 2:6 26.3 + 16.3 8.2+4.2 
T2-Comp (n=l4) 8:6 56±4 5±3 
T2-SD (n= 10) 8:2 66± 10 5±2 
Normal controls (n=10) 4:6 
·---- . -- -- -- -- - -· -
.. 
- - ·-- -
Total 45:32 
Legend Table I: A total number of 67 patients and I 0 normal controls were included in this 
study. Patients were sub-grouped according to the presence or absence of microvascular 
complications and type of diabetes. The table presents the classification according to sex, age 
at onset and duration of diabetes. Data are presented in means± SD. 
High Glucose and NFKB-DNA binding activity 
Normal Diabetics TlDM 'r2DM Uncomp Tl-Comp T2-Comp Short M±SE controls Duration 
(n=10) (n= 67) (n=43) (n=24) (n=7) (n=28 ) (n= 14) (n= 18) 
NG 0.1± 0.08 0.3± 0.07 0.2 ± 0.08 o.:S± 0.1 0.2 ± 0.1 0.1 ± 0.09 0.5 ± 0.2 0.5 ± 0.1 
' 
High glucose 0.2 ± 0.08 0.5 ± 0.07 0.3 ± 0.08 0.7 ± 0.1 0.4 ± 0.1 0.2 ± 0.09 0.7 ± 0.2 0.7 ± 0.1 
(HG) 
' HG/NG (fold) "'1.7±0.2 2.1±0.1 "'*2.2 ± 0.1 IJ7± 0.2 1.9 ± 0.3 *"'*2.5 ± 0.1 2.0± 0.2 1.5 ± 0.2 
Table 2: High Glucose and NFKB-DNA binding activity in PBMC from Patients with Diabetes 
Patients were sub-grouped according to the presence or absence of rnicrov~cular complications and type of diabetes. Results are in means of folds (±. 
SE). 
"'vs all patients, p= 0.01, and vs patients with TlDM, p= 0.003 
""" vs those patients with T2DM, p= 0.02 
"'"""vs Normal Controls, p= 0.005, vs those patients with Uncomplicated, ~=0.047, and vs those patients with Short Duration, p= 0.00008 
Patient Characteristics for Study of Effect of Zopolrestat on High glucose -induced 
NFKB-DNA binding activity 
Uncomp TIDM- TIDM- T2DM-comp T2DM- Normal 
(n= 3) Comp Short (n=l4) SD Control 
(n=l) (n= 10) (n= 5) 
Sex I :2 1:0 8:6 8:2 4:1 
(m/f) 
Age at 26.5 ± 0.7 7 22 ± 9.5 56±4 66± 10 
onset 
(Years) 
Duration 15.5 ± 4.9 35 9 5±3 5±2 
(Years) 
Table 3: Characterisation of patients included in the study of zopolrestat and HG-
increased NFKB -DNA binding activity 
A total number of 32 patients were studied. Uncomp =those patients with TIDM with 
no microvascular complications after 20 years duration of diabetes. TIDM-Comp and 
12DM~Comp "those patients with either· TlDM or· T2DM~ and- nephropathy and 
retinopathy. SD = those patients with diabetes for 10 years or less with or without 
diabetes. AAO= Age at onset of diabetes. Data is shown as mean ± SD. 
11 
Normal Diabetes Patients with Patients without 
controls (n= 32) complications complications ANOVA 
Mean+ SE (n=5) (n=15) (n=17) 
High glucose 0.6±0.2 0.7± 0.05 0.7± 0.07 0.8 ±0.06 
(HG) 
HG+ARI 
Fold 
suggest 
use2 
decimal 0.35 ± 0.05 0.25 ± 0.07 0.4 ± 0.06 
s for 
these 
data 
0.4 ± 0.2 
0.6± 0.4 ±0.05 * 0.3 ± 0.06 0.5 ± 0.05 0.008 
0.09 
Table 4: Zopolrestat inhibits the high glucose increase in NFKB-DNA binding 
activity in patients with diabetes and normal controls 
Results are in mean of folds (± SE). 
*vs normal controls, p= 0.03 & vs all without comp, p= 0.01 
2 
1.8 
1.6 
1.4 
1.2 
OD 1 
0.8 
0.6 
0.4 
.L 
0.2 
0 
HG HG+S HG+10 HG+15 
Figure 1: Zopolrestat reduced the high glucose-increased NFKB-DNA binding 
activity in a dose-dependent fashion 
HG= HG-stressed cells without ARI, HG+S, IO, IS= HG with S, IO, IS J.1M of 
zopolrestat, respectively. Data are shown in means± SD 
17 
NS 
12 3 4 56 · ~~~~--~--~--~ 7 8 9 
Patients with DM Normal Controls 
Figure 2: High glucose-induced increase in NFKB-DNA binding activity is 
inhibited by an aldose reductase inhibitor 
Lanes 1, 4 and 7 represent PBMCs from 3 separate subjects grown under normal 
glucose conditions. Lanes 2, 5 and 8 represent the PBMCs grown under high glucose 
conditions and 3, 6 and 9 represent the PBMCs grown under high glucose and 10 l!M of 
zopolrestat. Lanes 1-6 for two patients with diabetes and lanes 7-9 correspond to a 
normal control. NS= non-specific band. 
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Aldose Reduc~ In:bibition Reduces: the High Glucose Induced 
Increase in Nuclear Factor Kappa B Binding Activity in.Cells from 
Patients with Diabetes Mellitus- · · 
OOHA HEGAZY, BINGMEI YANG, PETER OATES, ~EVERLEY 
MILLWARD,ANDREWDEMAINE. Plymout!i, Devon, United Kingdom; 
Groton~ Cl' · . 
Long term exp(,sUre to diabetes· ~ associated With metabOlic abnormalities 
such as redox imbalance.and oxidative stress that haVe been linked to the·devel-·. 
opment of .rucrovascular. aDd macro vascular complications. Previous studies 
·have shown that the redox-sensitive traoscri~ factor, nuclear factor kappa B 
(NFKB) iS activated in patients with microva"scutar coinplications. We inves- ,· 
.. tigated the·. NFKB. binding activity in peripheral blOOd ~o.nonuclear cells 
{PBMC) of67 cauc:asoid patients with diabdes{45 with type 1_.800'22 with type 2 ' 
diabetes mellitils, T1DM and T2DM) and 10 n<>rm;al healthy controls (NC) 
. by gel shift assay8. PBMC were exposed to high glu~ (31mM D-gl~~ 
. . . H'G) for 5 days. The bindiitg activity was lDQre·than two-fold higher in PBMC 
exposed to HG Compared to basal glucose ( 1lmm D-glucose,l3G). The increase 
· was -more pronqunced in diabetic patients compared with NC (2._1± 0.9 vs. 
1.6± 0.4, p=O.Ol). In additio~ TlDM pati~tS with i:nicroVascutar ~~had. 
a signifiCant ~ in the bindfug 'ctivity CQlilP3.COO to those with no corn-
. plications after 20 years of the disease (2.2±.0.8 vs 1.9± 0.6, p=0.04). When 
the PBMC,were cultured in the presence of 1~ of the aldose reductase 
inhibitor zopolrestat or; sorbinil.there vias a highly significant reduction in NFKB 
· binding activity {0.1 -1.0 fold, BG vs.HG; p=0.000006). The reduction was more 
p~nounce,:t"in patients compared to NC (0.4± 0.2 vs; 0.7~ 0.3, p=0.04). In 
conclusion; these results suggest that inhibition of the polyol pathway can ihflu-
ence high glucose-induced NFICB activation. The underlying mechanisms for 
this response are largety unknown but suggest that flux through the polyol path-
way and consequent redox chatiges pJay a key role in the activation ofNFlCB. · 
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Nuclear Factor 1CB Polymorphisms and Susceptibility to 1YPe 1 Diabetes 
:OOHAM. HEGAZY, BINGMEI YANG, ANDREAD. HOOOKINSON, 
ANN MILL WARD, ANDREW G. DEMAINE. Plymouth, Devon, United. 
Kingdom 
Nuclear factor kappa B (NFICB) is a member of the rei-family proteins 
and is an important transcription factor that is involved in the response to 
oxidative stress and inflammation. Target genes include those for 
~ytokines as well as HLA molecules. Recent studies suggest that it may be. 
involved in the development of diabetic microvascular complications. A 
highly polymorphic (CA) dinucleotide repeat microsatellite has been iden-
tified in the 5'-upstream region of the NF1CB gene. The aim was to inves-
. tigate whether this polyniorphic region was associated with susceptibility 
to type I diabetes or,, its late complications. Genomic DNA was extracted 
from the peripheral blood of 217 Caucasoid patients with type 1 diabetes 
and Ill normal healthy controls. Polymerase chain reaction was used to 
amplify the 5'promoter region containing the repeat region. Amplified 
fragments were separated by gel electrophoresis and visualised using 
image. analysis. 18 alleles (Al-A18) were identified. There was a highly 
significant decrease in the frequency of allele A14 (146 base pair) in th~ 
patients compared to the normal controls (0.03 vs 0.28 respectively, 
. x2=79.8, p<O.OOOOOI). In contrast, the frequency of the AIO allele was 
sigriificantly increased in the patients compared to the normal controh 
(0.17 vs 0.02, x2=32.8, p<O.OOOOl). More than 70 genotypes were identi· 
fied. A8/A14 was the most corninon genotype in the normal controls bu· 
was found in only 1/217 patients (12.6% vs 0.5% x2=22.1 p<0.000002) 
Similarly, the Al4/Al4 genotype was present in 9.9% of the normal con 
1r9ls but was absent from the patients (X2= 19 3, p<O.OOOO 1 ). There was ne 
association with microvascular complications, age at onset or gender ofthl 
patient. In conclusion, these results demonstrate that the NFKB gene ~: 
play a role in the susceptibility to type I diabetes. ' '~ 
~ :[ 
Genes and llmnunity (2001)2, 304-308 
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NFKB Pqlymorphisms and susceptibility to type 1 
diabetes 
DM Hegazy, DA O'Reilly, BM Yang, AD Hodgkinson, BA Millward and AG Demaine 
Department of Molecular Medicine, Postgraduate Medical School, University of Plymouth, Plymouth PL6 BBX, UK 
Nuclear factor kappa B (NFKB) is an important transcription factor that is involved in the response to oxidative stress and 
inflammation. Recent studies suggest that it may be involved in the development of diabetic microvascular complications. 
A highly polymorphic (CA) dinucleotide repeat microsatellite has been identified in the regulatory region of the NFKB gene. 
The aim of this study was to investigate whether this polymorphic region was associated with susceptibility to type 1 
diabetes, or its late complications. Genomic DNA was extracted from the peripheral blood of 217 patients with type 1 
diabetes mellitus (T1DM) and 111 nonnal healthy controls. In our population 18 alleles (A 1-A 18) were identified. There 
was a highly significant decrease in the frequency of allele 146 bp (A 14) in type 1 diabetes (0.03) compared with the 
nonnal controls (0.28) (;il = 79.8, Pc= 0.00001). In contrast, the frequency of the allele 138 bp (A 10} was significantly 
_increased in patients with type 1 diabetes (0.17) compared with the nonnal controls (0.02) (;il = 32.8, P < 0.00000). 
These results demonstrate that the NFKB gene may play a role in the susceptibility to type 1 diabetes: individuals with the 
A 10 allele may be more likely to develop diabetes compared with the A 14 allele. Genes and Immunity (2001) 2, 304-308. 
Keywords: type 1 diabetes; hyperglycaemia; nuclear factor kappa B; diabetic complications 
Introduction 
Type 1 diabetes mellitus (TIDM) is caused by the auto-
immune aestruction of the pancreatic beta (f3) cells in the 
islets of Langerhan. It is well known that genetic as well 
as environmental factors are implicated in the pathogen-
esis of this disease. The genes coding for certain major 
histocompatibility complex (MHC) HLA class ll alleles 
are strongly associated with susceptibility to TIDM in 
Caucasoid populations.1-3 The HLA susceptibility alleles 
. make a major contribution to the genetic component of 
TIDM, however, non-HLA loci including insulin and cer-
tain cytokine genes may also play an important to this 
disease.4-6 
Nuclear factor ~ppa B (NFKB) is a member of the rei-
family proteins and is an eukaryotic transcription factor 
that is intricately involved in mediating the immune 
response?-10 The gene coding for NFKB is located on 
chromosome 4q24 and promotes the expression of over 
150 target genes including those coding for cytokines 
such as tumour necrosis factor-a, and interleukin-1 f3; 
chemokines, adhesion molecules as well as increased 
expression of HLA molecules. It is also apparent that 
many viruses have NFKB binding sites in their genome 
thereby inducing increased viral transcription by the 
cell's own defence system. 
Inhibitor-KB proteins OKB) inhibit NFKB by trapping it 
in the cytoplasm. Phosphorylation of IKB by kinases 
allows activation of the NFKB, which translocates into the 
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nucleus and binds DNA motifs.8 Activation of NFKB and 
subsequent release of cytokines occurs through a redox-
sensitive mechanism11•12 and oxidative stress is the main 
inducer for activation of the pathway. NFKB plays a role 
in protecting cells from apoptosis by upregulating the 
synthesis of anti-apoptotic gene products.13 Long-term 
exposure to hyperglycaemia is an important risk factor 
for developing diabetic microvascular complications: 
neuropathy, nephropathy, and retinopathy.14•15 
Several studies have demonstrated that chronic hyper-
glycaemia causes metabolic abnormalities such as m<idat-
ive stress, hypoxia, advanced glycated end products 
(AGEs) and changes in the NADH/NAIY ratio may con-
tribute to the development of these complications.1c.-18 
The oxidative stress and AGEs produced by hypergly-
caemia are an important source for free radical oxygen 
intermediates (ROis); these free radicals are responsible 
for accelerating the vascular complications due to their 
inflammatory, necrotic and ischaemic effects. Recent 
studies have suggested that the increased activation of 
NFKB is associated with the development of diabetic 
microvascular complications in those patients with either 
J'lDM or T2D.19-22 It has previously been shown that 
increased activity of NFKB is present in the peripheral 
blood mononuclear cells isolated from patients with dia-
betic nephropathy.20 Hyperglycaemia has also bee.il 
shown to activate NFKB in porcine vascular smooth mus-
cle cellsY These studies suggested that NFKB might be 
involved in the pathogenesis of diabetic microvascular 
complication. The gene coding for aldose reductase 
(ALR2), the first and rate limiting of the polyol pathway 
has been also shown to have a NFKB binding site. 
Recently, a polymorphic dinucleotide (CA) repeat has 
been identified in close proximity to the coding region of 
the human NFKB gene23 at 4q24 (108 111 682- 108 111 727 
reverse strand-Human Genome Project (HGP) Working 
Draft at UCSC Blat search). To our knowledge this poly-
morphism has not previously been studied in either 
patients with TlDM or, other autoimmune disease. 
The aim of our study was to investigate the (CA) dinu-
cleotide repeat polymorphism in a large group of patients 
with TlDM with, and without microvascular compli-
cations. 
Results 
In our population, 1S alleles (A1-A1S) of the (CA) repeat 
microsatellite in the regulatory region of the NFKB gene 
were <;ietected. The size of the alleles ranged from 120 to 
154 base pairs (bp) (A1-A1S) (Figure 1). The observed and 
expected frequency of the alleles was similar in both the 
patient and normal control populations and therefore 
conformed to the Hardy-Weinberg equation. 
The frequency of the alleles in the patients and controls 
are shown in Table 1. The AS and A14 alleles were the 
most prevalent in the normal controls (19.S% and 2S.4% 
respectively). In contrast, in patients with TlDM there 
was a highly significant decrease in the frequency of both 
the AS as well as the A14 allele compared to the normal 
controls (6.2% vs 19.8%, )('- = 26.75, P < 0.0000002, Pc = 
0.0000034 and 3.9% vs 28.4%, )('- = 79.80 P < 0.000001, Pc 
= 0.000017 respectively). In patients with TlDM, there 
was a highly significant increase in the frequency of the 
A10 (138 bp) allele compared with the normal controls 
(17 5% vs 2.7% respectively,)('-= 32.S, P < 0.000001, odds 
ratio =9.4). 
More than 70 genotypes were identified in our popu-
lation. Table 2 shows the frequency of the common geno-
types. In the normal control population, the most corn-
' mon genotype was AS/ A14 but this was only found in 
one of the 217 patients with T1DM (12.6% vs 05%, x2 = 
22.1, P < 0.000002, Pc= 0.00014). The second most preva-
lent genotype in the normal control group was A14/ A14 
and this was completely absent from the patient group 
(9.9% vs 0.0% x2 = 19.3, P < 0.00001, Pc = 0.00007). Simi-
larly, the AS/ All genotype was found in 6.3% of the nor-
mal controls but was absent from the patient population 
()('- = 11.1, P < 0.0008). However, this difference was not 
A16 
A15 
A14 
A13 
Al2 
All 
AIO 
A9 
A8 
Figure 1 Autoradiograph is showing some of the CA dinucleotide 
repeat polymorphisms in the hwnan NFKB gene. Lane 1: AS/ A14, 
Lane 2: A13/A14, Lane 3: A8/AS, Lane 4: All/All, Lane 5: 
AS/ A13, Lane 6: A14/ A14, Lane 7: A 13/ A14, Lane S: AS/ All. 
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Table 1 The frequency{%) of NFKB microsatellite alleles in patients 
with type 1 diabetes an~ normal controls 
Alelle 
AI 
A2 
A3 
A4 
A5 
A6 
A7 
AS 
A9 
AIO 
All 
A12 
A13 
A14 
A15 
A16 
A17 
A18 
Type 1 diabetes 
(n =434) 
0.0 {0) 
1.61 {7) 
1.15 {5) 
6.22 {27) 
4.84 {21) 
5.76 (25) 
5.76 (25) 
6.22(27) 
14.98 (65) 
1751 (76) 
10.60 {46) 
7.60 {33) 
5.30 (23) 
3.92 (17) 
6.68 (29) 
1.61 {7) 
0.23 {1) 
0.0 (0) 
Namuzl amtrols 
(n = 222) 
0.45 (1) 
0.45 {1) 
0.0 (0) 
0.0 {0) 
. 0.0 {0) 
0.0 {0) 
0.45 {1) 
19.82 {44)'0 
9.91 {22) 
2.70 (6)•• 
9.91 {22) 
2.25 {5) 
11.26 {25) 
28.38 {63)••• 
7.21 {16) 
5.41 (12) 
0.90 (2) 
0.90 (2) 
Note: Allele frequencies are expressed as percentage of the total 
number of chromosomes. The numbers in parentheses is the num-
ber of chromosomes. •As P < 0.0000002, Pc< 0.000003 in the nor-
mal controls. vs patients subgroups. ••AtO P < 0.00000 in the 
patients subgroups vs normal controls . ... A14 P < 0.000001, Pc= 
0.000017 in normal controls vs subgroups of type 1 diabetes. 
Table 2 The frequency{%) of NFKB genotypes in patients with type 
1 diabetes and normal controls 
Genotypes Type I diabetes Normal ccmtrols 
(n = 217) (n = 111) 
AS/A9 3.23 450 
(7) (5) 
AS/All 0.00 6.31 
(0) {7) 
AS/A14 0.46 12.61 
(1) (14) 
A9/A10 11.98 3.60 
(26) (4) 
A9/Al5 4.15 0.90 
(9) (1) 
AlO/All 9.22 0.00 
(20) (O)• 
A14/A14 0.00 9.91 
(0) (11)"• 
XIX 70.96 62.16 
(154) {69) 
The table shows the frequency of genotypes with prevalence <3%. 
X= all other genotypes. "'The AlO/ All genotype is the most com-
mon in patients with type 1 diabetes. •01fle A14/ A14 genotype is 
prevalent with the normal controls. · 
significant after correction of the P-value (Pc = 0.06). In 
the patient group, the A9/ A10 genotype was the most 
common genotype and was present in four of the 111 
normal control subjects (12.0% vs 3.6%, x2 = 5.2, P < 0.02, 
Pc = NS). The A10/ All genotype was found in 9.2% of 
the patients but was absent from the normal control 
group x2 = 9.3, P < 0.002, Pc = NS). 
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Table 3 Frequency (%) of the most common NFKB genotypes 
with respect to age at onset of type 1 diabetes and gender 
Age at onset (years) 
< 10 10-20 >20 
Genotype (n = 42) (n = 68) (n = 107) 
M:F M:F M:F 
A9/A10 4.8 13.2 14.0 
0:2 4:5 8:7 
A10/A11 16.7 8.8 65 
1:6 2:4 4:3 
A10/X 14.3 16.2 12.2 
2:4 7:4 5:8 
XIX 64.2 61.8 67.3 
15:12 20:22 34:38 
The patients were classified into three groups according to the age 
at onset (AAO) of type 1 diabetes: < 10, 10-20, >20 years. 
Table 3 shows the frequency of the NFK~ genotypes 
with respect to age at onset of TIDM and gender. The 
patients were cat~gorised into < 10, 10-20 or >20 years 
age at onset of diabetes. There were no significant differ-
ences in the frequency of the genotypes with age at onset 
although the A9/ A10 genotype was found in only 4.8% 
of those diagnosed before the age of 10 years compared 
to 13.2% and 14.0% in the 10 to 20-year and > 20-year age 
at onset respectively. There were no significant differ-
ences in the frequency of the NFKB genotypes with gen-
der. Table 4 shows the frequency of the common NFKB 
alleles ~ith respect to the presence or absence of diabetic 
microvascular disease after 20 years duration of diabetes. 
Whilst A9 was more common in those with either dia-
betic microvascular disease compared to those with no 
complications after 20 years of diabetes, these differences 
were not significant. All the other frequencies of the 
alleles were similar between the patient subgroups. 
Table 4 Frequency (%) of the most common NFKB alleles with 
respect to presence or absence of diabetic microvascular compli-
cations 
Allele DC DN DNU DR 
(n = 76) (n = 96) (n = 110) (n = 152) 
A10 19.8 17.7 16.4 17.1 
(15) (17) (18) (26) 
A9 9.2 16.7 16.4 15.8 
(7) (16) (18) (24) 
All 11.8 10.4 9.1 11.2 
(9) (10) (10) (17) 
X 59.2 55.2 58.1 55.9 
(45) (53) (64) (85) 
OC, those patients with no nephropathy, retinopathy or overt 
neuropathy after 20 years duration of diabetes; ON, those patients 
with nephropathy; ONU, those patients with overt neuropathy; OR, 
those patients with retinopathy. There were no significant differ-
ences in the frequency of the NFKB alleles between any of the 
patient groups. 
Genes and Immunity 
Discussion 
To our knowledge, this is the first study of NFKB poly-
morphisms in either an autoimmune or inflammatory 
disease. The results suggest that the A10 allele may con-
tribute to the susceptibility of T1 DM whilst those individ-
uals with the A14 allele have a reduced risk of 
developing TlDM. This polymorphism is located in close 
proximity to the coding region of the NFKB gene. It has 
previously been shown that polymorphisms in the non-
coding regions of cytokine genes can influence 
expression2us whilst enhancer elements up to SO kb from 
the coding region can directly effect expression of tran-
scription factors.26 Consequently, the results described 
here could be attributed to differences in the expression 
of the NFKB gene. At the present time, nothing is known 
about the influence of this microsatellite on the 
expression of the NFKB gene, or regulatory sequences 
that may be located nearby. This may determine the 
direction and magnitude of the response of a cell to an 
external stress and whether it is channelled towards 
either apoptosis or, inflammation and necrosis. There is 
currently very little information on the mechanisms of 
islet f3-cell death during the pre-diabetic period in man. 
It is possible that the A10 allele is associated with pro-
inflammatory and anti-apoptotic responses whilst con-
versely, the A14 allele is anti-inflammatory and pro-
apoptotic. This might be related to variable amounts of 
NFKB protein. In the case C?f the anti-apoptotic response, 
too much protection of the cell perhaps because of its 
increased abundance would prevent apoptosis but would 
cause increased necrosis. This would have a detrimental 
effect by allowing intracellular proteins and other mol-
ecules to be exposed to the immune system thereby pro-
voking the autoimmune response. 
Recent studies have shown that increased activation of 
NFKB is significantly increased in patients with either 
TIDM or, T2D and micro vascular disease.19-22 In this 
study we have found no association with the NFKB allele 
or genotypes with either the presence or absence of dia-
betic microvascular complications in those patients with 
TlDM. It is possible that an association may exist with 
microvascular disease in those patients with T2DM. 
There is no information at the present time on the func-
. tional role of the A10, A14 or other polymorphisms in 
the regulatory t:egion of this gene. It is possible that these 
polymorphisms may be related to function perhaps by 
altering the efficiency of its transcription under different 
types of stress. Activation of NFKB occurs at the protein 
rather than the genetic level although prolonged chronic 
exposure to stress such as hyperglycaemia would lead to 
increase abundance of the transcription factor within the 
cell. IKB may also play an important role in enabling the 
translocation of the transcription factor to the nucleus. 
In conclusion, we have a strong association between a 
polymorphism in close proximity to the NFKB gene and 
susceptibility to TlDM but not with the long-term micro 
vascular complications of this disease. Previous studies 
have found no evidence for linkage of 4q24 with suscepti-
bility to T1 DM. However, these genome screens used 
highly selective multiplex families whilst in this study the 
majority of cases are sporadic cases. Further, the mul-
tiplex family studies were not always able to replicate 
the association of non-MHC genes with susceptibility to 
T1 DM across or even within similar populations. It 
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Table 5 Oinical characteristics of the patient subgroups 
Patimt subgrcwp DC DN DNU DR NC 
(n = 38) (n = 48) (n =55) (n = 76) (n = 111) 
Male:Female 14:24 22:26 26:29 37:39 58:53 
Age at onset of diabetes (years) 17.8±10.7 16.4 ±10.4 19.1 ± 11.3 18.1 ±105 
Duration of disease (years) 29.2±105 34.5±115 315±10.8 32.1 ±11.7 
DC, those patients with no microvascular complications after 20 years duration of diabetes; DN, those patients with diabetic nephropathy; 
DNU, those patients with overt diabetic neuropathy; DR, those patients with diabetic retinopathy; NC, normal healthy controls; data are 
shown as mean ± s.d. 
remains a possibility that the polymorphism is related to 
the presence or absence of microvascular complications 
rather than diabetes itself. Further studies are now 
required to determine whether there is any relationship 
between the NFKB alleles and function. 
Materials and methods 
Subjects 
Two hundred and seventeen British Caucasoid patients 
with TIDM with or without complications and 111 nor-
mal healthy controls (NC) were studied. All the patients 
had attended the Diabetic Clinic, Derriford Hospital, Ply-
mouth, UK The patients were classified according to 
their microvascular complications as follows: 
Uncomplicated diabetic controls (DC n = 38): these 
patients have had TIDM for at least 20 years but remain 
free of retinopathy, microalbuminuria (defined by the 
Diabetes Control and Complications Trial as I5-30 mg/1), 
proteinuria, and overt neuropathy. 
Nephropathy patients (DN n = 48): these patients have 
had TIDM for at least IO years with persistent pro-
teinuria (urine Albustix positive on at least three consecu-
tive occasions over I2 months or three successive total 
urinary albumin excretion (UAE) rates more than O.S 
g/24 h) in the absence of haematuria or infection on mid-
stream urine samples. The presence of nephropathy was 
always associated diabetic retinopathy. 
Retinopathy patients (DR n = 76): these patients had 
retinopathy def:med as more than five dots or blots per 
eye, hard or soft exudates, new vessels or flourescein 
angiographic evidence of maculopathy or previous laser 
treatment for preproliferative or proliferative retinopathy 
and maculopathy or vitrous haemorrhage. None of these 
patients had microalbuminuria or protienuria. 
Neuropathy patients (DNU n = SS): these patients had 
overt neuropathy defined as clinical evidence of periph-
eral or autonomic neuropathy. The criteria for inclusion 
in this category have previously been published.27 
Normal control samples were consisted of 80 cord bloods 
collected sequentially after normal obstetric delivery 
from the labour ward, Derriford Hospital. The remaining 
samples were obtained from normal healthy school-
children (n = 15) and adults (n = I6). The clinical charac-
teristics of the patients and control populations are 
shown in Table 5. 
Extraction of genomic DNA and analysis of the 
microsatellite polymorphism 
DNA was extracted from peripheral blood collected into 
EDTA-containing tubes using Nucleon ll DNA extraction 
kit (Tepnel Life Science PLC, Manchester, UK) following 
the manufacturer's instructions. Briefly, the samples were 
lysed and deproteinised before extraction with chloro-
form. Finally, DNA was isolated by ethanol precipitation 
and dissolved in-500 JJ.l of double distilled water. 
The (CA)n region was amplified by polymerase chain 
reaction (PCR) using primersD (NF@. .I IF) S'-CITCAG 
TATCTAAGAGTATCCT-3' (108 Ill 762 4q24 forward 
HGP-UCSC) and (NFKB 1 IR) 5'-CAAGfAAGAC 
TCTACGGAGfC-3' (108 Ill 625 4q24 revey-se HGP-
UCSC). The forward primer was labelled With [32P-y] 
dATP by T4 polynucleotide kinase (Amersham Pharma-
cia, UK Limited). Flfty to 100 ng of genomic DNA was 
used for amplification in a volume of 30 JJ.l with a hot 
start for 4 min at 94°C. Then 30 cycles were performed 
at 94"C for 30 sec, at 53.5°C for 2 min, at 72°C for 30 sec. 
The resulting fragments and a molecular weight ladder 
were electrophoresed through 6% denaturing polyacryla-
mide gels at 1800 W for 3 h. The dried gels were auto-
radiographed at -80°C for I8 h. The films were visualised 
for allelic and genotypic identifications. 
Statistical analysis 
The frequencies of alleles and genotypes were calculated 
by Statgraphics software (Statistical Graphics Corp, USA, 
I996). The comparison between patient's subgroups and 
control subjects was made by 2 x 2 contingency tables 
using the X: test. The P values were corrected for the 
number of comparisons made (Pc) using the Bonferroni 
inequality method,28 and Pc values of <0.05 were con-
sidered to be significant. 
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